Note: Descriptions are shown in the official language in which they were submitted.
PYRAZOLO[1,5-a][1,3,5]TRIAZINE AND PYRAZOLO[1,5-a]PYRIAHDINE
DERIVATIVES AS CDK INHIBITORS
FIELD OF THE INVENTION
This invention pertains to compounds which inhibit the activity of selective
transcriptional cyclin dependent kinases (CDKs) including CDK7, CDK9, CDK12,
CDK13 and
CDK18, more particularly transcriptional cyclin dependent kinase-7 (CDK7). The
invention also
provides pharmaceutically acceptable compositions comprising compounds of the
present
invention and methods of using said compositions in the treatment of diseases
or disorder
associated with selective transcriptional CDKs.
BACKGROUND OF THE INVENTION
One of the most important and fundamental processes in biology is the division
of cells
mediated by the cell cycle. This process ensures the controlled production of
subsequent
generations of cells with defined biological function. It is a highly
regulated phenomenon and
responds to a complex set of cellular signals both within the cell and from
external sources. A
complex network of tumor promoting and suppressing gene products are key
components of this
cellular signalling process. Over-expiession of tumor-promoting components or
the subsequent
loss of the tumor-suppressing products will lead to unregulated cellular
proliferation and the
generation of tumors (Pardee, Science 246:603-608, 1989).
Kinases are important cellular enzymes that perform essential cellular
functions such as
regulating cell division and proliferation, and also appear to play a decisive
role in many disease
states that are characterized by uncontrolled proliferation and
differentiation of cells. These
disease states encompass a variety of cell types and maladies such as cancer,
atherosclerosis,
restenosis and other proliferative disorders (Kris MG et al.,; "Efficacy of
gefitinib, an inhibitor of
the epidermal growth factor receptor tyrosine kinase, in symptomatic patients
with non-small
cell lung cancer: a randomized trial". JAMA 290 (16): 2149-58, October 2003).
Cyclin-dependent kinases (CDKs) are relatively small proteins, with molecular
weights
ranging from 34 to 40 kDa, and contain little more than the kinase domain. CDK
binds a
regulatory protein called a cyclin. Without cyclin, CDK has little kinase
activity; only the cyclin-
CDK complex is an active kinase. CDKs phosphorylate their substrates on
serines and
Date Recue/Date Received 2022-08-18
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
threonines, so they are serine-threonine kinases (Morgan, David 0., The Cell
Cycle: Principles
of Control. London: New Science Press, 1st edition, (2007)).
The members of the cyclin-dependent kinase (CDK) family play critical
regulatory roles
in cell proliferation. There are currently 20 known mammalian CDKs. While CDK7-
13 and 18
have been linked to transcription, only CDK1, 2, 4 and 6 show demonstrable
association with the
cell cycle. Unique among the mammalian CDKs, CDK7 has consolidated kinase
activities,
regulating both the cell cycle and transcription. In the cytosol, CDK7 exists
as a heterotrimeric
complex and is believed to function as a CDK1/2-activating kinase (CAK),
whereby
phosphorylation of conserved residues in CDK1/2 by CDK7 is required for full
catalytic CDK
activity and cell cycle progression (Desai et aL, MoL Cell BioL 15, 345-350
(1995)).
CDK7, which complexes with cyclin H and MAT1 , phosphorylates the cell cycle
CDKs
in the activation of T-loop, to promote their activities (see, e.g., Fisher et
al., 1994). As such, it
has been proposed that inhibiting CDK7 would provide a potent means of
inhibiting cell cycle
progression, which may be especially relevant given that there is compelling
evidence from gene
knockout studies in mice for lack of an absolute requirement for CDK2, CDK4
and CDK6 for
the cell cycle, at least in most cell types (see, e.g., Malumbres et al.,
2009), whilst different
tumors appear to require some, but be independent of other interphase CDKs
(CDK2, CDK4,
CDK6). Recent genetic and biochemical studies have confirmed the importance of
CDK7 for cell
cycle progression (see, e.g., Larochelle et al., 2007; Ganuza et aL, 2012).
Cyclin-dependent kinase 7 (CDK7) activates cell cycle CDKs and is a member of
the
general Transcription factor II Human (TFHH). CDK7 also plays a role in
transcription and
possibly in DNA repair. The trimeric Cak complex CDK7/CyclinH/IVIAT1 is also a
component
of IF IIH, the general transcription/DNA repair factor IIH (reviewed in
Morgan, D. 0., Annu Rev
Cell Dev Biol 13, 261-91, (1997)). As a TFHH subunit, CDK7 phosphorylates the
C'11)
(Carboxy-Terminal-Domain) of the largest subunit of RNA polymerase H (pot II).
The CTD of
mammalian poi II consists of 52 heptad repeats with the consensus sequence
1YSPTSPS7 and the
phosphorylation status of the Ser residues at positions 2 and 5 has been shown
to be important in
the activation of RNAP-II indicating that it is likely to have a crucial role
in the function of the
CTD. CDK7, which primarily phosphorylates Ser-5 (PS5) of RNAP-II at the
promoter as part of
transcriptional initiation (Gomes et al., 2006), incontrast with CDK9, which
phosphorylates both
Ser-2 and Ser-5 of the CTD heptad (Pinhero et aL, 2004).
2
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
In addition to CDK7, other CDKs have been reported to phosphorylate and
regulate RNA
pol (II) CID. The other CDKs include, Cdk9/ Cyclin Ti or T2 that constitute
the active form of
the positive transcription elongation factor (P-TEFb) (Peterlin and Price,
2006) and
Cdk12/Cyclin K and Cdk13/Cyclin K as the latest members of RNAPII CTD kinases
(Bartkowiak et al., 2010; Blazek et al., 2011).
Disruption of RNAP II CTD phosphorylation has been shown to preferentially
effect
proteins with short half-lives, including those of the anti-apoptotic BCL-2
family. (Konig et al.,
"The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bc1-2
and induces
growth arrest and apoptosis in chronic B-cell leukemia lines." (Blood 1, 4307-
4312 (1997); Gojo
et al.) The transcriptional non-selective cyclin-dependent kinase inhibitor
flavopiridol induces
apoptosis in multiple myeloma cells through transcriptional repression and
down-regulation of
Mcl-1; (C/in. Cancer Res. 8, 3527-3538 (2002)).
This suggests that the CDK7 enzyme complexes are involved in multiple
functions in the
cell: cell cycle control, transcription regulation and DNA repair. It is
surprising to find one
kinase involved in such diverse cellular processes, some of which are even
mutually exclusive. It
also is puzzling that multiple attempts to find cell cycle dependent changes
in CDK7 kinase
activity remained unsuccessful. This is unexpected since activity and
phosphorylation state of its
substrate, CDC2, fluctuate during the cell cycle (Larochelle, S. et al. Genes
Dev 12,370-81,
(1998)). Indeed, flavopiridol, a non-selective pan-CDK inhibitor that targets
CID kinases, has
demonstrated efficacy for the treatment of chronic lymphocytic leukemia (CLL),
but suffers
from a poor toxicity profile (Lin et aL, "Phase II study of flavopiridol in
relapsed chronic
lymphocytic leukemia demonstrating high response rates in genetically high-
risk disease." J.
Clin. Oncol. 27, 6012-6018 (2009); Christian et al., "Flavopiridol in chronic
lymphocytic
leukemia: a concise review." Clin. Lymphoma Myeloma 9 Suppl. 3, S179-S185
(2009)).
In-vitro studies revealed substrate preferences for the different CDK7
complexes,
indicating that CDK7 may form different complexes with different substrate
specificity and
presumably different in-vivo functions (Frit, P. et al., Biochimie 81, 27-38,
(1999); Schutz, P. et
al. Cell 102, 599-607, (2000)).
Various CDK inhibitors have been reported in the literature including
W02006052936
A2, W02007038314A2, W02008119792A1, W02013169401A1, US 20020091263A1 ,
3
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
W02008151304A1, W02010103486A1, W02010003133A2, W02005026129A1,
W02012045195A1, W02007038314A2 etc.
There is a need for new compounds, faimulations, treatments and therapies to
treat
diseases and/or disorders associated with selective transcriptional CDKs
including CDK7,
CDK9, CDK12, CDK13 and CDK18; more particularly CDK7. It is, therefore, an
object of this
invention to provide compounds useful in the treatment and/or prevention or
amelioration of
such diseases and/or disorders.
BRIEF DESCRIPTION OF ACCOMPANYING DRAWINGS:
Figure 1: In vivo antitumor activity of CDK7 inhibitor in the MV4-11 AML
xenograft
model in athymic nude mice.
SUMMARY OF THE INVENTION
Provided herein are pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5 -a]
pyrimidine
derivatives and pharmaceutical compositions thereof, which are useful as
selective
transcriptional CDK inhibitors.
In one aspect of the present invention, it comprises compounds of formula (I):
R,
Nrs,
N N
R2
}IN X LI- (1)
II R6
p (R4) 0 L2 (RAI
or a pharmaceutically acceptable salt or a stereoisomer thereof;
wherein,
X is CH or N;
Ring A is monocyclic or bicyclic aryl, heteroaryl or heterocycloalkyl;
Ring B is cycloalkyl, heterocycloalkyl, aryl, heteroaryl or absent;
R1 is hydrogen, alkyl or cycloalkyl;
R2 is an optionally substituted alkyl, cycloalkyl or heterocycloalkyl; wherein
the optional
substituents are amino, halo, hydroxy, alkyl, alkoxy, alkoxyalkoxy,
alkylamino, cyano, nitro or
haloalkyl;
4
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
R3 at each occurrence independently is halo, alkyl, hydroxy, alkoxy, amino,
alkylamino,
cyano, nitro or haloalkyl;
R4 at each occurrence independently is halo, alkyl, hydroxy, alkoxy, -(NH)q-
S(0)2-
R5 R5" R5"
R5
CH=CH2, -(NH)q-CH2-CH=CH-C(0)-NRaRb, c) R5 or 0 R5 or 0
wherein R5 and R5"at each occurrence independently are hydrogen or alkyl; R5'
is hydrogen,
halo, alkyl, alkoxyalkyl or -CH2-NRaRb;
R6 is hydrogen or alkyl;
R2 and Rb are independently hydrogen or alkyl; or Ra and Rb along with the
nitrogen atom
to which they are attached form an optionally substituted heterocyclic ring
having 0-2 additional
heteroatoms selected from 0, S and N; wherein the optional substituent is one
or more alkyl or
halo;
L1 is -0-, -S-, -NH- or absent;
L2 is absent or optionally substituted C1-C6 alkylene, wherein one or more
methylene
units of the alkylene is optionally and independently replaced with -C(0)-, -0-
, -N(R7)- or
cycloalkylene; wherein R7 is hydrogen or alkyl;
m is 0 to 1;
n is 0, 1 or 2;
p is 1, 2 or 3; and
q is 0 to 1.
In another aspect, the present invention provides a pharmaceutical composition
comprising the compound of formula (I) and atleast one pharmaceutically
acceptable excipient
(such as a pharmaceutically acceptable carrier or diluent).
In yet another aspect, the present invention relates to the preparation of
compounds of
formula (O.
In yet another aspect of the present invention, provided herein are
pyrazolo[1,5-
a][ 1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives of formula (I),
which are useful for
medical use. In particular for the treatment or prevention of diseases and/or
disorders where
selective transcriptional CDK inhibition is desired.
5
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
DETAILED DESCRIPTION OF THE INVENTION
Unless defined otherwise, all technical arid scientific terms used herein have
the same
meaning as is commonly understood by one of skill in art to which the subject
matter herein
belongs. As used in the specification and the appended claims, unless
specified to the contrary,
the following terms have the meaning indicated in order to facilitate the
understanding of the
present invention.
As used herein, the term "optionally substituted" or "suitable groups" refers
to
replacement of one or more hydrogen radicals in a given structure with a
radical of a specified
substituent including, but not limited to: halo, alkyl, alkenyl, alkynyl,
aryl, heterocyclyl, thiol,
alkylthio, arylthio, alkylthioalkyl, arylthioalkyl, alkylsulfonyl,
alkylsulfonylalkyl,
arylsulfonylalkyl, alkoxy, aryloxy, aralkoxy, aminocarbonyl,
alkylaminocarbonyl,
arylaminocarbonyl, alkoxycarbonyl, aryloxycarbonyl, haloalkyl, amino, cyano,
nitro,
alkylamino, arylamino, alkylaminoalkyl, arylaminoalkyl, aminoalkylamino,
hydroxy,
alkoxyalkyl, carboxyalkyl, alkoxycarbonylalkyl, aminocarbonylalkyl, acyl,
aralkoxycarbonyl,
carboxylic acid, sulfonic acid, sulfonyl, phosphonic acid, aryl, heteroaryl
and heterocyclic. It is
understood that the substituent may be further substituted.
As used herein, unless otherwise defined the term "alkyl" alone or in
combination with
other term(s) means saturated aliphatic hydrocarbon chains, including C1-C10
straight or Ci-Cio
branched alkyl groups. Examples of "alkyl" include but are not limited to
methyl, ethyl, propyl,
isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, isopentyl or neopentyl and
the like.
As used herein, the term "halo" or "halogen" alone or in combination with
other teint(s)
means fluorine, chlorine, bromine or iodine.
The term "hydroxy" or "hydroxyl" refers to ¨OH group.
The term "amino" refers to ¨NH2 group.
As used herein, the term "alkoxy" or "alkoxyl" refers to the group alkyl-0- or
-0-alkyl,
where alkyl groups are as defined above. Exemplary C1-C10 alkyl group
containing alkoxy
groups include but are not limited to methoxy, ethoxy, n-propoxy, n-butoxy, t-
butoxy and the
like. An alkoxy group can be unsubstituted or substituted with one or more
suitable groups.
As used herein, the term "alkoxylalkoxy" refers to the group alkyl-O-alkoxy-
or -alkoxy-
0-alkyl, where alkoxy groups are defined above. Exemplary alkoxylalkoxy groups
include but
6
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
are not limited to methoxyethoxy, ethoxyethoxy, methoxypropoxy, ethoxymethoxy,
ethoxypropoxy, propoxymethoxy, propoxyethoxy and the like.
As used herein, the term "cycloalkyl" alone or in combination with other
term(s) means -
C3-C10 saturated cyclic hydrocarbon ring. A cycloalkyl may be a single ring,
which typically
contains from 3 to 7 carbon ring atoms. Examples of single-ring cycloalkyls
include but are not
limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and
the like. A
cycloalkyl may alternatively be polycyclic or contain more than one ring.
Examples of
polycyclic cycloalkyls include bridged, fused and spirocyclic carbocyclyls and
the like.
As used herein, the term "aryl" is optionally substituted monocyclic, bicyclic
or
polycyclic aromatic hydrocarbon ring system of about 6 to 14 carbon atoms.
Examples of a C6-
C14 aryl group include, but are not limited to phenyl, naphthyl, biphenyl,
anthryl,
tetrahydronaphthyl, fluorenyl, indanyl, biphenylenyl and acenaphthyl. Aryl
group can be
unsubstituted or substituted with one or more suitable groups.
The term "heterocycloalkyl" refers to a non-aromatic, saturated or partially
saturated,
monocyclic or polycyclic ring system of 3 to 15 members having at least one
heteroatom or
heterogroup selected from 0, N, S, S(0), S(0)2, NH or C(0) with the remaining
ring atoms
being independently selected from the group consisting of carbon, oxygen,
nitrogen and sulfur.
Examples of "Heterocycloalkyl" include, but are not limited to azetidinyl,
oxetanyl,
imidazolidinyl, pyrrolidinyl, oxazolidinyl, thiazolidinyl, pyrazolidinyl,
tetrahydrofuranyl,
piperidinyl, piperazinyl, tetrahydropyranyl, morpholinyl, oxapiperazinyl,
oxapiperidinyl,
tetrahydrofuryl, tetrahydropyranyl, tetrahydrothiophenyl, dihydropyranyl,
indolinyl,
indolinylmethyl, azepanyl and their N-oxides thereof. Attachment of a
heterocycloalkyl
substituent can occur via either a carbon atom or a heteroatom. A
heterocycloalkyl group can be
optionally substituted with one or more suitable groups by one or more
aforesaid groups.
As used herein, the term "heteroaryl" alone or in combination with other
term(s) means a
completely unsaturated ring system containing a total of 5 to 14 ring atoms.
At least one of the
ring atoms is a heteroatom (i.e., oxygen, nitrogen or sulfur), with the
remaining ring
atoms/groups being independently selected from the group consisting of carbon,
oxygen,
nitrogen or sulfur. A heteroaryl may be a single-ring (monocyclic), bicyclic
or polycyclic ring
system. Examples of "heteroaryl" include but are not limited to pyridyl,
pyridine- 1-oxide,
7
CA 02978170 2017-08-29
WO 2016/142855
PCT/11B2016/051302
indolyl, benzimidazolyl, benzothiazolyl and the like. The term heteroaryl
includes their N-
oxides thereof.
The term "heteroatom" as used herein designates a sulfur, nitrogen or oxygen
atom.
As used herein, the term "compound(s)" comprises the compounds disclosed in
the
present invention.
As used herein, the term "comprise" or "comprising" is generally used in the
sense of
include, that is to say permitting the presence of one or more features or
components.
As used herein, the term "or" means "and/or" unless stated otherwise.
As used herein, the term "including" as well as other forms, such as
"include", "includes"
and "included" is not limiting.
As used herein, the term "composition" is intended to encompass a product
comprising
the specified ingredients in the specified amounts, as well as any product
which results, directly
or indirectly, from combination of the specified ingredients in the specified
amounts. By
"pharmaceutically acceptable" it is meant the carrier, diluent or excipient
must be compatible
with the other ingredients of the formulation and not deleterious to the
recipient thereof.
As used herein, the term "treat", "treating" and "treatment" refer to a method
of
alleviating or abrogating a disease and/or its attendant symptoms.
As used herein, the term "prevent", "preventing" and "prevention" refer to a
method of
preventing the onset of a disease and/or its attendant symptoms or barring a
subject from
acquiring a disease. As used herein, "prevent", "preventing" and "prevention"
also include
delaying the onset of a disease and/or its attendant symptoms and reducing a
subject's risk of
acquiring a disease.
As used herein, the term "subject" to which administration is contemplated
includes, but
are not limited to humans and/or non-human animals; for example, mammals and
birds. In
certain embodiments the animal is mammal. A non-human animal may be transgenic
animal.
As used herein, the term "administer", "administering" or "administration"
refers to
implanting, absorbing, ingesting, injecting, inhaling or otherwise introducing
a compound of
formula (I) or a pharmaceutical composition thereof.
8
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
As used herein, the term "therapeutically effective amount" refers to that
amount of the
compound being administered sufficient to prevent development of or alleviate
to some extent
one or more of the symptoms of the condition or disorder being treated.
"Pharmaceutically acceptable" means that, which is useful in preparing a
pharmaceutical
composition that is generally safe, non-toxic and neither biologically nor
otherwise undesirable
and includes that which is acceptable for veterinary as well as human
pharmaceutical use.
The term "stereoisomers" or "isomers" refers to any enantiomers,
diastereoisomers or
geometrical isomers of the compounds of formula (I), (IA), (IB), (IC), (ID),
(lb) and (IF);
wherever they are chiral or when they bear one or more double bonds. When the
compounds of
the formula (I), (IA), (IB), (IC), (ID), (IE) and (IF); and related formulae
are chiral, they can
exist in racemic or in optically active form. It should be understood that the
invention
encompasses all stereochemical isomeric forms, including diastereomeric,
enantiomeric and
epimeric forms, as well as d-isomers and /-isomers and mixtures thereof.
Individual
stereoisomers of compounds can be prepared synthetically from commercially
available starting
materials which contain chiral centers or by preparation of mixtures of
enantiomeric products
followed by separation such as conversion to a mixture of diastereomers
followed by separation
or recrystallization, chromatographic techniques, direct separation of
enantiomers on chiral
chromatographic columns or any other appropriate method known in the art.
Starting compounds
of particular stereochemistry are either commercially available or can be made
and resolved by
techniques known in the art. Additionally, the compounds of the present
invention may exist as
geometric isomers. The present invention includes all cis, trans, syn, anti,
entgegen (E) and
zusammen (Z) isomers as well as the appropriate mixtures thereof.
As used heren the term "CDK" refers to a cyclin-dependent kinase. A CDK binds
a cyclin
(e.g. , Cyclin H), which is a regulatory protein. CDKs phosphorylate their
substrates at serines
and threonines. CDKs include CDK1, CDK2, CDK2, CDK4, CDK5, CDK7, CDK8, CDK9,
CDK10, CDK11, CDK12, CDK13, CDK14, CDK16, CDK18 and CDK20. CDK7 is a CDK
wherein the substrate is Cyclin H, MAT! (e.g., MNAT1) or Cyclin H and MAT1
complex. The
term CDK inhibitor refers to selective transcriptional CDK inhibitor.
The present invention provides substituted pyrazolo[1,5-a][1,3,5]triazine and
pyrazolo[1,5-a]pyrimidine derivatives of formula (I), which are useful for the
inhibition of
9
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
selective transcriptional CDKs, particularly selective transcriptional CDK7,
CDK9, CDK 12,
CDK13 or CDK18, more particularly selective transcriptional CDK7.
The present invention further provides pharmaceutical compositions comprising
the said
substituted pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine
compounds and their
derivatives as therapeutic agents.
According to first embodiment, the present invention provides compounds of
formula (I)
R
N
MN X 1:1-R2
(I)
OA 0 R6
p ( R4) 111. L _2 (RDn
or a pharmaceutically acceptable salt or a stereoisomer thereof;
wherein,
X is CH or N;
Ring A is monocyclic or bicyclic aryl, heteroaryl or heterocycloalkyl;
Ring B is cycloalkyl, heterocycloalkyl, aryl, heteroaryl or absent;
R1 is hydrogen, alkyl or cycloalkyl;
R2 is an optionally substituted alkyl, cycloalkyl or heterocycloalkyl; wherein
the optional
substituents are amino, halo, hydroxy, alkyl, alkoxy, alkoxyalkoxy,
alkylamino, cyano, nitro or
haloalkyl;
R3 at each occurrence independently is halo, alkyl, hydroxy, alkoxy, amino,
alkylamino,
cyano, nitro or haloalkyl;
R4 at each occurrence independently is halo, alkyl, hydroxy, alkoxy, -(NH)q-
S(0)2-
R5 R5" R5"
R5
V.I.T.-ky. R5' Aii-j-\T-R5'
CH=CH2, -(NH)q-CH2-CH=CH-C(0)-NRaRb, 0 R5 or 0 R5 or 0
wherein R5 and R5 "at each occurrence independently are hydrogen or alkyl; R5'
is hydrogen,
halo, alkyl, alkoxyalkyl or -CH2-NRaRb;
R6 is hydrogen or alkyl;
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
Ra and Rb are independently hydrogen or alkyl; or Ra and Rb along with the
nitrogen atom
to which they are attached form an optionally substituted heterocyclic ring
having 0-2 additional
heteroatoms selected from 0, S and N; wherein the optional substituent is one
or more alkyl or
halo;
L1 is -0-, -S-, -NH- or absent;
L.2 is absent or optionally substituted C1-C6 alkylene, wherein one or more
methylene
units of the alkylene is optionally and independently replaced with -C(0)-, -0-
, -N(127)- or
cycloalkylene; wherein R7 is hydrogen or alkyl;
m is 0 to 1;
n is 0, 1 or 2;
p is 1, 2 or 3; and
q is 0 to!.
In another embodiment of the present invention, the compound of formula (I) is
a
compound of formula (IA):
RI
'1\1, N
1IN N L--(R2 (IA)
0 0 R6
p(R4) L2 (R3)n
or a pharmaceutically acceptable salt thereof or a stereoisomer thereof;
wherein,
ring A, ring B, L1, L2, R1, R2, R3, Itt, R6, m, n and p are same as defined in
formula (I).
In yet another embodiment of the present invention, the compound of formula
(I) is a
compound of formula (IB):
11
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
RI
Nq
N N
HN X 12-1-R2
(1B)
T p(R4) -2 rist, m
R6
(RAI
or a pharmaceutically acceptable salt thereof or a stereoisomer thereof;
wherein,
X, ring B, L1, L2, RI, R2. R3, R4, R6, m, n and p are same as defined in
formula (I).
In yet another embodiment of the present invention, the compound of formula
(I) is a
compound of formula (IC):
Ri
Nq
N
_IL
HN X Nr-R2
0 R6
p (R4) L2 (R3)n (IC)
or a pharmaceutically acceptable salt thereof or a stereoisomer thereof;
wherein,
R2 is optionally substituted cycloalkyl or optionally substituted
heterocycloalkyl;
X, ring A, ring B, L2, RI, R3, 1(4, R6, m, n and p are same as defined in
formula (I).
In another embodiment of the present invention, the compound of formula (I) is
a
compound of formula (ID):
Ri
Nq
N N
...A. _I(
FIN X N'R2
p(R4) L2 (ID)
R6
(R3)n
or a pharmaceutically acceptable salt thereof or a stereoisomer thereof;
wherein,
12
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
R2 is optionally substituted cycloalkyl or optionally substituted
heterocycloalkyl;
X, ring B, L2, R1, R3/ R4, R6, m, n and p are same as defined in formula (I).
In another embodiment of the present invention, the compound of formula (I) is
a
compound of formula (ih):
N,4-11
N N
HNx0 ( p(R4) 1E)
R6
(R3)n
or a pharmaceutically acceptable salt thereof or a stereoisomer thereof;
wherein,
X, ring B, L., R1 R3, Ita, R6, In, n and p are same as defined in formula (I).
In another embodiment of the present invention, the compound of formula (I) is
a
compound of formula (IF):
RI
N N
HN,1*...x,L--r- R2
(IF)Nm
R6
(R3)n
(R4)p
or a pharmaceutically acceptable salt thereof or a stereoisomer thereof;
wherein,
X, L1, R1, R2, R3, Rit, R6, m, n and p are same as defined in formula (I).
According to one embodiment, the present invention provides compounds of
foimula (I)
and (IA); wherein, ring A is aryl; and ring B, X, L1, L2, R1, R2, R3, R4, R6,
m, n and p are same as
defined in formula (I).
According to another embodiment the present invention provides compounds of
formula
(I) and (IA); wherein ring A is monocyclic or bicyclic heteroaryl or
heterocycloalkyl and their N-
13
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
oxides thereof; and ring B, X, LI, I-2, RI, R2, R3, R4, R6, m, n and p are
same as defined in formula
(I).
According to yet another embodiment the present invention provides compounds
of
formula (I), (IB), (IC), (ID), (IE) and (IF); wherein X is N.
According to yet another embodiment the present invention provides compounds
of
formula (I), (IA), (TB), (IC), (ID) and (IE); wherein, L2 is absent or
selected from -NHC(0)-, -
o
N
)()
C(0)NH-, -0C(0)-, H 7 9 " and
According to yet another embodiment the present invention provides compounds
of
formula (I), (IA), (TB), (IC), (ID) and (lE); wherein ring B is absent or
selected from phenyl,
cyclohexyl, piperidinyl, pyrrolidinyl, azitidinyl, 1-methyl-1H-pyrazole,
piperazinyl and
morpholinyl.
The embodiments below are illustrative of the present invention and are not
intended to
limit the claims to the specific embodiments exemplified.
According to certain embodiments of the present invention, specifically
provided are
compounds of formula (I), (IA), (TB), (IC), (ID), (IE) and (IF); wherein, R1
is hydrogen, alkyl or
cycloalkyl; preferably the said alkyl is ethyl or isopropyl and the said
cycloalkyl is cyclopropyl.
According to certain embodiments of the present invention, specifically
provided are
compounds of foimula (I), (IA), (M) (IC), (ID), (IE) and (IF); wherein, R2 is
optionally
substituted cycloalkyl or heterocycloalkyl; preferably optionally substituted
cycloalkyl is
OH
\eja \eõ...1:121\
HH2 .
or \ and i
, n
particular optionally substituted
NH
0 NH
heterocycloalkyl is \ \ F
ss<cll
N¨ 0
7 \ or
7
14
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
According to certain embodiments of the present invention, specifically
provided are
compounds of formula (I), (IA), (TB), (IC), (ID), (IE) and (IF); wherein, R2
is alkyl optionally
substituted with amino, alkoxy or alkoxylalkoxy; preferably R2 is methyl,
aminobutyl,
methoxyethyl, isobutanyl and methoxyethoxyethyl. .
According to certain embodiments of the present invention, specifically
provided are
compounds of formula (I), (IA), (TB), (IC), (ID), (IE) and (IF); wherein, 1245
is hydrogen or alkyl;
preferably the said alkyl is methyl.
According to certain embodiments of the present invention, specifically
provided are
compounds of formula (I), (IA) and (IC); wherein, ring A is phenyl,
piperidinyl, pyridyl and
pyridine-N-oxide.
According to certain embodiments of the present invention, specifically
provided are
compounds of formula (I), (IA), (TB), (IC), (ID), (IE) and (IF); wherein, R3
is halo or alkyl;
preferably the said halo is fluoro and the said alkyl is methyl or ethyl.
According to certain embodiments of the present invention, specifically
provided are
compounds of formula (I), (IA), (I13), (IC), (ID), (IE) and (IF); wherein, R4
is -(NH)q-S(0)2'
R5 Rs'' R5"
R5
?elrci,....R5I
or
CH=CH2, ¨(NH)q¨CH2-CH=CH-C(0)-NRaRb, 0 R5 Li R5 Or 0
and R5, R5I, R5", R., Rb and q are same as defined in formula (I).
According to the preceding embodiment, specifically provided are compounds of
formula
(I), (IA), (IB), (IC), (ID), (IE) and (IF); wherein, R4 is
0 0 0 0
N s.)0y
\ \
7 7 \ 7 =
7
0 0 0
N
N \
0
7 7 9
0 0
N 0 I
11
N riI I
0 0
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
0
11 H
0 0 0
N ) N )=======11-----F
Tf
'NF or
9 9 9
0 0 0
F
ss=
9
According to certain embodiments, the present invention provides compounds of
the
formula (I) in which m' and 'n' are independently 0 or 1; and 'p' is 1.
According to certain embodiments, the present invention provides a compound
selected
from the group consisting of:
Compound
IUPAC name
No:
1. 1-acryloyl-N-(3-(((8-isopropy1-2-((tetrahydro-2H-pyran-4-
yDamino)pyrazolo[1,5-
a][1,3,5]triazin-4-yDamino)methyl)phenyppiperidine-3-carboxamide;
2. 1-acryloyl-N-(3-(48-isopropy1-2-((tetrahydro-2H-pyran-4-yDamino)pyrazolo
[1,5-
a][1,3,5]triazin-4-yl)amino)methyl)phenyl)azetidine-2-carboxamide;
3. 1-acryloyl-N-(3-(((8-isopropy1-2-((tetrahydro-2H-pyran-4-
yl)amino)pyrazolo [1,5-
a][1,3,5]triazin-4-yl)amino)methyl)phenyl)pyrrolidine-2-carboxamide;
4. 1-acryloyl-N-(3-(48-isopropy1-2-((tetrahydro-2H-pyran-4-yDamino)pyrazolo
[1,5-
a][1,3,5]triazin-4-yl)amino)methyl)phenyl)pyrrolidine-3-carboxamide;
5. Isomer-1:, 1-acryloyl-N-(34(8-isopropy1-2-((tetrahydro-2H-pyran-4-yDamino)
pyrazolo[1,5-a][1,3,5]triazin-4-ypainino)methyl)phenyppyrrolidine-3-
carboxamide;
6. Isomer-2: 1-acryloyl-N-(3-(((8-isopropy1-2-((tetrahydro-2H-pyran-4-
yDamino)
pyrazolo[1,5-a][1,3,5]triazin-4-yDamino)methyl)phenyppyrrolidine-3-
carboxamide;
16
CA 02978170 2017-08-29
WO 2016/142855 PCT/1112016/051302
7. ( 1,4-cis)-4-acrylamido-N-(3 -4(8-isopropy1-2-((tetrahydro-2H-pyran-4-
yl)amino)pyrazolo [ 1,5-a][ 1,3,5 ]triazin-4-yl)amino)methyl)phen
yl)cyclohexane-1 -
carboxamide;
8. 1-acryloyl-N-(3-(((8-isopropyl-2-(( 1-methylpiperidin-4-
yDamino)pyrazolo[ 1,5-
a] [ 1,3, 5]triazin-4-yDamino)methyl)phenyppiperidine-3-c arboxamide;
9. (1,4-cis)-4-acrylamido-N-(3-(((2-(((1r,40-4-hydroxycyclohexypamino)-8-
isopropylpyrazolo[1,5-a] [1,3,5 ]triazin-4-yDamino)methypphenyl)cyclohexane- 1-
carboxamide;
10. Isomer-1: 4-acrylamido-N-(3-4(2-((3-hydroxycyclohexypamino)-8-
isopropyl
pyrazolo[ 1,5-a] [ 1,3,5]triazin-4-yDamino)methyl)phenyl)cyclohexane- 1-
carboxamide;
11. Isomer-2: 4-acrylamido-N-(3-(((2((3-hydroxycyclohexypamino)-8-
isopropyl
pyrazolo[ 1,5-a][1,3,5]triazin-4-yparnino)methyl)phenyl)cyclohexane- 1 -
carboxamide;
12. Isomer-1: 1-acryloyl-N-(3-(((2-((3-hydroxycyclohexyl)amino)-8-
isopropyl
pyrazolo[ 1,5-a] [ 1,3,5]tri azin-4-yDamino)methyl)phenyl)pyrrolidine-3-
carboxamide;
13. Isomer-2: 1-acryloyl-N-(3-(42-((3-hydroxycyclohexypamino)-8-
isopropyl
pyrazolo[ 1,5-a] [ 1,3,5]triazin-4-yl)amino)methyl)phenyppyrrolidine-3-
carboxamide;
14. 1-acryloyl-N-(3-(((2-(((3S,4S)-3-fluoropiperidin-4-yl)amino)-8-
isopropyl
pyrazolo[ 1,5-a] [ 1,3,5]tri azin-4-yDamino)methyl)phenyl)pyrrolidine-3-
carboxamide;
15. 1 -acryloyl-N-(3-(((24(3-aminocyclohexyparnino)-8-isopropylpyrazolo[
1,5-
a] [ 1,3, 5]triazin-4-yl)amino)methyl)phenyl)pyrrolidine-3-carboxamide;
16. 1-acryloyl-N-(3-(((8-isopropy1-2-((tetrahydro-2H-pyran-3-
yDamino)pyrazolo [1,5-
a] [ 1,3, 5]triazin-4-yDamino)methyl)phenyl)piperidine-2-c arboxamide;
17. N-(3 -(((8-isopropy1-2-((tetrahydro-2H-pyran-4-yDamino)pyrazolo[1,5 -
a][ 1,3, 5]triazin-4-y1)amino)methy1) phenyl)- 1-(3-methylbut-2-enoyl)azetich
ne-2-
17
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
carboxamide;
18. 1-acryloyl-N-(3-(48-isopropy1-2-((tetrahydro-2H-pyran-4-
yparnino)pyrazolo[1,5-
a][1,3,5]triazin-4-yDamino)methyl)phenypazetidine-3-carboxamide;
19. (R)-1-acryloyl-N-(3-(((8-isopropy1-2-((tetrahydro-2H-pyran-4-
yDamino)pyrazolo[1,5-a][1,3,5]triazin-4-yDamino)methypphenypazetidine-2-
carboxamide;
20. (S)-1-acryloyl-N-(3-(((8-isopropy1-2-((tetrahydro-2H-pyran-4-
yDamino)pyrazolo[1,5-a][1,3,5]triazin-4-yDamino)methypphenypazetidine-2-
carboxamide;
21. 1-acryloyl-N-(3-(((8-isopropy1-2-((tetrahyclro-2H-pyran-4-
yDamino)pyrazolo[1,5-
a][1,3,5]triazin-4-yDamino)methyl)phenyppiperidine-2-carboxamide;
22. 3-acrylamido-N-(3-4(8-isopropy1-2-((tetrahydro-2H-pyran-4-
yDamino)pyrazolo[1,5-a][1,3,5]triazin-4-yDamino)methypphenyl)cyclohexane-1-
carboxamide;
23. 4-acryloyl-N-(3-(((8-isopropy1-2-((tetrahydro-2H-pyran-4-
yDamino)pyrazolo[1,5-
a][1,3,5]triazin-4-yDamino)methyl)phenyl)morpholine-2-carboxamide;
24. 4-acryloyl-N-(3-(((8-isopropy1-2-((tetrahydro-2H-pyran-4-
yDamino)pyrazolo[1,5-
a][1,3,5]triazin-4-yDamino)methypphenyl)morpholine-3-carboxamide;
25. N-(3-(((8-isopropy1-2-((tetrahydro-2H-pyran-4-yl)amino)pyrazolo[1,5-
a][1,3,5]triazin-4-yDamino)methyl)pheny1)-4-propioloylmorpholine-3-
c arboxamide;
26. 4-acryloyl-N-(4-ethy1-3-(08-isopropy1-2-((tetrahydro-2H-pyran-4-
yDamino)
pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl)morpholine-3-
carboxamide;
27. 1-acryloyl-N-(3-(((8-isopropy1-2-((tetrahydro-2H-pyran-4-
yDamino)pyrazolo[1,5-
a][1,3,5]triazin-4-yDamino)methyl)-4-methylphenyl)azetidine-2-carboxamide;
28. 1-acryloyl-N-(5-(((8-isopropy1-2-((tetrahydro-2H-pyran-4-
yDamino)pyrazolo[1,5-
a][1,3,5]triazin-4-yDamino)methyl)-2-methylphenypazetidine-2-carboxamide;
29. 1-acryloyl-N-(4-fluoro-3-(((8-isopropy1-2-((tetrahydro-2H-pyran-4-
yDamino)
18
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
pyrazolo[1,5-a][1,3,5]triazin-4-yDamino)methyl)phenypazetidine-2-carboxamide;
30. 1-acryloyl-N-(2-fluoro-3-(((8-isopropy1-2-((tetrahydro-2H-pyran-4-
yl)amino)
pyrazolo[1,5-a] [1,3,5]tri azin-4-yl)amino)methyl)phenyl)azetidine-2-carbox
amide ;
31. 1-acryloyl-N-(3-fluoro-5-(48-isopropy1-2-((tetrahydro-2H-pyran-4-
yDamino)
pyrazolo[1,5-a][1,3,5]triazin-4-yDamino)methypphenyl)azetidine-2-carboxamide;
32. 1-acryloyl-N-(4-fluoro-3-(((8-isopropy1-2-((tetrahydro-2H-pyran-4-
yl)arnino)
pyrazolo[1,5-a][1,3,5]triazin-4-yDamino)methyl)phenyl)pyrrolidine-3-
carboxamide;
33. 1-acryloyl-N-(3-fluoro-5-(48-isopropy1-2-((tetrahydro-2H-pyran-4-
y1)amino)
pyrazolo[1,5-a][1,3,5]triazin-4-yDamino)methyl)phenyl)pyrrolidine-3-
carboxamide;
34. 1-acryloyl-N-(3-(48-isopropy1-2-((tetrahydro-2H-pyran-4-
yDamino)pyrazolo [1,5-
a][1,3,51triazin-4-yl)amino)methyl)-4-methylphenyl)piperidine-2-carboxamide;
35. 1-acryloyl-N-(2-fluoro-3-(48-isopropy1-2-((tetrahydro-2H-pyran-4-
yl)amino)
pyrazolo[1,5-a][1,3,5]triazin-4-yDamino)methyl)phenyl)piperidine-2-
carboxamide;
36. 1-acryloyl-N-(3-fluoro-5-(((8-isopropy1-2-((tetrahydro-2H-pyran-4-
yl)amino)
pyrazolo[1,5-a] [1,3,5] triazin-4-yDamino)methyl)phenyl)piperidine-2-
carboxamide;
37. 1-acryloyl-N-(4-fluoro-3-0(8-isopropy1-2-((tetrahydro-2H-pyran-4-
yl)amino)
pyrazolo[1,5-a][1,3,5]triazin-4-yDamino)methyl)phenyl)piperidine-2-
carboxamide;
38. (1,4-cis)-4-acrylamido-N-(2-fluoro-3-(((8-isopropy1-2-((tetrahydro-2H-
pyran-4-
yl)amino)pyrazolo[1,5-a][1,3,5]triazin-4-yDamino)methypphenyl)cyclohexane-1-
carboxamide;
39. (1,4-cis)-4-acrylamido-N-(4-fluoro-3-(((8-isopropyl-2-((tetrahydro-2H-
pyran-4-
yDamino)pyrazolo[1,5-a][1,3,5]triazin-4-yDamino)methypphenyl)cyclohexane-l-
carboxamide;
40. 4-acryloyl-N-(5-(((8-isopropy1-2-((tetrahydro-2H-pyran-4-
yl)amino)pyrazolo [1,5-
19
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
a] [1,3,5] triazin-4-yDamino)methyppyridi n-3-yl)morpholine-3-c arboxamide;
40A. 3-acryl amido-N-(3-4( 8-i sopropy1-2-((tetrahydro-2H-pyran-4-yDamino)
pyrazolo[1,5-a] [1,3,5] tri azin-4-yl)amino)methyl)pheny1)-4-methylbenz ami de
;
40B. 5-acryl amido-N-(3-4( 8-i sopropy1-2-((tetrahydro-2H-pyran-4-yDamino)
pyrazolo[1,5-a] [1,3,5] tri azin-4-yDamino)methyppheny1)-2-methylbenzamide ;
40C. 1-acryloyl-N-(3-(48-isopropy1-2-((tetrahydro-2H-pyran-4-
yDamino)pyrazolo [1,5-
a] [1,3,5] triazin-4-yDamino)methyppheny1)-6-methylpiperidine-2-carboxamide;
40D. 1-acryloyl-N-(3-0(8-isopropy1-2-(((S)-tetrahydro-2H-pyran-3-yl)amino)
pyrazolo[1,5-a][1,3,5]triazin-4-yDamino)methyl)phenyl)piperidine-2-
carboxamide;
40E. 1-acryloyl-N-(3-0(8-isopropy1-2-(((R)-tetrahydro-2H-pyran-3-yDamino)
pyrazolo[1,5-a] [1,3,5] tri azin-4-yDamino)methyl)phenyppiperidine-2-
c arboxamide;
41. (S)-N-(1-acryloylpiperidin-3-y1)-3-(((8-isopropy1-2-((tetrahydro-2H-
pyran-4-
yDamino)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methy1)benzamide;
42. 1-acryloyl-N-(4-fluoro-3-0(8-isopropy1-2-((tetrahydro-2H-pyran-4-
yDamino)pyrazolo[1,5-a][1,3,5]triazin-4-yDamino)methypphenypazetidine-2-
carboxamide;
43. 1-acryloyl-N-(2-fluoro-5-(48-isopropy1-2-((tetrahydro-2H-pyran-4-
yl)amino)
pyrazolo[1,5-a] [1,3,5] tri azin-4-yDamino)methyl)phenyppyrroli dine-3 -
c arboxamide;
44. 1-acryloyl-N-(2-fluoro-5-(48-isopropy1-2-((tetrahydro-2H-pyran-4-
yl)amino)
pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl)piperidine-2-
carboxamide;
45. 1-acryloyl-N-(3-(14(84 sopropy1-2-((tetrahydro-2H-pyran-4-
yl)amino)pyrazolo [1,5-a] [1,3,5]triazin-4-yDamino)ethyl)phen yl)piperidine-3-
c arbox amide ;
46. 3-(08-isopropy1-2-((tetrahydro-2H-pyran-4-yDamino)pyrazolo[1,5-
a] [1,3,5] triazin-4-yl)amino)methyl)phenyl 4-acryloylpiperazine-1 -c arboxyl
ate;
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
47. 3-acrylamido-N-(3-(((8-isopropy1-2-((tetrahydro-2H-pyran-4-yDamino)
pyrazolo[1,5-a][1,3,5]triazin-4-yDamino)methyl)phenyl)benzamide;
48. 2-acrylamido-N-(3-(((8-isopropy1-2-((tetrahydro-2H-pyran-4-yl)amino)
pyrazolo[1,5-a][1,3,51triazin-4-yl)amino)methyl)phenyl)benzamide;
48A. 3-acrylamido-N-(3-0(8-isopropy1-2-((tetrahydro-2H-pyran-4-yl)amino)
pyrazolo[1,5-a][1,3,5]triazin-4-yparnino)methyl)pheny1)-2-methylbenzamide;
49. (E)-44(3-(((8-isopropy1-2-((tetrahydro-2H-pyran-4-yDamino)pyrazolo[1,5-
a][1,3,5]triazin-4-yl)amino)methyl)phenyl)amino)-N,N-dimethylbut-2-enamide;
50. (E)-4-(diethylamino)-N-(3-(((8-isopropy1-2-((tetrahydro-2H-pyran-4-
yDamino)pyrazolo[1,5-a][1,3,5]triazin-4-yDamino)methypphenyl)but-2-enamide;
51. (E)-N-(3-(((8-isopropy1-2-((tetrahydro-2H-pyran-4-yDamino)pyrazolo[1,5-
a][1,3,5]triazin-4-yDamino)methyl)pheny1)-4-morpholinobut-2-enamide;
52. (E)-4-(4-ethylpiperazin-1-y1)-N-(34(8-isopropy1-2-((tetrahydro-2H-pyran-
4-
yDamino)pyrazolo[1,5-a][1,3,5]triazin-4-ypainino)methyl)phenyl)but-2-enamide;
53. (E)-4-(dimethylamino)-N-(3-(((8-isopropy1-2-((tetrahydro-2H-pyran-4-
yDamino)pyrazolo[1,5-a][1,3,5]triazin-4-yDamino)methyl)phenyl)but-2-enamide;
54. (E)-N-(34((8-isopropy1-2-((tetrahydro-2H-pyran-4-yDamino)pyrazolo[1,5-
a][1,3,5]triazin-4-yDamino)methyl)pheny1)-4-(pyrrolidin-1-yl)but-2-enamide;
55. (E)-N-(3-(((8-isopropy1-2-((tetrahydro-2H-pyran-4-yl)amino)pyrazolo[1,5-
a][1,3,5]triazin-4-yDamino)methyl)pheny1)-4-(piperidin-1-yl)but-2-enamide;
56. (E)-4-(3-fluoropyrrolidin-1-y1)-N-(3-4(8-isopropy1-2-((tetrahydro-2H-
pyran-4-
yDamino)pyrazolo[1,5-a][1,3,5]triazin-4-yDamino)methypphenyl)but-2-enamide;
57. (E)-4-(3,3-difluoropyrrolidin-1-y1)-N-(3-(48-isopropyl-2-((tetrahydro-
2H-pyran-
4-yDamino)pyrazolo[1,5-a][1,3,5]triazin-4-y1)amino)methyl)phenyl)but-2-
enamide;
58. (E)-4-(3-fluoropiperidin-1-y1)-N-(3-(((8-isopropy1-2-((tetrahydro-2H-
pyran-4-
yDamino)pyrazolo[1,5-a][1,3,5]triazin-4-yDamino)methyl)phenyl)but-2-enamide;
59. (E)-4-(dimethylamino)-N-(3-fluoro-5-(((8-isopropy1-2-((tetrahydro-2H-
pyran-4-
yDamino)pyrazolo[1,5-a][1,3,5]triazin-4-yDamino)methypphenyl)but-2-enamide;
21
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
60. (E)-4-(dimethylamino)-N-(2-fluoro-3-(((8-isopropy1-2-((tetrahydro-2H-
pyran-4-
yl)amino)pyrazolo [1,5-a] [1,3,5]triazin-4-yl)amino)methyl)phen yl)but-2-
enamide ;
61. (E)-N-(3-fluoro-5-(((8-isopropy1-2-((tetrahydro-2H-pyran-4-yDamino)
pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)pheny1)-4-morpholinobut-2-
enamide;
62. (E)-4-(dimethylamino)-N-(2-4(8-isopropy1-2-((tetrahydro-2H-pyran-4-
yDamino)
pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl)but-2-enamide;
63. (E)-N-(4-(((8-isopropy1-2-((tetrahydro-2H-pyran-4-yDamino)pyrazolo [1,5-
a]
[1,3,5]triazin-4-yDamino)methyl)pheny1)-4-(pyrrolidin-1-yl)but-2-enamide;
64. (E)-1-(4-(dimethylamino)but-2-enoy1)-N-(2-fluoro-5-(((8-isopropy1-2-
((tetrahydro-2H-pyran-4-yDamino)pyrazolo[1,5-a][1,3,5]triazin-4-
yl)amino)methyl)phenyl)pyrrolidine-3-carboxamide;
65. (E)-1-(but-2-enoy1)-N-(3-(((8-isopropy1-2-((tetrahydro-2H-pyran-4-
yeamino)
pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl)azetidine-2-
carboxamide;
66. N-(3 -(((8-isopropyl-2-((tetrahydro-2H-pyran-4-yDamino)pyrazolo[1,5 -a]
[1,3,5]
triazin-4-yl)amino)methyl)pheny1)-1-propioloylazetidine-2-carboxamide;
67. N-(3-(((8-isopropyl-2-((tetrahydro-2H-p yran-4-yDamino)pyrazolo[1,5 -a]
[1,3,5]triazin-4-yl)amino)methyl)phen y1)-1-methacrylo ylazetidine-2-
carbox amide;
68. (E)-N-(3-(((8-isopropy1-2-((tetrahydro-2H-pyran-4-yDamino)pyrazolo [1,5-
a]
[1,3,5]triazin-4-yDamino)methyl)pheny1)-1-(4-methoxybut-2-enoyl)pyrrolidine-3-
carboxamide;
69. (E)-1-(4-(dimethylamino)but-2-enoy1)-N-(3-(((8-isopropy1-2-((tetrahydro-
2H-
pyran-4-yl)amino)pyrazolo[1,5-a][1,3,5]triazin-4-yDamino)methyl)phenyl)
pyrrolidine-3-carbox amide;
70. (E)-1-(4-(dimethylamino)but-2-enoy1)-N-(4-fluoro-3-(((8-isopropy1-2-
((tetrahydro-2H-pyran-4-yDamino)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)
methyl)phenyppyrrolidine-3-c arbox amide ;
71. (E)-1-(4-(dimethylamino)but-2-enoy1)-N-(3-fluoro-5 -(((8-isopropy1-2-
22
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
((tetrahydro-2H-pyran-4-yDamino)pyrazolo[1,5-a][1,3,5]triazin-4-yDamino)
methyl)phenyl)pyrrolidine-3-carboxamide;
72. (E) - 1-(4-(dimethylamino)but-2-enoy1)-N-(3-(1-((8-isopropy1-2-
((tetrahydro-2H-
pyran-4-yl)amino)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)ethyl)phenyl)
piperidine-3-carboxamide;
73. (E)-4-(4-(dimethylamino)but-2-enoy1)-N-(3-(((8-isopropy1-2-((tetrahydro-
2H-
pyran-4-yDamino)pyrazolo[1,5-a][1,3,5]triazin-4-yDamino)methyl)phenyl)
morpholine-3-carboxamide;
74. (E) -1-(4-(dimethylamino)but-2-enoy1)-N-(3-(((8-isopropy1-2-
((tetrahydro-2H-
pyran-4-yDamino)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl)
piperidine-2-carboxamide;
75. 3-(((8-i sopropy1-2-((tetrahydro-2H-pyran-4-yl)amino)pyrazolo[1,5-
a][1,3,5]
triazin-4-yDamino)methyl)phenyl(E)-4-(4-(dimethylamino)but-2-enoyl)
piperazine-l-carboxylate;
76. (E) - 1-(4-(dimethylamino)-4-oxobut-2-en-1-y1)-N-(3-(((8-isopropy1-2-
((tetrahydro-
2H-pyran-4-yDamino)pyrazolo[1,5-a][1,3,51triazin-4-yDamino)methyl)
phenyDazetidine-2-carboxamide;
77. (E)-N-(3-0(8-isopropy1-2-((tetrahydro-2H-pyran-4-yDamino)pyrazolo[1,5-
a][1,3,5]triazin-4-yl)amino)methyl)pheny1)-1-(4-(pyrrolidin-1-yDbut-2-
enoyDpiperidine-2-carboxamide;
78. N-(3-(((8-isopropy1-2-((tetrahydro-2H-pyran-4-yDarnino)pyrazolo[1,5-
a][1,3,5]triazin-4-yl)amino)methyl)pheny1)-1-(vinylsulfonyl)piperidine-2-
carboxamide;
79. N-(2-((3-(((8-isopropy1-2-((tetrahydro-2H-pyran-4-yl)amino)pyrazolo[1,5-
a][1,3,5]triazin-4-yl)amino)methyl)phenyl)amino)-2-oxoethyl)acrylamide;
80. N-(143-(08-isopropy1-2-((tetrahydro-2H-pyran-4-yDamino)pyrazolo[1,5-
a][1,3,5]triazin-4-yDamino)methypphenypamino)-1-oxopropan-2-ypacrylamide;
81. N-(24(3-4(8-isopropy1-2-((tetrahydro-2H-pyran-4-yDamino)pyrazolo[1,5-
a][1,3,5]triazin-4-yDamino)methyl)phenyDatnino)-2-oxoethyl)-N-methyl
acrylamide;
23
CA 02978170 2017-08-29
WO 2016/142855 PCT/1112016/051302
82. N-(1-((3-(((8-isopropy1-2-((tetrahydro-2H-pyran-4-yl)amino)pyrazolo[1,5-
a][1,3,5]triazin-4-yl)amino)methyl)phenyl)amino)-2-methyl-l-oxopropan-2-
yl)acrylamide;
83. 1-acrylamido-N-(3-(08-isopropy1-2-((tetrahydro-2H-pyran-4-
yDamino)pyrazolo
[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl)cyclopropane-1-carboxamide;
84. N-(3-(((8-isopropy1-2-((tetrahydro-2H-pyran-4-yDamino)pyrazolo[1,5-a]
[1,3,5]triazin-4-yDamino)methyl)pheny1)-1-(N-methylacrylamido)cyclopropane -
1-carboxamide;
85. 4-acrylamido-N-(3-4(8-isopropy1-2-((tetrahydro-2H-pyran-4-
yl)amino)pyrazolo
[1,5-a][1,3,5]triazin-4-yl)amino)methyl)pheny1)-1-methyl-1H-pyrazole-3-
carboxamide;
86. 1-acryloyl-N-(3-((8-isopropy1-2-((tetrahydro-2H-pyran-4-
yl)amino)pyrazolo[1,5-
a][1,3,5]triazin-4-yDamino)phenypazetidine-2-carboxamide;
87. (1,4-cis)-4-acrylamido-N-(34(8-isopropy1-2-((tetrahydro-2H-pyran-4-
yDamino)
pyrazolo[1,5-a][1,3,5]triazin-4-yDamino)phenybcyclohexane-1-carboxamide;
88. 1-acryloyl-N-(3-0(8-ethyl-241-methylpiperidin-4-yl)oxy)pyrazolo[1,5-
a][1,3,5]
triazin-4-ybamino)methyl)phenyppiperidine-4-carboxamide;
89. 1-acryloyl-N-(3-(((2-((l-methylpiperidin-4-yl)oxy)pyrazolo [1,5-a]
[1,3,5]triazin-4-
ypamino)methyl)phenyl)piperidine-3-carboxamide;
90. (1,4-cis)-4-acrylamido-N-(3-(((8-ethy1-24(1-methylpiperidin-4-
ypoxy)pyrazolo
[1,5-a] [1,3,5]triazin-4-yDamino)methyl)phenyl)cyclohexane-1-carboxamide;
91. (1,4-trans)-4-acrylamido-N-(3-(48-isopropray1-24(1-methylpiperidin-4-
yl)oxy)
pyrazolo[1,5-a][1,3,5]triazin-4-yDamino)methypphenyl)cyclohexane-l-
carboxamide;
92. Isomer-1: 4-acrylamido-N-(3-(((24(3-fluoro-1-methylpiperidin-4-yDamino)-8-
isopropylpyrazolo [1,5-a] [1,3,51triazin-4-yDamino)methyl)phenyl)cyclohexane-1-
carboxamide;
93. Isomer-2: 4-acrylamido-N-(3-(424(3-fluoro-1-methylpiperidin-4-yl)amino)-8-
isopropylpyrazolo [1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl)cyclohexane-1-
24
CA 02978170 2017-08-29
WO 2016/142855 PCT/1112016/051302
carboxamide;
94. 1-acryloyl-N-(3-(48-isopropy1-241-methylpiperidin-4-ypoxy)pyrazolo[1,5-
a] [1,3,5]triazin-4-yl)amino)methyl)phenyl)azetidine-2-carboxamide;
95. 1-acryloyl-N-(3-(((8-isopropy1-2-((tetrahydro-2H-pyran-4-yDoxy)pyrazolo
[1,5-
a] [1,3,5]triazin-4-yl)amino)methyl)phenyppyrrolidine-3-carboxamide;
96. 1-acryloyl-N-(3-(48-isopropy1-2-((tetrahydro-2H-pyran-4-ypoxy)pyrazolo
[1,5-
a][1,3,5]triazin-4-yDamino)methypphenyl)piperidine-3-c arboxamide;
97. (1,4-cis)-4-acrylamido-N-(3-(08-isopropy1-2-((tetrahydro-2H-pyran-4-
ypoxy)
pyrazolo[1,5-a][1,3,5]triazin-4-yDamino)methyl)phenyl)cyclohexane-1-
carboxamide;
98. Isomer-1: 4-acrylamido-N-(3-M2-((3-fluorotetrahydro-2H-pyran-4-
ypoxy)-8-
isopropylpyrazolo[1,5-a] [1,3,5 ]triazin-4-yDamino)methyl)phenyl)c yclohexane-
1-
carboxamide;
99. Isomer-2: 4-acrylamido-N-(34((24(3-fluorotetrahydro-2H-pyran-4-
ypoxy)-8-
isopropylpyrazolo[1,5-a][1,3,51triazin-4-yDamino)methypphenypcyclohexane-1-
carboxamide;
100. (1,4-cis)-4-acrylamido-N-(3 -(((8-i sopropy1-2-((tetrahydrofuran-3-
ypox y)pyrazolo
[1,5-a] [1,3 ,5]triazin-4-yl)amino)methyl)phenyl)c yclohexane-l-c arboxamide;
101. (1,4-cis)-4-acrylamido-N-(3-(((8-isopropy1-2-((1-methylpyrrolidin-3-
yl)oxy)
pyrazolo[1,5-a][1,3,5]triazin-4-yDamino)methyl)phenyl)cyclohexane-1-
carboxamide;
102. 1-acryloyl-N-(3-(((2-isobutoxy-8-isoprop ylpyrazolo [1,5-a]
[1,3,5]triazin-4-
yl)amino)methyl)phenyl)pyrrolidine-3-carboxamide;
103. 1-acryloyl-N-(3-(((8-isopropy1-2-(2-methoxyethoxy)pyrazolo[1,5-a]
[1,3,5]triazin-
4-yl)amino)methyl)phenyl)p yrrolidine-3-carbox amide;
104. 1-acrylo yl-N-(3-(((8-isopropy1-2-(2-(2-methoxyethox
y)ethoxy)pyrazolo[1,5-
a] [1,3,5]triazin-4-yl)amino)methyl)phenyl)pyrrolidine-3-carboxamide;
105. (1,4-cis)-4-acrylamido-N-(3-(((8-cyclopropy1-2-((l-methylpiperidin-4-
yl)oxy)
pyrazolo[1,5-a][1,3,5yriazin-4-yl)arnino)rnethyl)plienyl)cyclohexane-1-
CA 02978170 2017-08-29
WO 2016/142855 PCT/1112016/051302
carboxamide;
106. (1,4-cis)-4-acrylamido-N-(3-(((8-isopropy1-2-((tetrahydro-2H-pyran-4-
yDamino)
pyrazolo[1,5-a] [1,3,5] tri azin-4-yl)amino)methyl)phenyl)cyclohex ane- 1-
carboxamide ;
107. 1-acryloyl-N-(3-(((2-(4- aminobutoxy)-8-i soprop ylpyrazolo [1,5-a] [1
,3,5]tri azin-4-
ypamino)methyl)phenyl)piperi dine-4-c arboxamide
108. 1-acryloyl-N-(3-(((8-isopropyl-2-((1 -methylpiperidin-4-
yl)oxy)pyrazolo[1,5-
a] [1,3, 5] triazin-4-yDamino)methypphenyppyrrol idine-3-carboxamide ;
109. Isomer-1: 1-acryloyl-N-(3-(((8-isopropy1-24(1-methylpiperidin-4-
yl)oxy)
pyrazolo[1,5-a] [1,3,5] tri azin-4-yDamino)methyl)phenyl)pyrrolidine-3-
c arboxamide ;
110. Isomer-2: 1-acryloyl-N-(3-(((8-isopropy1-24(1-methylpiperidin-4-
yl)oxy)
pyrazolo[1,5-a] [1,3,5] tri azin-4-yDamino)methyl)phen yl)pyrrolicline-3-
c arbox amide;
111. 1-acryloyl-N-(3-(((8-isopropyl-2-((1 -methylpiperidin-4-
y1)oxy)pyrazolo[1,5-
a] [ 1,3,5] tri azin-4-yDamino)methypphenyppiperidi ne-4-c arbox amide;
112. 4-acryloyl-N-(3-(((8-isopropyl-24( 1-methylpiperidin-4-ypoxy)p
yrazolo[1,5-
a] [1,3, 5] triazin-4-yDamino)methyl)phenyl)morpholine-2-carbox amide ;
113. 4-acryloyl-N-(3-(((8-isopropyl-2-((1 -methylpiperidin-4-yl)oxy)p
yrazol o[1,5-
a] [1,3, 5] triazin-4-yDamino)methypphen yl)morpholine-3-carbox amide ;
114. 3-acryl amido-N-(3-((( 8-i sopropy1-2-((1 -methylpiperi din-4-
yl)oxy)pyrazolo[1,5-
a] [1,3, 5] triazin-4-yDamino)methyl)phenypcyclohexane-1-carboxamide ;
115. (1,4-cis)-4-acry1amido-N-(3-(((8-isopropy1-2-((1-methylpiperidin-4-
yl)oxy)
pyrazolo[1,5-a] [1,3,5]triazin-4-yDamino)methyl)phenyl)c yc lohex ane-l-
c arbox amide ;
116. 1-acrylo yl-N-(3-(((8-isopropy1-2-((1 -methylpiperidin-4-
yl)oxy)pyrazolo[1,5-
a] [1,3, 5] tri azin-4-yl)amino)methyl)phenyl)piperidine-3-c arboxamide;
117. 1-acryloyl-N-(2-fluoro-5-4(84 sopropy1-24(1-methylpiperidin-4-
yl)oxy)pyrazolo[ 1,5-al [ 1,3,5 jtriazin-4-yDamino)methyl)phenyl)piperidine-3-
26
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
carboxamide;
118. (1,4-cis)-4-acrylamido-N-(2-fluoro-5-(08-isopropy1-24(1-
methylpiperidin-4-
yl)oxy)pyrazolo[1,5-a] [1,3,5 ]triazin-4-yDamino)methyl)phenyl)cyclohex ane-1-
carboxamide;
119. 1-acryloyl-N-(3-(14(84 sopropy1-24(1-methylpiperidin-4-
yl)oxy)pyrazolo[1,5-
a] [1,3, 5]triazin-4-yDamino)ethypphenyl)piperidine-3-carbox amide;
120. 2-(1-acryloylpiperidine-3-carboxamido)-5-(48-isopropy1-24(1-
methylpiperidin-4-
yl)oxy)pyrazolo[1,5-a] [1,3,5 ]triazin-4-yDamino)methyl)pyridine 1-oxide;
121. 3-4(8-isopropyl-24(1-methylpiperidin-4-yl)ox y)pyrazolo [1 ,5-a]
[1,3,5]triazin-4-
yDamino)methyl)phenyl 4-acryloylpiperazine-1-carboxylate;
122. (E)-1-(4-(dimethylamino)but-2-enoy1)-N-(3-(((8-isopropyl-2-((1-
methylpiperidin-
4-y1)oxy)pyrazolo [1,5-a] [1,3,5 ]triazin-4-yDamino)methypphenyl)piperidine-3-
carboxamide;
123. (E)-1-(4-(dimethylamino)but-2-enoy1)-N-(2-fluoro-5-(48-isopropy1-24(1-
methylpiperidin-4-yDoxy)pyrazolo [1,5-a] [1,3,5] triazin-4-yl)amino)methyl)
phenyl)piperidine-3-carboxamide;
124. (1,4-cis)-44(E)-4-(dimethylamino)but-2-enamido)-N-(2-fluoro-5-4(8-
isopropy1-
24(1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)
phenyl)c yclohexane-l-c arbox amide ;
125. 4-acrylamido-N-(3-48-isopropy1-2-((1-methylpiperidin-4-yl)oxy)pyrazolo
[1 ,5-
a] [1,3,5]triazin-4-yl)amino)phenyl)benzamide;
126. (1,4-cis)-4-acrylamido-N-(34(8-isopropy1-24(1-methylpiperidin-4-
yl)oxy)
pyrazolo[1,5-a] [1,3,5]triazin-4-yl)amino)phenyl)cyclohexane-1-carbox amide;
127. 1-acryloyl-N-(3((8-i sopropy1-24(1-methylpiperidin-4-
yl)oxy)pyrazolo[1,5-
a] [1,3, 5]triazin-4-yl)amino)phenyl)piperidine-4-carboxamide;
128. N-(1 -acryloylpiperidin-4-y1)-3((8-isopropy1-24(1 -methylpiperidin-4-
yl)oxy)pyrazolo[1,5-a] [1,3,5 ]triazin-4-yDamino)benzamide;
129. N-(1 -acryloylpiperidin-3-y1)-3((8-isopropy1-24(1 -methylpiperidin-4-
yl)oxy)
pyrazolo[1,5-a][1,3,5]triazin-4-yl)arnino)benzamide;
27
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
130. (E)-4-(4-(dimethylamino)but-2-enamido)-N-(34(8-isopropy1-2-((1-methyl
piperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)phenyl)benzamide;
131. (1,4-cis)-44(E)-4-(dimethylamino)but-2-enamido)-N-(34(8-isopropy1-24(1-
methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-yDamino)phenyl)
cyclohexane-l-carboxamide;
132. (1,4- Trans)-44(E)-4-(dimethylamino)but-2-enamido)-N-(3-48-isopropyl-
24(1-
methylpiperidin-4-yDoxy)pyrazolo[1,5-a][1,3,5]triazin-4-yDamino)phenyl)
cyclohexane-1-carboxamide;
133. (E)-N-(1-(4-(dimethylamino)but-2-enoyDpiperidin-3-y1)-3-48-isoprop y1-
24(1-
methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)benzamide;
134. (E)-N-(1-(4-(dimethylamino)but-2-enoyDpiperidin-4-y1)-3-48-isopropy1-
24(1-
rnethylpiperidin-4-yDoxy)pyrazolo[1,5-a][1,3,5]triazin-4-yDamino)benzamide;
135. (1,4-cis)-4-(((E)-4-(dimethylamino)-4-oxobut-2-en-1-yDamino)-N-(3-(((8-
isopropyl-2-((1-methylpiperidin-4-y1)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-
yDamino)methyl)phenyl)cyclohexane-1-carboxamide;
136. 1-acryloyl-N-(3-(((8-isopropyl-2-methoxypyrazolo[1,5-a][1,3,5]triazin-
4-y1)
amino)methyl)phenyl)piperidine-4-carboxamide;
137. (E)-4-(dimethylamino)-1-(4-(2-0(8-isopropy1-2-((tetrahydro-2H-pyran-4-
y1)
amino)pyrazolo[1,5-a][1,3,5]triazin-4-yDamino)methyl)phenyl)piperazin-l-y1)but-
2-en-1 -one;
138. (E)-1-(4-(((8-i sopropy1-2-((tetrahydro-2H-p yran-4-yDamino)pyrazolo
[1,5-a]
[1,3,5]triazin-4-yl)amino)methyl)piperidin-1-y1)-4-(pyrrolidin-1-y1)but-2-en-1-
one; and
139. 1-acryloyl-N-(3-(((3-isopropy1-5-((tetrahydro-2H-pyran-4-
yl)amino)pyrazolo[1,5-
a]pyrimidin-7-yl)amino)methyl)phenyl)azetidine-2-carboxamide,
or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.
In certain embodiments, the present invention provides a pharmaceutical
composition
comprising a compound of formula (I), (IA), (IB), (IC), (ID), (IE) and (IF) or
a pharmaceutically
acceptable salt thereof or a stereoisomer thereof as described herein and at
least one
pharmaceutically acceptable excipient (such as a pharmaceutically acceptable
carrier or diluent).
28
CA 02978170 2017-08-29
WO 2016/142855
PCT/1132016/051302
Preferably, the pharmaceutical composition comprises a therapeutically
effective amount of at
least one compound described herein. The compounds described in the present
patent application
may be associated with a pharmaceutically acceptable excipient (such as a
carrier or a diluent) or
be diluted by a carrier or enclosed within a carrier which can be in the form
of a capsule, sachet,
paper or other container.
In yet another embodiment, the compounds of the present invention are thought
to be
kinase inhibitors. In certain embodiments, the compounds of the present
invention are CDK
inhibitors. In certain embodiments, the compounds of the present invention are
CDK7 inhibitors.
In certain embodiments, the compounds of the present invention are selective
CDK inhibitors
(e.g. , being more active in inhibiting a CDK than a non-CDK kinase). In
certain embodiments,
the compounds of the present invention are selective CDK7 inhibitors (e.g.,
being more active in
inhibiting CDK7 than a non-CDK7 kinase). In certain embodiments, the compounds
of the
present invention are selective CDK9 inhibitors. In certain embodiments, the
compounds of the
present invention are selective CDK12 inhibitors. In certain embodiments, the
compounds of the
present invention are selective CDK 13 inhibitors. In certain embodiments, the
compounds of the
present invention are selective CDK18 inhibitros.
In another embodiment, the present invention provides pharmaceutical
composition for
use in treating and/or preventing a disease and/or disorder associated with
selective
transcritptional CDKs.
In another embodiment, the present invention provides pharmaceutical
composition for
use in treating a subject suffering from a disease or condition associated
with aberrant activity of
selective transcriptional CDKs.
In another embodiment, the present invention provides pharmaceutical
composition
comprising the compound of formula (I), (IA), (IB), (IC), (ID), (IE) and (IF)
for use in treating
and/or preventing a disease and/or disorder associated with s selective
transcriptional CDK
inhibitors, in particularly selective transcriptional inhibitor is CDK7, CDK9,
CDK12, CDK13 or
CDK18; more particularly CDK7.
In another embodiment, the present invention provides pharmaceutical
composition
comprising the compound of formula (I), (IA), (IB), (IC), (ID), (IE) and (IF)
for use in treating a
subject suffering from a disease or condition associated with aberrant
activity of selective
29
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
transcriptional CDK inhibitors, in particularly selective transcriptional
inhibitor is CDK7, CDK9,
CDK12, CDK13 or CDK18; more particularly CDK7..
In yet another embodiment, the present invention provides a method of treating
disorders
or diseases or condition mediated by CDK in a subject comprising administering
a
therapeutically effective amount of a compound of the present invention, in
particularly CDK is
CDK7, CDK9, CDK12, CDK13 or CDK18, more particularly selective
trasnscriptional CDK7.
In yet another embodiment, the present invention provides a method of
inhibiting
selective transcriptional CDK inhibitors, in particularly selective
transcriptional inhibitor is
CDK7, CDK9, CDK12, CDK13 or CDK18; more particularly CDK7, in a subject in
need thereof
by administering to the subject one or more compounds described herein in the
amount effective
to cause inhibition of such receptor.
In another aspect of the present invention relates to methods of inhibiting
the activity of a
kinase in a biological sample or subject. In certain embodiments, the kinase
is selective
transcriptional CDK. In certain embodiments, the kinase is selective
transcriptional CDK7. In
other embodiments, the kinase is selective transcriptional CDK9, CDK12, CDK13
or CDK18.
In other embodiments, the activity of the kinase is aberrant activity of the
kinase. In other
embodiments, the inhibition of the activity of the kinase is irreversible. In
other embodiments,
the inhibition of the activity of the kinase is reversible. In other
embodiments, the methods of
inhibiting the activity of the kinase include attaching a compound of formula
(I) to the kinase.
In yet another embodiment, the compounds of present invention are selective
transcritpional CDK inhibitors, which are key regulators of the cell cycle.
In yet another embodiment, the compounds of present invention are selective
inhibitors
of transcriptional CDKs, which are key regulators of the cell cycle, inhibits
both cell cycle
progression and transcription.
In yet another embodiment, the compounds of present invention are selective
transcriptional CDK inhibitors, which are key regulators of the cell cycle,
inhibits both cell cycle
progression and transcription; wherein the selective transcriptional CDK
inhibitor is CDK7,
CDK9, CDK12, CDK13 or CDK18.
CA 02978170 2017-08-29
WO 2016/142855
PCT/11B2016/051302
In yet another embodiment, the compounds of present invention are selective
transcriptional CDK inhibitors, which are key regulators of the cell cycle,
inhibits both cell cycle
progression and transcription; wherein the selective transcriptional CDK
inhibitor is CDK7.
In yet another embodiment, the compounds of present invention also inhibits
the
phosphorylation of ser5 of RNA Polymerase II CTD, consistent with mechanism-
based
inhibition of CDK7.
In yet another embodiment, the compounds of present invention also inhibits
the
phosphorylation of ser2 and/or ser7 of RNA Polymerase II CTD, consistent with
mechanism-
based inhibition of transcriptional CDKs.
In yet another embodiment, the compounds of present invention (selective
translational
CDK inhibitors) when administered in vivo apoptotic response indicated by PARP
cleavage.
In yet another embodiment, the compounds of present invention (selective
translational
CDK inhibitors) after invivo administration may show pro-apoptotic effects the
down-regulation
of short half-life survival proteins like Mcl-I.
The compounds of the invention are typically administered in the form of a
pharmaceutical composition. Such compositions can be prepared using procedures
well known in
the pharmaceutical art and comprise at least one compound of the present
invention. The
pharmaceutical composition of the present invention comprises one or more
compounds
described herein and one or more pharmaceutically acceptable excipients.
Typically, the
pharmaceutically acceptable excipients are approved by regulatory authorities
or are generally
regarded as safe for human or animal use. The pharmaceutically acceptable
excipients include,
but are not limited to, carriers, diluents, glidants and lubricants,
preservatives, buffering agents,
chelating agents, polymers, gelling agents, viscosifying agents, solvents and
the like.
The pharmaceutical composition can be administered by oral, parenteral or
inhalation
routes. Examples of the parenteral administration include administration by
injection,
percutaneous, transmucosal, transnasal and transpulmonary administrations.
Examples of suitable carriers include, but are not limited to, water, salt
solutions,
alcohols, polyethylene glycols, peanut oil, olive oil, gelatin, lactose, terra
alba, sucrose, dextrin,
magnesium carbonate, sugar, amylose, magnesium stearate, talc, gelatin, agar,
pectin, acacia,
31
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
stearic acid, lower alkyl ethers of cellulose, silicic acid, fatty acids,
fatty acid amines, fatty acid
monoglycerides and diglycerides, fatty acid esters and polyoxyethylene.
The pharmaceutical composition may also include one or more pharmaceutically
acceptable auxiliary agents, wetting agents, suspending agents, preserving
agents, buffers,
sweetening agents, flavouring agents, colorants or any combination of the
foregoing.
The pharmaceutical compositions may be in conventional forms, for example,
tablets,
capsules, solutions, suspensions, injectables or products for topical
application. Further, the
pharmaceutical composition of the present invention may be formulated so as to
provide desired
release profile.
Administration of the compounds of the invention, in pure form or in an
appropriate
pharmaceutical composition, can be carried out using any of the accepted
routes of
administration of pharmaceutical compositions. The route of administration may
be any route
which effectively transports the active compound of the patent application to
the appropriate or
desired site of action. Suitable routes of administration include, but are not
limited to, oral, nasal,
buccal, dermal, intradermal, transdermal, parenteral, rectal, subcutaneous,
intravenous,
intraurethral, intramuscular or topical.
Solid oral formulations include, but are not limited to, tablets, capsules
(soft or hard
gelatin), dragees (containing the active ingredient in powder or pellet form),
troches and
lozenges.
Liquid formulations include, but are not limited to, syrups, emulsions and
sterile
injectable liquids, such as suspensions or solutions.
Topical dosage forms of the compounds include ointments, pastes, creams,
lotions,
powders, solutions, eye or ear drops, impregnated dressings and may contain
appropriate
conventional additives such as preservatives, solvents to assist drug
penetration.
The pharmaceutical compositions of the present patent application may be
prepared by
conventional techniques known in literature.
Suitable doses of the compounds for use in treating the diseases or disorders
described
herein can be determined by those skilled in the relevant art. Therapeutic
doses are generally
identified through a dose ranging study in humans based on preliminary
evidence derived from
the animal studies. Doses must be sufficient to result in a desired
therapeutic benefit without
32
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
causing unwanted side effects. Mode of administration, dosage forms and
suitable
pharmaceutical excipients can also be well used and adjusted by those skilled
in the art. All
changes and modifications are envisioned within the scope of the present
patent application.
In one embodiment the compounds as disclosed in the present invention are
formulated
for pharmaceutical administration.
Yet another embodiment of the present invention provides use of the compounds
as
disclosed in the present invention in the treatment and prevention of diseases
or disorder
associated with selective transcriptional CDK inhibitors, in particularly
selective transcriptional
CDK inhibitor is CDK7, CDK9, CDK12, CDK13 or CDK18; more particularly CDK7.
Yet another embodiment of the present invention provides use of the compound
or a
pharmaceutically acceptable salt thereof, in treating and/or preventing a
disease for which the
symptoms thereof are treated, improved, diminished and/or prevented by
inhibition of selective
transcriptional CDK inhibitors, in particularly selective transcriptional
inhibitor is CDK7, CDK9,
CDK12, CDK13 or CDK18; more particularly CDK7.
According to yet another embodiment, the selective transcriptional CDK's
mediated
disorder or disease or condition is proliferative diseases or disorder or
condition.
According to aforesaid embodiment, the proliferative diseases or disorders or
conditions
are selected from but are not limited to the group consisting of a cancer, an
inflammatory
disorder, an auto-inflammatory disorder or an infectious disease.
In other embodiments, the proliferative disease to be treated or prevented
using the
compounds of foimula (I) will typically be associated with aberrant activity
of CDKs, more
particularly with CDK7, CDK9, CDK12, CDK13 or 18. Aberrant activity of CDK7,
CDK9,
CDK12, CDK13 or CDK18 may be an elevated and/or an inappropriate (e.g.,
abnormal) activity
of CDK7, CDK9, CDK12, CDK13 or CDK18. In certain embodiments, CDK7, CDK9,
CDK12,
CDK13 or CDK18 are not overexpressed, and the activity of CDK7, CDK9, CDK12,
CDK13 or
CDK18 are elevated and/or inappropriate. In certain other embodiments, CDK7,
CDK9, CDK12,
CDK13 or CDK18 are overexpressed, and the activity of CDK7, CDK9, CDK12, CDK13
or
CDK18 are elevated and/or inappropriate. The compounds of formula (I), and
pharmaceutically
acceptable salts or stereoisomers, and compositions thereof, may inhibit the
activity of CDK7,
CDK9, CDK12, CDK13 or CDK18 are been useful in treating and/or preventing
proliferative
diseases.
33
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
According to yet another embodiment, the compounds of the present invention
are
expected to be useful in the therapy of proliferative diseases such as viral
diseases, fungal
diseases, neurological/neurodegenerative disorders, autoimmune, inflammation,
arthritis, anti-
proliferative (e.g., ocular retinopathy), neuronal, alopecia and
cardiovascular diseases.
According to yet another embodiment, the compounds of the present invention
are useful
in the treatment of a variety of cancers, including but not limited to
carcinoma, including that of
the breast, liver, lung, colon, kidney, bladder, including small cell lung
cancer, non-small cell
lung cancer, head and neck, thyroid, esophagus, stomach, pancreas, ovary, gall
bladder, cervix,
prostate and skin, including squamous cell carcinoma; hematopoietic tumors of
lymphoid
lineage, including leukemia, acute lymphoblastic leukemia, acute lymphocytic
leukemia,
Hodgkins lymphoma, non-Hodgkins lymphoma, B-cell lymphoma, T- cell lymphoma,
hairy cell
lymphoma, myeloma, mantle cell lymphoma and Burkett's lymphoma; hematopoietic
tumors of
myeloid lineage, including acute and chronic myelogenous leukemias,
myelodysplastic
syndrome and promyelocytic leukemia; tumors of masenchymal origin, including
fibrosarcoma
and rhabdomyosarcoma; tumors of the central and peripheral nervous system,
including
astrocytoma, neuroblastoma, glioma and schwannomas; and other tumors,
including seminoma,
melanoma, osteosarcoma, teratocarcinoma, keratoctanthoma, xenoderoma
pigmentosum, thyroid
follicular cancer and Kaposi's sarcoma.
According to yet another embodiment, the subject is a mammal including human.
According to yet another embodiment the present invention provides compounds
for use
as a medicament.
According to yet another embodiment the invention provides the use of the
compounds of
the present invention in the manufacture of a medicament.
According to yet another embodiment the invention provides the use of the
compounds of
the present invention in the manufacture of a medicament for the treatment of
diseases and/or
disorder associated with selective transcriptional CDK inhibition.
According to yet another embodiment the present invention provides compounds
for use
as a medicament for the treatment of diseases and/or disorder associated with
selective
transcriptional CDK inhibition.
According to yet another embodiment the present invention comprises an
additional step
of administering to the subject in need thereof one or more additional
chemotherapeutic agents
34
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
independently selected from anti-proliferative agents, anti-cancer agents,
immunosuppressant
agents and pain-relieving agents.
The method(s) of treatment of the present invention comprises administering a
safe and
effective amount of a compound according to formula (I) or a pharmaceutically
acceptable salt
thereof to a patient (particularly a human) in need thereof.
Compounds of the invention are indicated both in the therapeutic and/or
prophylactic
treatment of the above-mentioned conditions. For the above-mentioned
therapeutic uses the
dosage administered will, of course, vary with the compound employed, the mode
of
administration, the treatment desired and the disorder or disease indicated.
The compounds of the present invention may be used as single drug or as a
pharmaceutical composition in which the compound is mixed with various
pharmacologically
acceptable materials.
According to one embodiment, the compounds of the present invention can also
contain
unnatural proportions of atomic isotopes at one or more of the atoms that
constitute such
compounds. For example, the present invention also embraces isotopically-
labeled variants of
the present invention which are identical to those recited herein, but for the
fact that one or more
atoms of the compound are replaced by an atom having the atomic mass or mass
number
different from the predominant atomic mass or mass number usually found in
nature for the
atom. All isotopes of any particular atom or element as specified are
contemplated within the
scope of the compounds of the invention and their uses. Exemplary isotopes
that can be
incorporated in to compounds of the invention include isotopes of hydrogen,
carbon, nitrogen,
oxygen, phosphorous, sulfur, fluorine, chlorine and iodine, such as 2H ("D"),
3H, tc, 13c, 14c,
13N, 15N, 150, 170, 180, 32P, 33P, 35S, 18F, 36C1, 123I and 1251 Isotopically
labeled compounds of the
present invention can generally be prepared by following procedures analogous
to those
disclosed in the schemes and/or in the examples herein below, by substituting
an isotopically
labeled reagent for a non-isotopically labeled reagent.
General Procedures:
Compounds of the present invention may be prepared by synthetic chemical
processes,
examples of which are shown herein. It is meant to be understood that the
order of the steps in
the processes may be varied, that reagents, solvents and reaction conditions
may be substituted
CA 02978170 2017-08-29
WO 2016/142855
PCT/1132016/051302
for those specifically mentioned and that vulnerable moieties may be protected
and deprotected,
as necessary.
A general approach for the synthesis of compounds of general formula (I) is
depicted in
below schemes. As used herein the below schemes the terms 'R1', 'It2', `R3',
'ILC, 'R6', 'A', '13',
'Li', `1_,2% `m"n' and 13' are same as described in compound of formula (I).
General synthesis for the preparation of key intermediates (formula 1.5) and
(formula
3.4) were described in the given scheme-a and scheme-b respectively:
Scheme-a:
N H2
.ssckm R 1 R 1
RI Nq Nil
Nq02N Li (R3)n
N N _1 ii ...1.k. jc
N X S*---- UN X , S
0-'"---,
a....k. ,LL _ Route-R FI m 0' s0
X S--
.. m 6 R
.0 R6 1.2 0 1.3
NH2 02N (113 )ri 02N (RAI
2.1 ,c3)NA.
1_, I = -OH or
Route-b -NIL
B ocHN (R3)n 11¨R2
RI RI
N,q, Nq
IT N N N
HN '?(is*--- ...i.,
ra HN X L.-- R2
1
0 R6 m
0 R6 1.4
BocHN (R3).
2.2 02N (R3).
. '
. RI ,... RI RI
Isilq, N1:1 3, , (-kis,
N N N N N
-.4... jk, .,.k. _II,
p
L 1¨R2 _ HN X 1,---R2
1
_.......2
., HN X LI
0. s0 L1 = -OH or m
,emR6 a R6
2.3 -N112 2.4 0 R6 13
BocHN (R3)11 Boa IN (R3).
H2N (R3)n
The general procedure for the preparation of key inteimediate (1.5) was
synthesized in
two routes by using compound of formula -1.0 as starting material.
Route-a:
The compound of foimula-1.0 can be treated with formula-1.1 in presence of
suitable
base such as DIPEA, TEA and the like, in presence of suitable polar solvents
such as ACN, 1,4-
36
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
dioxane, DMSO, DCE and the like at a temperature of about 20 C to 35 C for
about 2 to 24 h to
provide the compounds of formula-1.2. Compounds of formula-1.2 can be further
treated with
mCPBA in presence of suitable solvents such as DCM, CHC13, DCE and the like at
a
temperature of about 0 C to 35 C for about 2 to 24 h to provide the compounds
of formula-1.3.
The compounds of formula 1.4 (wherein L1= NH) can be synthesized by treating
compounds of
formula 1.3 with appropriate amine with or without solvent (solvents such as
NMP and the like)
at a temperature of about 100 C to 150 C for about 1 to 24 h. Alternatively,
the compounds of
formula 1.4 (wherein L1 = 0) can be synthesized by treating compounds of
formula 1.3 with
appropriate alcohol in the presence of suitable base such as NaH, LiH, KH,
K2CO3 or Cs2CO3
and the like in suitable solvents such as THF, DMSO, DMF, 1,4-dioxane or
diethyl ether and the
like, at a temperature of about -30 C to 100 C for about 1-24 h. Compounds of
formula-1.4
undergoes reduction of nitro group in presence of suitable reagents like zinc
dust/NH4C1 or
Fe/NH4C1 or Zn/aq.NH4C1 with appropriate combinational ratios of solvents such
as
THF:MeOH:Water, THF:Et0H:water, methanol:water, ethanol:water, methanol or
ethanol and
the like at a temperature of about 20 C to 120 C for about 1-24 h to provide
the compounds of
formula 1.5.
Route-b:
The compound of foimula 1.5 can be prepared by using compound of formula-1.0,
on
reacting with the compound of fonnula 2.1 and proceeded till the formation of
compound of
formula 2.4 by using the procedure similar to the preparation of compound of
formula 1.4 as
depicted in route-a. The resultant compound of formula 2.4 is further
undergoes deprotection of
Boc in presence of suitable reagents such as TFA and the like, in presence of
suitable solvent
such as DCM, chloroform, THF or 1,4-dioxane and the like, at a temperature of
about 20 C to
35 C for about 2 to 24 h to provide the compounds of formula-1.5.
The general procedure for the preparation of key intermediate (3.4) was
synthesized
according to scheme-b:
Scheme-b:
37
CA 02978170 2017-08-29
WO 2016/142855
PCT/1132016/051302
31 NH2
t K Ne"-11
NqN
Boc ITNõlX.,.. 134 L2 (R3)n _____ k, A S'''.-
0 , 411 R6 0 .e
R6
3.3
Boc .,,2 (R3)n Boo Lõ (RAI
1.0 3.2
Li = -OH or
-NH2
L 1-R2
RI
N N
HN X LRj-- 2
al
ROC IMF L2 .. (RA
3.4
The compounds of general formula-3.4 can be prepared by using compound of
formula
1.0 and reacting with compound of formula 3.1 and further proceeded to the
formation of
compound of formula 3.4 according to the procedure depicted in route-b of
scheme-a.
5 General scheme for the preparation of compound of formula (I):
The compound according to general foimula (I) was prepared according to the
procedure
depicted in route-a and route-b of scheme-I and scheme-II by using compound of
formula -1.5 as
starting material.
Scheme-I:
___ ,R, RI
Nia N(=j
N N (R4) 0 OH N R P 0 jz.....
HN X L-1- 2 . HN X 'ILL!R2
m Route-a m
ID R6 1.5 By 45 R6
112N (R3)n p(R4) ...2 (R3).
Formula-I
Y.
Route-b Boc OH (R4)p OH CI
0
RI Iti
Nq Nq,
N N N N
-.4 X L -1-Q. --R,
HN i - Boc-deprotection HN X L,
-
m
Hoc A
iaL2 (R, a la1/4-R.5
L iR2 (R3L
- 3.4 3.5
38
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
Route-a:
The compound of formula (I) can be synthesized by treating compound of formula-
1.5
with appropriate acid in the presence of suitable reagents such as HATU,
EDC.HC1-HOBt and
the like, in the presence of suitable base such as DIPEA or TEA and the like,
in a suitable solvent
such as DMF, THF, DMSO or DCM and the like at a temperature of about 20 C to
35 C for
about 1-24 h.
Route-b:
The compound of formula 3.4 was prepared according to the procedure depicted
in route-
a of scheme-I. The resulting compound of formula-3.4 undergoes deprotection of
Boc in
presence of suitable reagent TFA and the like, in presence of suitable solvent
such as DCM,
chloroform, THF or 1,4-dioxane and the like, at a temperature of about 20 C to
35 C for about 2
to 24 h to provide the compounds of formula-3.5. The compound of formula-3.5
can be treated
with appropriate acid chloride in presence of suitable base TEA or DIPEA and
the like, in
presence of suitable solvent such as DCM, chloroform, THF or 1,4-dioxane and
the like, at a
temperature of about 20 C to 35 C for about 2 to 24 h to provide the compounds
of formula-I.
Alternatively, the compound of formula-I can be synthesized by treating
formula-3.5 with
appropriate acid in the presence of suitable reagents such as HATU, EDC.HC1-
HOBt and the
like, in the presence of suitable base such as DIPEA or TEA and the like, in a
suitable solvent
such as DMF, THF, DMSO or DCM and the like at a temperature of about 20 C to
35 C for
about 1-24h.
Alternatively, the compound of formula (IF) of compound of formula (I),
wherein ring B
is absent was prepared according to the procedure depicted in scheme-II by
using compound of
formula -1.5 as starting material.
Scheme-H:
RI
NT(
N N N N
--fl
k= HN R ______________________ R
FIN X j:
L r 2 X i- 2
0 R6 R6
H2N (R3)n (R3),
1.5 (R4)p Formula-IF
39
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
The compounds of formula-IF of formula (I) can be prepared by treating
compound of
formula-1.5 with respective acid chloride (prepared from respective
haloalkenoic acid in
presence of suitable reagents such as oxalyl chloride in a suitable solvent
such as DMF or THF
and the like) in presence of base such as DIPEA or TEA in presence of suitable
solvent such as
DCM, chloroform, THF or 1,4-dioxane and the like, at a temperature of about 20
C to 35 C for
about 2 to 24 h. The obtained compound can be treated with various types of
amines in presence
of base such as K2CO3, Na2CO3 and the like in a suitable solvent such as ACN,
THF, DMF,
DMSO and the like, at a temperature of about 20 C to 100 C for about 2 to 24
h.
Abbreviations:
The following abbreviations refer respectively to the definitions herein: LDA
(Lithium
diisopropylamide); K2CO3 (Potassium carbonate); PdC12(dppf)2-DCM (1,1'-
Bis(diphenylphosphino)ferroceneklichloropalladium(II); dichloromethane
complex), DHP (3,4-
Dihydro-2H-Pyran); PTSA (p-Toluenesulfonic acid); EDCI
(1-Ethy1-3-(3-
dimethylaminopropyl)carbodiimide; Dikis (Bis(triphenylphosphine)palladium(11)
dichloride);
NH3 solution (Ammonia solution); Prep Column (Preparative column); Prep TLC
(Preparative
Thin layer Chromatography); rt (Retention time); RT (Room temperature); DMF
(Dimethylformamide); h (hour); LC-MS (Liquid chromatography mass
spectroscopy); NaOH
(Sodium hydroxide); Na2SO4 (Sodium sulphate); ACN/CH3CN (Acetonitrile); HCI
(Hydrochloric acid); THF (tetrahydrofuran); DCM (Dichloromethane); TFA
(Trifluoroacetic
acid); TLC (Thin layer chromatography); DIPEA (Diisopropyl Ethyl amine); DMSO-
d6
(Dimethyl sulfoxide-d); HATU (1-[Bis(dimethylamino)methylene]-1H-1,2,3-
triazolo[4,5-
b]pyridinium 3-oxid-hexafluorophosphate); Boc20 (Ditert-butyl dicarbonate);
HPLC (High
pressure liquid chromatography); NaHCO3 (Sodium bicarbonate); NaH (Sodium
hydride); SEM
Chloride (2-(Trimethylsilyl)ethoxy methylchloride); Cs2CO3 (Cesium carbonate);
BINAP (2,2'-
Bis(diphenylphosphino)-1,1'-binaphthyl); Pd2(dba)3
(Tris(dibenzylideneacetone)dipalladium(0));
TEA (triethyl amine), TPP (Triphenyl phosphine), DIAD
(Diisopropylazodicarboxylate), LiBH4
(Lithium borohydride), TMSC1 (Chlorotrimethylsilane).
Examples:
Although the invention has been illustrated by certain of the preceding
examples, it is not
to be construed as being limited thereby; but rather, the invention
encompasses the generic area
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
as hereinbefore disclosed. Various modifications and embodiments can be made
without
departing from the spirit and scope thereof.
The MS data provided in the examples described below were obtained as follows:
Mass spectrum: LC/MS Agilent 6120 Quadrapole LC/MS.
The NMR data provided in the examples described below were obtained as
follows:
1H-NMR: Varian 400 MHz.
The microwave chemistry was performed on a CEM Explorer.
Synthesis of Intermediates:
The procedure for the compounds of formula (I) are detailed herein below
stepwise
including the general synthesis of various intermediates involved in process
of manufacture of
the compounds according to the present invention.
Intermediate-I: Synthesis of 4-chloro-2-(methylthio)pyrazolo [1,5-a] [1, 3,5]
tri azine.
CI
--1LN-N ______________________________ POCI3 .1. iv
1-IN N
-
S N
S N
This intermediate was prepared from the procedure depicted in US2008/045536 by
using
2-(methylthio)pyrazolo[1,5-a][1,3,5]triazin-4(3H)-one (prepared according to
US2006/106019)
as starting material; LCMS: m/z = 200.9 (M+H)+.
Intermediate-2: Synthesis of 4-chloro-8-ethyl-2-(methylthio)pyrazolo[1,5-
a][1,3,5]triazine.
Step-1: Synthesis of 2-formylbutanenitrile.
I I
0
LDA 2.0M solution in THF (55mL) was added to a stirred solution of
butyronitrile (7.5g,
108.6mmo1) in dry THF(50mL) at -78 C. The resulting reaction mixture was
stirred at -78 C for
15min. Ethylfaimate (8.03g, 108.6mmo1) was added at -78 C and then allowed to
stir the
reaction mixture for overnight. After completion of the reaction, the reaction
mixture was
quenched with ice water, adjusted to pH 4 by using 2NHC1 and extracted with
ethyl acetate
.. (2x100mL). The combined organic phase was washed with brine, dried over
Na2SO4, filtered and
41
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
concentrated to afford the title compound (5.6g crude). The obtained product
was taken for next
step without purification.
Step-2: Synthesis of 4-ethyl-1H-pyrazol-5 -amine.
I I
N\)
0
Hydrazine hydrate (5.6mL) was added to a solution of 2-formylbutanenitrile
(5.6g,
57.73mmo1) in ethanol (112mL) at room temperature followed by acetic acid
(0.5mL). Then the
reaction mixture was heated at 90 C for 6h. After completion of the reaction,
cooled to room
temperature and quenched with ice-water, adjusted the pH 9 by using K2CO3 and
the reaction
mixture was extracted with ethyl acetate (2x25mL). The combined organic phase
was washed
with brine, dried over Na2SO4, filtered and concentrated to afford the title
compound (5.6g
crude) taken for next step without purification; LCMS: rn/z = 120.3 (M+H)+.
Step-3: Synthesis of 8-ethyl-2-thioxo-2,3-dihydropyrazolo[1,5-al[1,3,51triazin-
4(1H)-one.
- 0
0 0
NH2 A A N
- 0 NCS HN
H-NAJ, SNH
_
To a solution of 4-ethyl-1H-pyrazol-5-amine (5.0g, 44.6mmol) in DCM (20mL) was
added 0-ethyl carbonisothiocyanatidate (5.9g, 45.03mm01) drop wise at 0 'C.
The reaction
mixture was allowed to stirred at room temperature for lh. The solid obtained
was filtered and
dried to afford the intermediate of N-((4-ethy1-1H-pyrazol-5-
yOcarbamothioyDbutyramide (3.5g,
32.40%) LCMS: m/z = 242.8 (M+H)+. The intermediate formed was further
dissolved in
acetonitrile (100mL), added K2CO3 (6.2g, 44.9mmol) and the reaction mixture
was heated at 60
C for 3h. After completion of the reaction, the reaction mixture quenched with
water and
acidified with 2N HC1. The solid obtained was filtered and dried to afford the
title compound
(2.6g, 91.22 %); LCMS: m/z = 197.0 (M+H)4.
Step-4: Synthesis of 8-ethyl-2- (meth ylthio)pyrazolo [ 1,5-al [1,3 ,51tri
azin-4(3H)-one .
42
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
0 0
HN MANI '"N
S N
I I
2M NaOH (10mL, 20mmo1) was added to a stirred solution of 8-ethy1-2-thioxo-2,3-
dihydropyrazolo[1,5-a][1,3,5]triazin-4(1H)-one (2.0g, 10.19mmol) in ethanol
(40mL) at 0 C.
The resulting reaction mixture was stirred at 0 'V for 10min. Added methyl
iodide (1.5g,
10.50mmo1) at 0 C; after completion of the addition, the reaction mixture was
maintained at
room temperature for 4h. After completion of the reaction, volatiles were
removed under reduced
pressure and obtained residue was diluted with ice-cold 2N HCl, the solid
precipitated was
filtered and dried under vacuum to afford the title compound (1.7g, 79.43%).
IHNMR (DMSO-
d6): 5 12.73 (s, 1H), 7.90 (s, 1H), 2.58-2.51 (q, 2H), 2.50 (s, 3H), 1.23-1.19
(t, 3H). LCMS: m/z
= 210.9 (M-FH)+.
Step-5: Synthesis of 4-chloro-8-ethyl-2-(methylthio)pyrazolo11,5-
a111,3,51triazine.
o Cl
HN N
S N S)1q
N,N-Diethyl aniline (3.6g, 24.1mmol) was added to a stirred solution of 8-
ethy1-2-
(methylthio)pyrazolo[1,5-a][1,3,5]triazin-4(3H)-one (1.7g, 8.08mmo1) in P0C13
(35mL) at 0 C.
The reaction mixture was heated at 90 C for 4h. After completion of the
reaction, the reaction
mixture was concentrated under vacuum and diluted with ice-cold water. The
aqueous layer was
extracted with ethyl acetate (2x50mL). The combined organic phase was washed
with brine,
dried over Na2SO4, filtered and concentrated under reduced pressure. The
residue was purified
using combiflash (0-20%Et0Ac/Hexane) to afford desired title compound (1.5g,
81.52%);
LCMS: m/z = 228.9 (M H)+.
The below intermediates-3 and 4 were prepared according to the above protocol
(Intermediate-2) by using appropriate reactants, reagents at suitable
conditions. The
characterization data of the intermediates are summarized herein.
Int Analytical Int
Structure Structure Analytical
Data
No. Data No.
43
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
Cl CI
LCMS: m/z
N 1\1-- N N-1\1 LCMS: m/z =
3 =192.0 (M- 4
S)4*
N 243.1 (M+1)
51)+.
Intermediate-5: Synthesis of tert-butyl (3-(aminomethyl)-4-
ethylphenyl)carbamate.
Step-1: Synthesis of tert-butyl (4-bromo-3-cyanophenyl)carbamate.
Br Br
CN a CN
NH2 NHBoc
Di-tert-butyl dicarbonate (1.14g, 4.8mmo1) was added to a solution of 5-amino-
2-
bromobenzonitrile (0.8g, 4mm01) and DMAP (0.58g, 4.8namol) in DCM (20mL) and
the
resulting reaction mixture was stirred for 8h at room temperature. After
completion of reaction,
the reaction mixture was diluted with ice cold water and extracted with DCM
(3x50 mL). The
combined organic phase was washed with brine, dried over sodium sulphate,
filtered and
concentrated under reduced pressure. The residue was purified by 100-200 mesh
silica column
by eluting with 15% ethyl acetate-hexane to afford the title compound (1g,
83%). LCMS: m/z =
297.15 (M+H)+.
Step-2: Synthesis of tert-butyl (3-cyano-4-ethylphenyl)carbamate.
OH
Br
CN CN
NHBoc NHBoc
Tert-butyl (4-bromo-3-cyanophenyl)carbamate (4.0g, 18.6 mmol), Ethyl boronic
acid
(1g, 3.3 mrnol), Cs2CO3 (3.21g, 9.9 mmol) were taken in a pressure vessel. A
mixture of toluene
(10 mL) and ethanol (1mL) was added. The suspension was degassed and flushed
with nitrogen
gas for 15 min. Then Pd(PPh3)4 (0.38g, 0.33mmo1) was added, the pressure
vessel was sealed
and heated overnight at 110 C. After completion of the reaction, cooled to
room temperature
and was quenched with water and diluted with ethyl acetate. The aqueous layer
was separated
and extracted with ethyl acetate (2x25mL). The combined organic phase was
washed with brine,
dried over Na2SO4, filtered and concentrated. The residue was purified by 100-
200 silica gel
44
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
column chromatography to afford desired title compound (0.28g, 66%); LCMS: m/z
= 247.2
(M+H)+.
Step-3: Synthesis of tert-butyl (3-(aminomethyl)-4-ethylphenybcarbarnate.
CN
NH2
NHBoc NHBoc
Nickel chloride hexahydrate (0.17g, 1.2mmol) was added to a cooled solution of
tert-
butyl (3-cyano-4-ethylphenyl)carbamate (0.5g, 2mmol) in methanol at 0 C and
stirred the
reaction mixture for 10 min and added sodium borohydride (0.53g, 14mmol) lot
wise at 0 C.
The resulting reaction mixtures was stirred for lh at room temperature and
cooled to 0 C and
added diethylene triamine (0.24g, 2.4mmo1) and stirred for lh at room
temperature and
concentrated under vacuum. The residue was diluted with water, precipitated
solid was filtered
out and dried. Purified the crude using combiflash to afford the title
compound (0. 35g, 65%);
LCMS: m/z = 251.1 (M+H)+.
The below intermediates-6 and 7 were prepared according to the above protocol
(step-1
& 3 of intermediate-5) by using appropriate reactants, reagents at suitable
conditions. The
.. characterization data of the intermediates are summarized herein.
Int Analytical Int
Structure Structure Analytical
Data
No. Data No.
H2N LCMS: m/z
BocHNIN H2 LCMS: m/z =
6 F =241 7
224 (M-f-H)+.
NHBoc (M+H)+.
Intermediate-8: Synthesis of 1-acryloylpiperidine-4-carboxylic acid.
OH
C1 (3,0-AOH
111,1JJ
2M NaOH (7.8mL, 15.5mmol) was added to a solution of piperidine-4-carboxylic
acid
(1.0 g, 7.81mmol) in (20mL) of THF:Water (6:4) at 0 C and then stirred for
10min. Added
acryloyl chloride (0.7g, 7.69mmo1) at 0 C, then the reaction mixture was
allowed to room
temperature and stifled for 1h. After completion of the reaction, the reaction
mixture was
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
quenched with ice water, adjusted pH to 4 by citric acid and extracted with
ethyl acetate
(2x100mL). The combined organic phase was washed with brine, dried over
Na2SO4, filtered and
concentrated. The obtained product was triturated with diethyl ether, solid
was filtered and dried
to afford the title compound (0.45g, 32.14%). iHNMR (DMSO-d6): 6 12.35 (s,
1H), 6.82-6.73
(m, 1H), 6.08-6.02 (dd, 1H), 5.65-5.61 (dd, 1H), 4.24-4.19 (d, 1H), 3.96-3.91
(d, 1H), 3.15-3.05
(t, 1H), 2.82-2.74 (t, 1H), 2.53-2.44 (m, 1H), 1.84-1.79 (m, 2H), 1.43-1.35
(m, 2H); LCMS: rn/z
= 184 (M+H) .
The below intermediates-9 to 14 were prepared according to the above protocol
(intermediate-8) by using appropriate reactants, reagents at suitable
conditions. The
characterization data of the intermediates are summarized herein.
Analytical
Analytical
Int No. Structure hit No. Structure
Data
Data
9 0 10 0
OH LCMS: m/z = )L LCMS:
m/z =
CI-OH
Nf 156.05
N 170.00
(M+H)+. , (M+H)+. -
-0
, -
11 LCMS: m/z = 12
0 170 f LCMS:
m/z =
N
10_1 (M+ 185.21
COOH H) CATrOH
+ (M+H) .
0
.
13 o
LCMS: m/z = 14
.õ...1.(1 LCMS:
m/z =
0 CrkOH
198.21 --- 8 Clyaff
198.21
H
(M+H)+. o (M+H)+.
Intermediate-15: Synthesis of N-(3-aminopheny1)-4-nitrobenzamide.
sp
so OH H2N is NH2 0
Ai,. N AO
02N
,..-., , gri H NFT2
v2,N
To a cooled solution of 4-nitro benzoic acid (0.3g, 1.85mmol) in DMF (2mL) at
0 C was
added HATU (0.84g, 2.22mm01) followed by DIPEA (0.47mL, 3.7mmol) and finally
added 1,3-
46
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
diaminobenzene (0.2g, 1.85mm01). The reaction mixture was stirred for lh at
room temperature.
The reaction mixture was quenched with ice-water and diluted with ethyl
acetate. The aqueous
layer was separated and extracted with ethyl acetate (2x25mL). The combined
organic phase was
washed with brine, dried over Na2SO4, filtered and concentrated the crude
residue (0.2g crude).
LCMS: m/z = 258.10 (M+H)+.
Intermediate-16: Synthesis of tert-butyl (S)-3-(3-
(aminomethypbenzamido)piperidine-1-
carboxylate.
Step-1: Synthesis of tert-butyl (S)-3-(3-cyanobenzamido)piperidine-1-
carboxylate.
Boc
0 0
NC isOH 116õ 0C NH2 NC (s)
IN
HATU (1.94g, 5.1mmol) and DIPEA (1.25mL, 6.8mmo1) were added to a cooled
solution
of 3-cyanobenzoic acid (0.5g, 5.98mmo1) in dry DMF (5mL) at 0 C. Tert-butyl
(S)-3-
aminopiperidine-1-carboxylate (0.66g, 3.4rnmol) was to the reaction mixture
and stirred for 2h at
room temperature. After completion of reaction, the reaction mixture was
diluted with ice-water
and diluted with ethyl acetate. The aqueous layer was separated and extracted
with ethyl acetate
(2x25mL). The combined organic phase was washed with brine, dried over Na2SO4,
filtered and
concentrated the crude residue (0.8g crude). LCMS: rn/z = 330 (M+H) .
Step-2: Synthesis of tert-butyl (S)-3-(3-(aminomethvbbenzamido)piperidine-1-
carboxylate.
Bee Bee
LJ =
0 (s)
(s)
NC
-1=1. H2N 4111
Nickel(II) chloride hexahydrate (0.29g, 1.23mm01) was added to a solution of
tert-butyl
(S)-3-(3-cyanobenzamido)piperidine-1-carboxylate (0.8g, 2.47rnm01) in Me0H
(10mL) at 0 C,
followed by NaB1-L4 (0.73g, 19.32mmo1) was added portion wise. The resulting
reaction mixture
was stirred at ambient temperature for iii, then cooled to 0 C and added
diethylenetriamine
(0.25g, 2.46mm01) and allowed to stir at ambient temperature for lh. After
completion of the
reaction, the reaction mixture was concentrated under vacuum, diluted with
ethyl acetate
(30mL), washed with water and brine solution. The organic layer was dried over
Na2SO4, filtered
and concentrated the crude residue (0.5g, crude). LCMS: miz = 334 (M+H)+.
47
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
The below Intemtediate-17 was prepared according to the above protocol
(Intermediate-
16) by using appropriate reactants, reagents at suitable conditions. The
characterization data of
the intermediates are summarized herein.
Int No. Structure Analytical Data
Boc
17
NH2 LCMS: m/z = 334.2 (M+H)+.
0
Intermediate-18: Synthesis of tert-butyl 34(5-(aminomethyl)-2-
fluorophenyl)carbamoyl)
piperidine-l-c arboxyl ate.
Step-1: Synthesis of tert-butyl 34(5-cyano-2-fluorophenyl)carbamoyl)piperidine-
1-carboxylate.
0 OH F 0
F )
POC13, Py 4410k N11 NBoc
NC NH2 ONBoc NC
To a cooled solution of l-(tert-butoxycarbonyl)piperidine-3-carboxylic acid
(1g,
4.3mm01) in pyridine (5mL) at 0 C was added 3-amino-4-fluorobenzonitrile
(0.59g, 4.3mm01)
followed by POC13 (0.68g, 4.3mmo1), The reaction mixture was stirred for 2h at
room
temperature. The reaction mixture was quenched with ice-water and diluted with
ethyl acetate.
The aqueous layer was separated and extracted with ethyl acetate (2x25mL). The
combined
organic phase was washed with brine, dried over Na2SO4, filtered and
concentrated to crude
residue (1.1g). LCMS: m/z = 346.15(M-H)+.
Step-2: Synthesis of tert-butyl 34(5-(aminomethyl)-2-
fluorophenyl)carbamoyl)piperidine-1-
carboxylate.
0
0
H2N
NC N)LC...) ________________ NAn
Boc
Boc
Nickel chloride hexahydrate (0.29g, 1.21mmol) was added to a cooled solution
of tert-
butyl 3-((5-cyano-2-fluorophenyl)carbamo yl)piperidine-l-carbox ylate (1.1g,
3.1mmol) in
methanol at 0 C and stirred the reaction mixture for 10 min and added sodium
borohydride
(0.84g, 22.1mmol) lot wise at 0 C, stirred the reaction mixture for 1 h at
room temperature,
further cooled to 0 C and added diethylenetriarnine (0.32g, 3.1mmol) and
stirred for lh at room
48
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
temperature and concentrated under vacuum. Diluted the reaction mixture with
water, solid
separated was filtered and dried. The obtained crude was purified by using
combiflash to afford
the title compound (0.8g, 72%). LCMS: m/z = 352 (M+H)+.
The below Intermediates-19 to 20 were prepared according to the above protocol
(Intermediate-18) by using appropriate reactants, reagents at suitable
conditions. The
characterization data of the intermediates are summarized herein.
Int Int
Structure Analytical Data Structure
Analytical Data
No. No.
Boc1<ji HF 0 N.:)..a---NH2
19 0 LCMS: m/z = 20 0fN )
LCMS: m/z =
336.15 (M-1) +. Boc 335.1
(M+H)+.
NH2
1
Intermediate-21: Synthesis of tert-butyl 3-((3-(1-
aminoethyl)phenyl)carbamoyl)piperidine-1-
carboxylate.
Step-1: Synthesis of tert-butyl 3-((3-acetylphenyl)carbamoyl)piperidine-1-
carboxylate.
OOH 0 0
H
Ti2N
________________________________________________________ BocNrar.N
Cõ,1Boc o
The process of this step was adopted from intermediate-15 (1.2g). LCMS: m/z =
347.1
(M+H)+.
Step-2: Synthesis of tert-butyl (E)-34(3-(1-
(hydroxvimino)ethyl)phenyl)carbamoyl) piperidine-
1-carbox vl ate.
0
BocairN ____________________________________ BocarN
0 WI
0
=
To a solution of tert-butyl 3((3-acetylphenyl)carbamoyDpiperidine-l-
carboxylate (1.2 g,
3.4mmol) in Et0H(20 mL) was added 50% Aq. NH2OH solution (0.57mg,17.3mmol) at
RT. The
reaction mixture was stirred at 80 C for 2h. The reaction mixture was
concentrated to afford
desired title compound (1.1g, 88%). LCMS: m/z = 362.1 (M+H)+.
Step-3: Synthesis of tert-butyl 3-((3-( 1 -aminoethyl)phenybc
arbamoyl)piperidine-l-c arboxylate.
49
,OH
BocaH H NH2
IN BocNO1.yJJ
To a solution of tert-butyl (E)-343-(1-(hydroxyimino)ethyl)phenyl)carbamoyl)
piperidine-l-carboxylate (1g,2.7mm01) in acetic acid (5mL) was added zinc
(0.905g, 13.8mmo1).
The reaction mixture was stirred at room temperature for 4h. After completion
of the reaction the
reaction mixture was filtered through celiteTand diluted with ethyl acetate.
The aqueous layer was
separated and extracted with ethyl acetate (2x25mL). The combined organic
phase was washed
with Wine, dried over Na2SO4, filtered and concentrated to afford desired
title compound (0.9g,
crude). LCMS: m/z = 347.7 (MA-11) .
Intermediate-22: Synthesis of tert-butyl 4-(3-aminobenzamido)piperidine-1-
carboxylate.
Step-1: Synthesis of tert-butyl 4-(3-nitrobenzamido)piperidine- 1 -
carboxylate.
NH2 0Zpoc
02N lot
oui+ BocNa ______________________________
02N
The process of this step was adopted from intermediate-15 (1.2g crude).
Step-2: Synthesis of tert-butyl 443-aminobenzamido)piperidine-1-carboxylate.
0 .ONBoc 0 Croc
02N N . H2N
NH4C1 (3.67g, 68.7mmo1) and Zinc (2.24g,34.3mmo1) was sequentially added to a
solution of tert-butyl 4-(3-nitrobenzamido)piperidine-1-carboxylate (1.2g,
3.4mmol) in mixture
of THF:MeOH:water (2:1:1, 40mL) at 0 C and the resulting reaction mixture was
stirred at
ambient temperature for 3h. After completion of the reaction, the reaction
mixture was filtered
through celite pad and washed with ethyl acetate. Filtrate was concentrated
and quenched with
ice-water and diluted with ethyl acetate. The aqueous layer was separated and
extracted with
ethyl acetate (2x25mL). The combined organic phase was washed with brine,
dried over Na2SO4,
filtered and concentrated the crude residue (0.9g). LCMS: rn/z = 264.20 (M-
tert-Bu-F1)+.
Intermediate-23: Synthesis of 3-fluoro-l-methylpiperidin-4-ol.
Step-1: Synthesis of tert-butyl 3-fluoro-4-hydroxypiperidine-1-carbox yl ate.
Date Recue/Date Received 2022-08-18
CA 02978170 2017-08-29
WO 2016/142855
PCT/1B2016/051302
JyF
0 OH
CITF
Boc Boc
To a solution of tert-butyl 3-fluoro-4-oxopiperidine-1-carboxylate (10g,
45.87mmo1,
W02015/022662) in Me0H (200mL) was added sodiumborohydride (2.5g, 69.44mmo1)
lot wise
at 0 C. Then the reaction mixture was allowed to stir at room temperature for
lh. After
completion of the reaction, the reaction mixture was concentrated under vacuum
and diluted with
ice-cold saturated ammonium chloride solution. The aqueous layer was extracted
with ethyl
acetate (2x50mL). The combined organic phase was washed with brine, dried over
Na2SO4,
filtered and concentrated under reduced pressure to afford the title compound
(9.1g, crude).
LCMS: m/z = 220.0 (M H)+.
Step-2: Synthesis of tert-butyl 4-(benzyloxy)-3-fluoropiperidine-1-
carboxylate.
OH OBn
Boc Boc
NaH (60%) (2.5g, 104.16mmol) was added to a solution of tert-butyl 3-fluoro-4-
hydroxypiperidine- 1 -carboxylate (9.0g, 0.04 lmmol) in DMF (180mL) under
inert atmosphere at
0 C and stirred for 25 min. Benzylbromide (7.0g, 0.040mmo1) was added, the
resulting reaction
mixture was allowed to RT and stirred for 5h. After completion of the
reaction, cooled to room
temperature and was quenched with ice-water and diluted with ethyl acetate
(25mL). The
aqueous layer was separated and extracted with ethyl acetate (2x100naL). The
combined organic
phase was washed with brine, dried over Na2SO4, filtered and concentrated. The
residue was
purified by column chromatography (0-10% Et0Ac/hexane) to afford title
compound (10.5g,
83.33%). LCMS: ink = 310.3 (M+H)+.
Step-3: Synthesis of 4-(benzyloxy)-3-fluoropiperidine.
OBn OBn
Boc
To a solution of tert-butyl 4-(benzyloxy)-3-fluoropiperidine-1-carboxylate
(10.0g,
32.32mmo1) in DCM (30mL) was added TFA (15.0mL) drop wise at 0 C. Then the
reaction
51
CA 02978170 2017-08-29
WO 2016/142855
PCT/1B2016/051302
mixture was allowed to stirred at room temperature for 5h. After completion of
the reaction, the
reaction mixture was concentrated under vacuum and treated with ice-cold
NaHCO3 solution.
The aqueous layer was extracted with ethyl acetate (2x50rnL). The combined
organic phase was
washed with brine, dried over Na2SO4, filtered and concentrated under reduced
pressure to afford
the title compound (7.5g, crude). LCMS: m/z = 209.7(M H) .
Step-4: Synthesis of 4-(benzyloxv)-3-fluoro-1-methylpiperidine.
OBn OBn
cc:F.
To a solution of 4-(benzyloxy)-3-fluoropiperidine (8.0g, 38.27mmo1) in THF
(160mL)
was added TEA (3.9g, 38.61mmol), followed by dimethylsulfate (4.9g, 38.84mm01)
at 0 C.
Then the reaction mixture was allowed to stirred at room temperature for 2h.
After completion of
the reaction, the reaction mixture was concentrated under vacuum and the
residue was diluted
with water and ethyl acetate, separated the organic phase. The organic phase
was washed with
brine, dried over Na2SO4, filtered and concentrated under reduced pressure to
afford the title
compound (2.5g, crude). LCMS: m/z = 225.4(M+H)+.
Step-5: Synthesis of 3-fluoro-1-methylpiperidin-4-ol.
OBn OH
ciTF JF
Pd/C (10%) (0.9g) was added to a solution of 4-(benzyloxy)-3-fluoro- 1 -
methylpiperidine
(2.5g, 11.19mmol) in ethanol was taken in par shaker (250mL), applied 50psi
hydrogen pressure,
maintained for 24h at RT. After completion of the reaction, the reaction
mixture was filtered
through celite pad and the filtrate was concentrated under reduced pressure to
afford the title
compound (2.0g, crude). LCMS: m/z = 134.1(M+H)+.
Intermediate-24: Synthesis of 8-ethyl-2-(methylthio)-N-(3-n
itrobenzyl)pyrazolo [1,5-
a][1,3,5]triazin-4-amine.
52
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
02N
ci NO2 NH
N H2N
N
DIPEA (2.0g, 15.5mmo1) was added to a stirred solution of (3-nitrophenyl)
methanamine.HC1 (1.45g, 7.71mmol) in acetonitrile (50mL) at 0 C. Then added 4-
chloro-8-
ethy1-2-(rnethylthio)pyrazolo[1,5-a][1,3,5]triazine (1.7g, 7.43mmo1;
intermediate-2). The
resulting reaction mixture was stirred at ambient temperature for 2h. After
completion of the
reaction, concentrated the reaction mixture to remove volatiles and the
residue was diluted with
ice-cold water, the solid obtained was filtered and dried to afford the title
compound (2.4g,
94.11%). LCMS: m/z = 345.2 (M+H)+.
The below Intermediates-25 to 28 were prepared according to the above protocol
(intermediate-24) by using appropriate reactants, reagents at suitable
conditions. The
characterization data of the intermediates are summarized herein.
Int Analytical Int
Structure Structure Analytical
Data
No. Data No.
02N 02N op
LCMS: m/z = LCMS: m/z =
11H 26 NH
316.9 (M H) . NN 359.05 (M+H)+.
BocHN NHBoc
LCMS: = 40
NH LCMS: m/z =
27 "'" 457.1 (MI-H)'. 28 NH
N,
429 (M-FH)+.
S N
Intermediate-29: Synthesis of N4-(5-amino-2-ethylbenzy1)-8-isopropyl-N2-
(tetrahydro-2H-
pyran-4-yl)pyrazolo[1,5-a] [1,3, 5] triazine-2,4-diamine.
53
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
Step-1: Synthesis of tert-butyl (4-ethy1-3-(((8-isopropy1-2-
(methylsulfonyl)pyrazolor1,5-
al [1,3,51triazin-4-yl)amino)methyl)phenyl)carbamate.
BocHN io BocHN is
NH NH
el- NT N
qµS )N
0
m-CPBA (0.45g, 0.26mmo1) was added portion wise to a solution of tert-butyl (4-
ethyl-3-
(((8-isopropyl-2-(methylthio)pyrazolo[1,5-a][1,3,5]triazin-4-yDamino)methyl)
phenyl)carbamate
(0.4g, 0.87mmo1, intermediate-27) in DCM (10mL). The resulting reaction
mixture was stirred at
ambient temperature for 4h. After completion of the reaction, the reaction
mixture was
concentrated under vacuum and purified the residue in 100-200 mesh silica
column by eluting
with 40-50% ethyl acetate-hexane to afford the title compound (0.38g, 83%).
LCMS: m/z =
489.1 (MI-H)'.
Step-2: Synthesis of tert-butyl (4-ethy1-3-4(8-isopropy1-2-((tetrahydro-2H-
pyran-4-
yflamino)pyrazolof 1,5-all 1.3,51triazin-4-yl)amino)methyl)phenyl)carbamate.
BocHN BocHN as
oNH2
NH NH
N
N N
0
A mixture of 4-aminotetrahydropyran (0.44g, 4.36mmo1) and tert-butyl (4-ethy1-
3-(((8-
isopropyl-2-(methylsulfonyl)pyrazolo [1,5-a][1,3,5]triazin-4-
yl)amino)methyl)phenyl) carbamate
(0.38g, 0.72mmo1) were heated at 100 C for 2h. After completion of the
reaction, cooled to
room temperature and was quenched with ice-water and diluted with ethyl
acetate. The aqueous
layer was separated and extracted with ethyl acetate (2x25mL). The combined
organic phase was
washed with brine, dried over Na2SO4, filtered and concentrated. The residue
was purified by
.. 100-200 silica gel column chromatography to afford desired title compound
(0.28g, 66%).
LCMS: m/z = 510.3 (M+H)+.
Step-3: Synthesis of N4-(5-amino-2-ethylbenzy1)-8-isopropyl-N2-(tetrahydro-2H-
pyran-4-
yflpyrazolo11,5-al 11,3,51triazine-2,4-diamine.
54
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
BocHN io
NH NH
N
N N
TFA (0.5mL) was added to a solution of tert-butyl (4-ethyl-3-(((8-isopropyl-2-
((tetrahydro-2H-pyran-4-yDamino)pyrazolo[1,5-a] [1,3,5]triazin-4-
yDamino)methyl)phenyl)
carbamate (0.28g, 0.48mmo1) in DCM (2.5mL) at 0 C. The reaction mixture
allowed to stir at
room temperature for 2h. After completion of the reaction, the reaction
mixture was concentrated
under vacuum to afford desired title compound (0.22g of TFA salt); LCMS: m/z =
410.2
(M+H) .
The below Intermediates-30 to 32 were prepared according to the above protocol
(Inteimediate-29) by using appropriate reactants, reagents at suitable
conditions. The
characterization data of the intermediates are summarized herein.
Jut Analytical Int
Structure Structure Analytical
Data
No. Data No.
H3N
LCMS: tn/z H2N
=400 L LCMS: m/z =
30 NH 31 NH
W
(M+H)+. N N 383.1 (M+H)+.
N N
NH2
LCMS: m/z
32 NH =382
OO r
N (M+H)4.
N N
[I
Intermediate-33: Synthesis of N4-(3-aminobenzy1)-8-isopropyl-N2-(tetrahydro-2H-
pyran-4-
yflpyrazololl,5-al [1,3,51triazine-2,4-diamine.
Step-1: Synthesis of 8-isopropyl-2-(methyls ulfony1)-N-(3-nitrobenz
yflpyrazolo [1,5-al f 1,3,2
triazin-4-amine.
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
0,N 0,N
NH NH
IV-- 14- NN
-
õ
S N
mCPBA (1.73g, 10.05mmo1) was added portion wise to a solution of 8-isopropy1-2-
(methylthio)-N-(3-nitrobenzyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine (1.2g,
3.35mmol) in DCM
(150mL). After completion of the reaction, the reaction mixture was extracted
with 2M aq.
NaOH and DCM. The organic phase was washed with brine, dried over Na2SO4,
filtered and
concentrated to afford the title compound (1g, 76%). LCMS: m/z = 391.1 (M+H)+.
Step-2: Synthesis of 8-isopropyl-N4-(3-nitrobenzy1)-N2-(tetrahydro-2H-pyran-4-
yl)pyrazolo
[1,5-al [1,3,5[triazine-2,4-diamine.
0,N 02N
NH NFI2
0,) NH
JN ____
N N N
A mixture of 4-aminotetrahydropyran (0.26g, 2.56mmo1) and 8-isopropy1-2-
(methylsulfony1)-N-(3-nitrobenzyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine (0.2g,
0.51mmol) were
allowed to heat at 100 C for 2-12h. After completion of the reaction, the
reaction mixture was
cooled to room temperature, quenched with ice-water and diluted with ethyl
acetate. The
aqueous layer was separated and extracted with ethyl acetate (2x25mL). The
combined organic
phase was washed with brine, dried over Na2SO4, filtered and concentrated. The
residue was
purified by 100-200 silica gel column chromatography to afford desired title
compound (0.2g,
95%). LCMS: m/z = 412.49 (M+H)+.
Step-3: Synthesis of N4-(3-aminobenzy1)-8-isopropyl-N2-(tetrahydro-2H-pyran-4-
y1)
pyrazolof 1,5-a1[1,3,51triazine-2,4-diamine.
56
CA 02978170 2017-08-29
WO 2016/142855 PCT/1132016/051302
02N op H2N op
.IH NH
õ.1,..... -.... ,...k.. --..
N N N N
H H
To a solution of 8-isopropy1-2-((1-methylpiperidin-4-
ypoxy)-N-(3-
nitrobenzyppyrazolo[1,5-a][1,3,5]triazin-4-amine (0.65g, 1.52mmo1) in
THF:MeOH:Water
(3:2:1) were added zinc (0.5g, 7.64mmo1) and ammonium chloride (0.4g,
7.64mmo1). The
reaction mixture was stirred at room temperature for 4h. After completion of
reaction the
reaction mixture filtered through celite and diluted with ethyl acetate. The
aqueous layer was
separated and extracted with ethyl acetate (2x25mL). The combined organic
phase was washed
with brine, dried over Na2SO4, filtered and concentrated. The residue was
purified by 100-200
silica gel column chromatography to afford desired title compound (0.5g, 83%).
LCMS: m/z =
382.4 (M+H)+.
The below intermediates-34 to 38 were prepared according to the above protocol
(inteimediate-33) by using appropriate reactants, reagents at suitable
conditions. The
characterization data of the intermediates are summarized herein.
Int Analytical Int Analytical
Structure Structure
No. Data No. Data
H2N is H2N is
LCMS: m/z =
LCMS: m/z =
395.21
34 NH 381 (M+H)+. 35 NH
00 -J. N N (M+H)+.
... "-...'LN-1:\ '.' T.D., N ' N--
14 H
H2N 0 117N op
LCMS: m/z = LCMS: m/z =
396.65 396.35
36 cOL5 111H 37 NH
(MA-H)+. H0.0 NoLN,NN (M-FH)+.
INILNI-V.___ H
H
57
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
H2N
LCMS: m/z =
38 NH 499.2
Bc,,Na
- (M+H)+.
H
Intermediate-39: Synthesis of N4-(3-aminopheny1)-8-isopropyl-N2-(tetrahydro-2H-
pyran-4-
yl)pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine.
Step-1: Synthesis of 8-isopropyl-2-(methylthio)-N-(3-nitrophenyl)pyrazolof 1,5-
al [1,3,51 triazin-
4-amine.
HiN so No2
4111 õr,
N N -1\1N, HN
N
_______________________________________________ N
The process of this step was adopted from interrnediate-24 (2g, 47%). LCMS:
rn/z =
345.0 (M+H) .
Step-2: Synthesis
of 8-isopropv1-2-(methylsulfonv1)-N-(3-nirrophenvl)pyrazolo[1,5-
al [1,3,51triazin-4-amine.
IS
HN NO2 02N NH
""
N N-N
N N
S N S N
0
The process of this step was adopted from step-1 of intermediate-29 (2.0g,
93%). LCMS:
m/z = 376.95 (M+H)+.
Step-3: Synthesis
of 8-isopropyl-N4-(3-nitropheny1)-N2-(tetrahydro-2H-pyran-4-
yl)pyrazolo[1,5-al [1,3,51triazine-2,4-diamine.
02N NH
HN NO2
N k N
N
_ N
0
58
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
The process of this step was adopted from step-2 of intermediate-29 (1.2g,
94%). LCMS:
m/z = 398 (M+H)+.
Step-4: Synthesis of N-4-(3-aminophen y1)-8-i sopropyl-N2-
(tetrahydro-2H-p yran-4-
yl)pyrazolo 1 ,5-all1,3,51triazine-2,4-diam ine.
01111
HN NO2 HN NH
N 2
TNJ". =
N N
The process of this step was adopted from step-3 of intennediate-33 (0.9g,
75%). LCMS:
m/z = 368.5 (M-41) .
Intermediate-40: Synthesis of N-(3-aminobenzy1)-8-ethy1-2-((1-methylpiperidin-
4-y1)oxy)
pyrazolo11,5-a][1,3,5]triazin-4-amine.
Step-1: Synthesis of 8-ethyl-2-(methyl sulfon y1)-N-(3-nitrobenz yl)p yrazolo
f 1,5-al F 1,3,51triazin-
4-amine.
02N 02N
NH NH
N -N
N N N
s
O N
'0
The process of this step was adopted from step-1 of intermediate-29 (1.98g,
72.52%).
LCMS: m/z = 377.2 (M+H)+.
Step-2: Synthesis of 8-ethy1-2-((1-methylpiperidin-4-yfloxy)-N-(3-
nitrobenzyl)pyrazolol1,5-
4-1,3,51triazin-4-amine.
02N opi 02N
NH HO-CN- NH
-N _________________________________________
N N.
;S, N
b
NaH (0.25g, 10.6 mmol) was added to a solution of 1-methylpiperidin-4-ol
(1.2g,
10.4mmo1) in THF (40mL) under inert atmosphere at 0 C and allowed to stir for
25 min. Then
59
CA 02978170 2017-08-29
WO 2016/142855 PCT/1132016/051302
8-ethy1-2-(methylsulfony1)-N-(3-nitrobenzyl)pyrazolo[1,5-a] [1,3,5]triazin-4-
amine (1.0g,
2.65mmo1) was added at same temperature and the resulting reaction mixture was
allowed to stir
at RT for 2h. After completion of the reaction, reaction mixture was cooled to
room temperature,
quenched with ice-water and diluted with ethyl acetate (25mL). The aqueous
layer was separated
and extracted with ethyl acetate (2x100mL). The combined organic phase was
washed with
brine, dried over Na2SO4, filtered and concentrated. The residue was purified
by combifiash (0-
10% Me0H/DCM) to afford title compound (0.6g, 55.04%). LCMS: m/z = 412.9
(M+H)+.
Stev-3: Synthesis of N-(3-aminobenzy1)-8-ethyl -24(1 -methylpiperidin-4-
yboxv)p yrazolo [1,5-
[1,3,51triazin-4-amine.
02N 00
HõN
NH NH
N _________________________________________
N
0 N
NN
The process of this step was adopted from step-3 of intermediate-33 (0.49g,
81.66%).
LCMS: m/z = 381.48 (M+H).
The below intermediates-41 to 51 were prepared according to the above protocol
(intermediate-40) by using appropriate reactants, reagents at suitable
conditions. The
characterization data of the intermediates are summarized herein.
Int Analytical Int Analytical
Structure Structure
No. Data No. Data
H2N
4 H2N LCMS:
LCMS: m/z =
482.40
41 NH 396.21 42 NH
-N
N (M-FH). BocNao (M+H)+.
+
H2N tis
LCMS: m/z = H2N op
401.8 LCMS: m/z =
43 NH
N 44 NH
(M+H)+. -N
414.1 (M-FH)+.
0 N 0 N
CA 02978170 2017-08-29
WO 2016/142855 PCT/1112016/051302
,
H2N lis H2N 0
LCMS: m/z = LCMS: m/z =
45 NH
46 NH
...1-.
N - 1 * 1 - = µ 355.1 (M+H) N-' N-N, 357.4(M+H)+.
112N 0
112N 00
LCMS: m/z =
LCMS: m/z =
47 islr 399.15 (M- 48 NH
369.1 (M-1-1-1)+.
""cr----- ------eN).. H)+.
\------o N
H2N is H2N 0
LCMS: m/z = LCMS: nilz =
49 NH 383.21 50 \ NH
.1. ..N 382.15
(m+H)+. 1N-1 N: T,),__I ...._,...
(M-FH)+.
0 N N".....4*.'0 N
H2N =
LCMS: m/z =
470.35
51 MIN 'N
B,,..14......,,,,,x;CN,L.,........ (M+H)+.
1
The present invention is further exemplified, but not limited, by the
following examples
that illustrate the preparation of compounds according to the invention
Example-1: Synthesis of 1-acryloyl-N-(3-(((8-isopropy1-2-
((tetrahydro-2H-pyran-4-
yl)amino)pyrazolo[1,5-a][1,3,5]triazin-4-yDamino)methyl)phenyppiperidine-3-
carboxamide
(Compound-1).
H2N,0 0 W
0 0
NH
%,õ).
NOHNH
N N N N
H H
61
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
To a cooled solution of 1-acryloylpiperidine-3-carboxylic acid (0.086g,
0.47mmo1,
intermediate-12) in DMF (4mL) at 0 C was added HATU (0.22g, 0.59mmo1) and
DIPEA
(0.2mL, 1.18mmol) and finally added N4-(3-aminobenzy1)-8-isopropyl-N2-
(tetrahydro-2H-
pyran-4-yl)pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine (0.15g, 0.39mmo1,
intermediate-33). The
reaction mixture was stirred for 2h at room temperature. After completion of
the reaction, the
reaction mixture was quenched with ice-water and diluted with ethyl acetate.
The aqueous layer
was separated and extracted with ethyl acetate (2x25mL). The combined organic
phase was
washed with brine, dried over Na2SO4, filtered and concentrated to crude
residue. The residue
was purified by combiflash to afford the title compound (0.05g, 25%). iHNIVIR
(DMSO-d6,
400M1-lz): ö 9.99-9.96 (d, 111), 8.95-8.70 (m, 1H), 7.72 (s, 1H), 7.51 (s,
211), 7.25-7.21 (t, 1H),
7.03-7.01 (d, 1H), 6.90-6.79 (m, 2H), 6.11-6.07 (d, 111), 5.68-5.63 (t, 1H) ,
4.59-4.46 (m, 21),
4.32-4.28 (d, 1H), 4.10-4.00 (m, 2H), 3.82 (s, 3H), 3.18-3.16 (d, 1H), 3.07-
3.00 (t, 1H), 2.91 (s,
1H), 2.78-2.67 (m, 111), 2.46 (m, 1H), 1.95-1.92 (m, 111), 1.84 (s, 1H), 1.73-
1.63 (m, 3H), 1.46-
1.35 (m, 3H), 1.23-1.22 (d, 611); LCMS: m/z = 547.9 (M+H)+.
The below compounds were prepared by procedure similar to the one described in
Example-1 with appropriate variations in reactants, quantities of reagents, in
presence of suitable
solvents at suitable reaction conditions. The physicochemical characteristics
of the compounds
are summarized herein below table.
Compd
Compound structure Analytical data
No
11-1 NMR (DMSO-d6, 400MHz): 10.18-10.17 (d, 1H),
7.87-7.34 (m, 3H), 7.27-7.21 (t, 1H), 7.08-7.06 (d, 1H),
00
o 6.36-6.29 (m, 1H), 6.13-6.05 (m, 1H) 5.73-
5.70 (m,
1H), 5.59-5.56 (t, 111), 5.06-4.79 (m, 1H), 4.59 (s, 2H),
2 NH
N
oTh4.21-4.15 (m, 1H), 3.90-3.80 (m, 3H), 3.37-3.31 (m,
N N 2H), 2.95-2.88 (m, 1H), 2.66-2.58 (m, 1H),
2.21-2.12
(m, 1H), 1.90-1.65 (m, 4H), 1.43 (s, 2H), 1.20 (s, 6H);
LCMS: m/z = 519.30 (M-FH) .
62
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
1H NMR (DMSO-d6, 400MHz): 5 10.14 (s, 1H), 10.02
o)L,
(s, 1H), 8.92 (s, 1H), 8.65 (s, 1H),7.70 (s, 111), 7.67-
7
.48 (m, 3H), 7.24-7.20 (m, 1H), 7.05-7.02 (s, 1H),
6.81 (s, 1H), 6.66-6.54 (m, 1H), 6.14-6.08 (m, 1H),
3 NH 5.70-
5.67 (in, 111), 4.62-4.58 (m, 211), 4.47-4.46 (m,
1H), 3.82 (s, 2H), 3.71-3.56 (m, 2H), 2.90 (s, 2H),
2.15-2.08 (m, 2H), 2.02-1.84 (m, 211), 1.59 (s, 1H),
1.44-1.37 (m, 2H), 1.30-1.23 (m, 6H); LCMS: m/z =
533.3 (M+H) .
1H NMR (DMSO-d6, 400MHz): 5 10.04-10.03 (d, 1H),
8.9 (s, 1H), 7.67 (s, 1H), 7.46 (m, 3H), 7.21-7.17 (t,
Nairg
0 111), 6.99-6.97 (d, 1H), 6.78 (s, 2H), 6.57-6.49 (m, 1H),
6.11-6.06 (m, 1H), 6.06 (s, 1H), 5.63-5.60 (m, 1H),
4 10-Th N11-14,,Ni, 4.55
(s, 1H), 3.78-3.74 (m, 3H), 3.67-3.63 (m, 2H),
3.58-3.52 (m, 2H), 3.25-3.17 (m, 1H), 3.15-3.13 (m,
1H), 2.86 (s, 2H), 2.16-2.06 (m, 3H), 1.93 (s, 1H),
1.53-1.33 (m, 3H), 1.18 (s, 6H); LCMS: m/z = 533.3
(M-FH)+.
Isomer-1: 1H NMR (DMSO-d6, 400MHz): 5 10.07-
10.06 (d, 1H), 8.90 (s, 1H), 7.71 (s, 1H), 7.51 (m, 2H),
H
N aikh,
RP 7.23-
7.21 (t, 111), 7.03-7.01 (d, 1H), 6.89-6.80 (m, 1H),
0
6.61-6.53 (m, 1H), 6.15-6.11 (m, 1H), 5.67-5.63 (m,
N:111-11,1 -N., 1H), 4.59 (s, 2H), 3.82-3.62
(m, 3H), 3.58-3.50 (m,
211), 3.39-3.37 (m, 111), 3.23-3.06 (m, 211), 2.89 (s,
2H), 2.19-1.83 (m, 2H), 1.59-1.38 (m, 3H), 1.27-1.23
(d, 2H), 1.11-1.02 (d, 6H); LCMS: m/z = 533.2
(M+H) .
63
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
Isomer-2: 1H NMR (DMSO-d6, 400MHz): 8 10.08-
iiµ11
o 10.06 (d, 1H), 8.90 (s, 1H), 7.71 (s, 1H), 7.50 (m, 2H),
7.25-7.21 (t, 1H), 7.03-7.01 (d, 1H), 6.89-6.80 (m, 1H),
Nfi
NN-N 6.61-6.53 (m, 1H), 6.15-6.11
(m, 111), 5.67-5.63 (m,
6 9^1 H
Hi), 4.58 (s, 2H), 3.82-3.62 (m, 511), 3.58-3.50 (m,
2H), 3.39-3.37 (m, 1H), 3.23-3.07 (m, 1H), 2.89 (s,
1H), 2.19-1.99 (m, 4H), 1.59-1.38 (m, 2H), 1.27-1.23
(d, 211), 1.23 (s, 611); LCMS: m/z = 533.25 (M+H)+.
1H NMR (DMSO-d6, 400MHz): 6 9.80 (s, 1H), 8.90 (s,
N
H 1H),
8.65 (s, 1H), 8.02-8.00 (d, 1H), 7.71 (s, 1H), 7.50
)::)r
(s, 2H), 7.23-7.19 (t, 1H), 6.99-6.97 (d, 1H), 6.82 (s,
...Nµ 111),
6.39-6.32 (m, 1H), 6.08-6.03 (d, 1H), 5.56-5.52
7 0 NN
(m, 1H), 4.59 (s, 2H), 4.05-4.00 (m, 1H), 3.87-3.83 (m,
411), 2.90 (s, 1H), 2.38-2.36 (m, 1H), 1.82-1.69 (m,
611), 1.59-1.53 (m, 6H), 1.19 (s, 6H); LCMS: m/z =
561.4 (M+H) .
1H NMR (DMSO-d6, 400MHz): 8 10.00-9.97 (d, 1H),
8.91-8.64 (m, 1H), 7.71 (s, 1H), 7.51 (s, 211), 7.25-7.23
11
(t, 1H), 7.02 (s, 1H), 6.90-6.75 (m, 2H), 6.11-6.07 (d,
1H), 5.69-5.63 (t, 1H), 4.60 (s, 2H), 4.49-4.28 (m, 1H),
8 NIHN_N, 4.13-
4.00 (m, 211), 3.65 (s, 3H), 3.23-3.16 (m, 2H),
3.07-3.01 (t, 1H), 2.90 (s, 1H), 2.78-2.67 (m, 3H), 2.42
(s, 1H), 2.20 (s, 311), 2.04-1.85 (m, 4H), 1.73-1.67 (m,
311), 1.49-1.34 (m, 4H), 1.23 (s, 611); LCMS: m/z =
560.5 (M+H)+.
1H NMR (DMSO-d6, 400MHz): 6 9.80 (s, 1H), 8.02-
-- N
rf.T' aim
0 'JP 8.00
(d, 1H), 7.87 (s, 1H), 7.72 (s, 1H), 7.61 (t, 1H),
7.50 (s, 2H), 7.23-7.19 (t, 2H), 7.08 (s,1H), 6.96 (s,
9 NH
Hoym NNN 2H), 6.38-6.31 (m, 1H), 6.08-
6.03 (m, 1H), 5.55-5.52
(m, 1H), 4.59-4.57 (m, 2H), 3.87 (s, 1H), 3.38 (s, 2H),
2.91 (s, 2H), 2.67 (s, 2H), 2.32 (s, 2H), 1.90-1.68 (m,
64
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
6H), 1.53-1.40 (m, 3H), 1.22-1.20 (d, 7H); LCMS: m/z
= 575.0 (M+H)+.
Isomer-1: 1H NMR (DMSO-d6, 400MHz): 6 9.80 (s,
1H), 8.60 (s, 1H), 8.02-8.00 (d, 1H), 7.70 (s, 1H), 7.50
(m, 2H), 7.23-7.19 (t, 1H), 6.98 (s, 1H), 6.55 (m, 1H),
6.39-6.32 (m, 1H), 6.08-6.03 (m, 1H), 5.56-5.53 (d,
1H), 4.60 (s, 4H), 4.11-4.09 (m, 1H), 3.89 (s, 1H), 3.69
(s, 111), 3.43-3.42 (m, 1H), 3.17-3.16 (d, 211), 2.91 (s,
2H), 2.67 (s, 2H), 2.38-2.37 (m, 1H), 1.83-1.69 (m,
5H), 1.60-1.50 (m, 4H), 1.23 (s, 61-1); LCMS: m/z =
10& HN
-N 575.40 (M+H)+.
11
TOr1N Isomer-2: 1H NMR (DMSO-d6, 400MHz): 8 9.79 (s,
1H), 8.60 (s, 1H), 8.02-8.01 (d, 1H), 7.69 (s, 1H), 7.55-
7.53 (m, 2H), 7.23-7.19 (t, 111), 6.98 (s, 1H), 6.55 (m,
1H), 6.39-6.32 (m, 1H), 6.08-6.04 (m, 1H), 5.56-5.53
(d, 1H), 4.60 (s, 2H), 4.38 (s, 1H), 4.13-4.09 (m, 2H),
3.90 (m, 2H), 3.17-3.16 (d, 2H), 2.91 (s, 1H), 2.67 (s,
2h), 2.38 (s, 1H), 1.80-1.68(m, 4H), 1.60-1.36 (m, 7H),
1.23(s, 6H); LCMS: m/z = 575.30 (M+H)+.
Isomer-1: NMR
(DMSO-d6, 400MHz): 8 10.03 (s,
111), 8.57 (s, 1H), 7.66 (s, 1H), 7.53-7.40 (m, 2H),
7.21-7.18 (t, 111), 6.99 (s, 1H), 6.69 (s, 1H), 6.58-6.50
NTrCN (m, 1H), 6.11-6.07 (m, 1H), 5.64-5.60 (m, 1H),
4.56 (s,
1101 0 211), 3.79-3.59 (m, 3H), 3.55-3.39 (m, 211), 3.20-
3.04
12 &
(m, 3H), 2.85 (s, 2H), 2.17-1.91 (m, 4H), 1.73-1.61 (m,
13
5H), 1.18 (s, 6H); LCMS: m/z = 546.90 (M+H)+.
Isomer-2: 1H NMR (DMSO-d6, 400MHz): 8 10.04-
10.02 (d, 1H), 8.54 (s, 111), 7.65 (s, 1H), 7.50-7.48 (m,
2H), 7.21-7.18 (t, 1H), 6.98 (s, 1H), 6.57-6.51 (m, 2H),
6.11-6.06 (m, 1H), 5.64-5.60 (m, 1H), 4.56-4.35 (m,
3H), 4.09-4.05 (m, 1H), 3.89 (s, 1H), 3.79-3.59 (m,
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
2H), 3.55-3.42 (m, 2H), 3.18-3.04 (m, 2H), 2.16-1.91
(m, 3H), 1.77-1.53 (m, 4H), 1.41-1.32 (m, 3H), 1.19 (s,
6H); LCMS: m/z = 547.20 (M+H)+.
Example-2: Synthesis of 1-acryloyl-N-(3-(((2-(((3R,4R)-3-fluoropiperidin-4-
yl)amino)-8-
isopropylpyrazolo [1,5-a] [1,3,5] triazin-4-yDamin o)methyl)phenyl)pyrrolidine-
3 -carboxamide
(Compound-14).
Step-1: Synthesis of tert-but vl (3R,4R)-4-((44(3-(1-acryloylpyrrolidine-3-
carboxamido)
benzy1)amino)-8-isopropy1pyrazo1o11.5-a111.3,51triazin-2-ynarnino)-3-
fluoropiperidine-1-
carboxylate.
H2N
0
NH --z..¨.)--N")--1(OH
N _______________________________________________________ NH
BoeN B a N F N
ocNO".
N N
H
To a cooled solution of 1-acryloylpyrrolidine-3-carboxylic acid (0.05g,
0.30mmo1,
intermediate-10) in DMF (2mL) at 0 C was added HATU (0.11g, 0.30mm01) and
DIPEA
(0.07mL, 0.40mmo1) and finally added tert-butyl (3R,4R)-44(44(3-
aminobenzypamino)-8-
isopropylpyrazolo [1,5-a] [1,3 ,5] triazin-2-yl)amin o)-3-fluoropiperidine-l-
carbox ylate (0.1g,
0.20mmol, intermediate-38). The reaction mixture was stirred for 2h at room
temperature. The
reaction mixture was quenched with ice-water and diluted with ethyl acetate.
The aqueous layer
was separated and extracted with ethyl acetate (2x20mL). The combined organic
phase was
washed with brine, dried over Na2SO4, filtered and concentrated to crude
residue. The residue
was purified by combiflash to afford desired title compound (0.1g, 76%).
Step-2: Synthesis of
1-acrvloyl-N-(3-(((2-(((3R,4R)-3-fluoropiperidin-4-vflamino)-8-
isopropylpyrazolo11,5-a111,3,51triazin-4-yl)amino)methyl)phenyl)pyrrolidine-3-
carboxamide.
0
0
0 0 411
NH NH
Boc;NO#F NJ'N "N\ HNO=F N#LN-N,
'N N = 'WIN
66
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
TFA (1mL) was added to a solution of tert-butyl (3R,4R)-4-((4-((3-(1-
acryloylpyrrolidine-3-carboxamido)benzypamino)-8-isopropylpyrazolo[1,5-
a][1,3,5]triazin-2-
yl)amino)-3-fluoropiperidine-l-carboxylate (0.1g, 0.15mmopin DCM (5mL) at 0
C. Then the
reaction mixture allowed stirring at room temperature for 12h. After
completion of the reaction,
.. the reaction mixture was evaporated to afford amine. The residue was
purified by prep. HPLC
(Method: A: 0.1% TFA, B: Acetonitrile:Me0H, Column: )(BRIDGE C-18 (19mm*150mm,
51-11n)) to afford desired title compound (0.04g, 50%). 1HNMR (DMSO-d6,
400MHz): 10.09-
10.07 (d, 1H), 8.80 (s, 3H), 7.79 (s, 1H), 7.62-7.51 (m, 211), 7.26-7.22 (t,
1H), 7.09-6.96 (m, 111),
6.61-6.54 (m, 1H), 6.15-6.10 (m, 1H), 5.75-5.65 (m, 2H), 4.63 (s, 2H), 4.25
(m, 2H), 3.82-3.63
(m, 311), 3.66-3.45 (m, 2H), 3.37-3.10 (m, 4H), 2.93-2.90 (t, 2H), 2.22-1.92
(m, 211), 1.71 (s,
211), 1.39 (s, 611); LCMS: m/z = 550.65 (M+H)+.
The below compounds were prepared by procedure similar to the one described in
Example-2 with appropriate variations in reactants, quantities of reagents, in
presence of suitable
solvents at suitable reaction conditions. The physicochemical characteristics
of the compounds
are summarized herein below table.
Compd
Compound structure Analytical data
No
N
0 41 111 NMR (DMSO-d6, 400MHz): 10.07-10.05 (d,
111),
8.54 (s, 1H), 7.78-7.70 (m, 4H), 7.48 (m, 211), 7.23-
7.19 (m, 1H), 7.07 (s, 1H), 6.99 (s, 1H), 6.57-6.51 (m,
NH
15 N 1H), 6.12-6.07 (d, 1H), 5.65-5.62 (m, 1H),
4.57 (s, 311),
N".
FI2N WIN --- 3.36-3.33 (m, 3H), 3.19-3.05 (m,
3H), 2.92-2.87 (m,
2H), 2.14-2.04 (m, 2H), 1.96-1.28 (m, 4H), 1.19 (s,
8H); LCMS: m/z = 546.25 (M-41)+.
Example-3: Synthesis of 1 -aeryloyl-N-(3-(08-isopropy1-2-(((S)-tetrahydro-2H-
pyran-3-
yl ) ami no )pyrazolo [1,5-al [1,3,5]triazi n-4-yDami
no)methyl)phenyl)piperidine-2-carboxami de
(Compound-16).
Step-1: Synthesis of tert-butyl 2-((3-(¶8-i sopropy1-2-MS)-
tetrahydro-2H-p yran-3-
vl)amino)pyrazolo 1,5-al 1-1,3,51triazin-4-
yflamino)methyl)phenyl)carbamoyl)piperidine-1-
carboxylate.
67
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
001
N
MP'
NH r,"..rCOOH
r
0 NH - N N l'`--;NB r INT
N N
N
To a cooled solution of 1-(tert-butoxycarbonyl)piperidine-2-carboxylic acid
(0.13g,
0.577mmo1) in DMF (10mL) at 0 C was added HATU (0.26g, 0.68mmo1) followed by
DIPEA
(0.2mL, 1.04mmol) and finally added (S)-N4-(3-aminobenzy1)-8-isopropyl-N2-
(tetrahydro-2H-
pyran-3-yl)pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine (0.2g, 0.524mmo1,
intermediate-34). The
reaction mixture was stirred for lh at room temperature. The reaction mixture
was quenched
with ice-water and diluted with ethyl acetate. The aqueous layer was separated
and extracted
with ethyl acetate (2x25mL). The combined organic phase was washed with brine,
dried over
Na2SO4, filtered and concentrated the crude residue was purified by 100-200
silica gel column
chromatography to afford desired title compound (0.14g, 42%). LCMS: m/z = 593
(M+H)+.
Step-2: Synthesis of N-(3-a(8-isopropy1-2-WS)-tetrahydro-2H-pyran-3-
ybamino)pyrazolo[1,5-
all1,3,51triazin-4-yl)amino)methyl)phenybpineridine-2-carboxamide.
ki iTh H
NBoc 010 VE 0
NH = NH
N N N N
TFA (0.5mL) was added to a solution of tert-butyl 2-((3-(((8-isopropyl-2-(((S)-
tetrahydro-2H-pyran-3-yl)amino)pyrazolo[1,5-a][1,3,5]triazin-4-
yDamino)rnethyl)phenyl)
carbamoyl)piperidine-1-carboxylate (0.14g, 0.23mm01) in DCM (5mL) at 0 C.
Then the reaction
mixture allowed to stir at room temperature for 2h. After completion of the
reaction, the reaction
mixture was concentrated under vacuum, to afford desired title compound
(0.12g, crude). LCMS:
m/z = 493 (M+H)+.
Step-3: Synthesis of 1-acrylo yl-N-(3-(((8-i sopropy1-2-(((S)-
tetrahydro-2H-pyran-3-
yl)amino)pyrazolo [ 1,5-al [1,3,51triazin-4-yflamino)methyl)phenyl)piperidine-
2-carboxamide.
68
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
H
N gam
HN 0 0) 0
0
NH
NH N
0 rci0
111: N N
N
To a cooled solution of N-(3-(((8-isopropy1-2-(((S)-tetrahydro-2H-pyran-3-
yDamino)pyrazolo[1,5-a][1,3,5]triazin-4-yDamino)methyl)phenyl)piperidine-2-
carboxamide
(0.12g, 0.24mmo1) in DCM (5mL) added TEA (0.1mL, 0.72mmo1) and stirred for
5min and
added acryloyl chloride (0.022g, 0.24mm01) diluted in DCM(1mL) drop wise at 0
C. The
reaction mixture was allowed to stir at room temperature for lh. After
completion of the
reaction, the reaction mixture quenched with water and then diluted with DCM
(10mL). Organic
layer washed with water followed by brine, dried over Na2SO4, filtered and
concentrated under
vacuum and purified by preparative HPLC (Method: A: water, B: Acetonitrile,
Column: Kinetex
EVO C-18 (150mm*21.2, 5 m) to afford desired title compound (0.03g, 30%) as
free base.
1HNMR (DMSO-d6, 400MHz): 6 9.92 (s, 111), 8.90-8.68 (d, 1H), 7.71 (s, 1H),
7.50 (s, 211), 7.25-
7.21 (t, 1H), 7.02 (s, 1H), 6.88-6.82 (m, 1H), 6.68 (s, 1H), 6.10-6.06 (d,
1H), 5.68-5.66 (d, 1H),
5.12 (s, 1H), 4.58 (s, 2H), 3.98-3.71 (m, 4H), 3.51-3.46 (t, 2H), 3.21 (t,
1H), 3.02 (t, 1H), 3.02-
2.91 (m, 3H), 2.12-2.09 (d, 111), 1.66-1.52 (m, 4H), 1.38 (s, 2H), 1.23 (s,
611); LCMS: rniz =
547.3 (M+H)+.
The below compounds were prepared by procedure similar to the one described in
Example-3 with appropriate variations in reactants, quantities of reagents, in
presence of suitable
solvents at suitable reaction conditions. The physicochemical characteristics
of the compounds
are summarized herein below table.
Compd.
Compound structure Analytical data
No.
P-,ir ah,
0= 40 1H NMR (DMSO-d6, 400MHz): 6 7.69 (s, 1H),
7.57
k 0
(m, 1H), 7.44 (m, 1H), 7.24 (in, 1H), 7.04 (m, 1H),
17 NH
N 5.65 (s, 111), 5.41 (s, 111), 4.88 (m,
111), 4.56 (m, 211),
Oa I: 1.4.
N N 4.08 (m, 1H), 3.78 (m, 3H), 3.42 (m, 3H),
2.88 (m,
69
CA 02978170 2017-08-29
WO 2016/142855 PCT/1112016/051302
2H), 2.13 (m, 1H), 2.09 (m, 3H), 1.96 (m, 3H), 1.63
(m, 2H), 1.42 (m, 2H), 1.20 (d, 6H), 1.08 (m, 2H);
LCMS: m/z = 547.7 (M+H)+.
o 1H NMR (DMSO-d6, 400MHz): 8 10.08 (s, 1H),
8.70
0 (s, 1H), 7.71 (s, 1H), 7.5-7.48 (m, 2H), 7.26
(t, 1H),
7.04 (d, 1H), 6.90 (m, 1H), 6.34 (m, 1H), 6.12 (d, 1H),
18 H N 5.68 (d, 111), 4.59-4.40 (m, 211), 4.37 (t,
1H), 4.35 (t,
1H), 4.08 (m, 111), 4.03 (m, 1H), 3.94 (m, 3H), 3.52
(m, 2H), 2.90 (m, 2H), 1.98-1.92 (m, 2H), 1.6-1.4 (m,
211), 1.23-1.07 (d, 611); LCMS: m/z = 518.7(M+H)+.
1H NMR (DMSO-d6, 400MHz): 8 10.15 (s, 1H), 8.70
(s, 1H), 7.70 (s, 1H), 7.54 (s, 2H), 7.26-7.22 (t, 1H),
CirgloH
N aaki
Lup 7.05-7.03 (d, 1H), 6.81 (s, 1H), 6.36-6.29 (m, 1H),
0
6.13-6.05 (m, 1H), 5.72-5.55 (m, 1H), 5.05-4.78 (m,
19
NIH
"'N N 1H), 4.58 (s, 2H), 4.20-4.15 (m, 1H), 3.90-
3.81 (m,
001,11,,N 4H), 2.49-2.44 (m, 2H), 2.21-2.07 (m, 1H), 1.81-1.72
(m, 2H), 1.44-1.37 (m, 4H), 1.21 (s, 6H); LCMS: m/z
= 519.20 (M-FH)+.
1H NMR (DMSO-d6, 400MHz): .5 10.15 (s, 1H), 8.70
H (d, 1H), 7.70 (s, 1H), 7.52-7.48 (s, 2H),
7.23 (t, 1H),
is)
XN 7.05 (d, 1H), 6.90-6.75 (m, 1H), 6.36-6.30
(m, 1H),
6.13-6.05 (m, 1H) 5.72-5.55 (m, 1H), 5.05-4.78 (m,
20 111
-N 1H), 4.58 (brs, 2H), 4.20-4.15 (m, 1H), 3.90-
3.81 (m,
N Nx
3H), 2.89 (brs, 1H), 2.49-2.44 (m, 2H), 2.21-2.12 (m,
1H), 1.81-1.74 (m, 2H), 1.65-1.30 (m, 4H),1.22 (s,
611); LCMS: m/z = 519.15 (M-FH) .
CA 02978170 2017-08-29
WO 2016/142855 PCT/1112016/051302
111 NMR (D1VISO-d6, 400MHz): 5 8.66-8.62 (m, 2H),
7.71 (s, 1H), 7.64-7.53 (m, 211), 7.25-7.21 (t, 1H), 7.03
airN 111 4
(m, 1H), 6.89-6.82 (m, 2H), 6.10 (d, 1H), 5.69-5.66 (d,
0.11 o
1H), 5.12-5.11 (d, 2H), 4.58 (m, 211), 3.98-3.95 (d,
21
N1FIN-N 111), 3.82 (m, 311), 3.51-3.46 (m, 1H), 2.99-
2.90 (m,
2H), 2.12-2.09 (d, 1H), 1.82 (m, 1H), 1.66-1.62 (m,
41-1), 1.38 (m, 4H), 1.23 (d, 6H); LCMS: m/z = 547.0
(M+H)+.
1H NMR (DMSO-do, 400MHz): 5 9.87 (s, 1H), 8.9-
JCLNCIH
N 8.98 (m, 2H), 7.71 (s, 1H), 7.50 (m, 2H),
7.22 (t, 1H),
7.0 (d, 1H), 6.90 (m, 1H), 6.81 (m, 1H), 6.21 (m, 1H),
22 NN 6.08 (d, 1H), 5.57 (d, 1H), 4.57 (m, 2H),
3.82-3.65 (m,
5H), 2.9 (m, 1H), 1.90-1.87 (m, 6H), 1.62-1.45 (m,
2H), 1.36-1.29 (m, 3H), 1.27-1.23 (d, 6H), 1.1-1.08
(m, 2H); LCMS: m/z = 561.7 (M+H)+.
1H NMR (DMSO-d6, 400MHz): 5 9.85 (d, 1H), 8.80
(OH
n.rNS+ N = (d, 1H), 7.72 (s, 1H), 7.62-7.57 (m, 2H),
7.25 (t, 1H),
7.07 (d, 1H), 6.85-6.79 (m, 2H), 6.19-6.11 (m, 111),
23 N:C14 5.74-5.72 (d,1H), 4.60-4.51 (m, 3H), 4.12-
3.83 (m,
4H), 3.90-3.70 (m, 3H), 3.55 (t, 1H), 3.10-2.80 (m,
311), 1.82 (brs, 1H), 1.65-1.35 (m, 411), 1.24 (s, 6H);
LCMS: m/z = 549.70 (M+H)+.
1H NMR (DMSO-d6, 400MHz): 5 9.96 (s, 1H), 8.70
C )rt (d, 1H), 7.71 (s, 1H), 7.65-7.45 (m, 2H),
7.24 (t, 1H),
N
7.04 (brs, 1H), 6.89-6.82 (m, 2H) 6.17-6.13 (m, 1H),
5.75-5.66 (m, 1H), 4.87-4.85 (m, 1H), 4.59 (brs, 2H),
24
4.29-4.26 (d, 1H), 3.89-3.65 (m, 6H), 3.60-3.45 (m,
1H), 2.90 (brs, 1H), 2.45-2.55 (m, 2H), L82 (brs, 1H),
1.70-1.30 (m, 411), 1.22 (d, 6H); LCMS: m/z = 549.40
(M+H)+.
71
CA 02978170 2017-08-29
WO 2016/142855 PCT/1112016/051302
111 NMR (DMSO-d6, 400MHz): 5 10.14-10.09 (d,
(i4r11 111), 8.95 (s, 1H), 8.70 (s, 1H), 7.71 (s,
1H), 7.49 (m,
2H), 7.27-7.23 (t, 1H), 7.06 (s, 1H), 6.81 (s, 1H), 4.80-
o
25 4.79 (d, 1H), 4.70 (s, 1H), 4.60 (s, 211),
4.35-4.26 (m,
tx" 111), 4.03-3.99 (t, 1H), 3.90-3.73 (m, 4H), 3.69-3.45
N
(m, 1H), 3.49-3.43 (m, 1H), 2.67 (s, 1H), 1.82 (s, 2H),
1.63 (s, 111), 1.45 (m, 3H), 1.22 (s, 611); LCMS: m/z =
547.70 (M+H)+.
1H NMR (DMSO-d6, 400MHz): 5 9.63 (s, 1H), 8.13
(s, 1H), 7.67 (s, 1H), 7.53-7.51 (m, 111), 7.42-7.41 (d,
=IsyC 1H), 7.15-7.12 (d, 1H), 6.41-6.39 (m, 1H),
6.12-6.07
0
ih0 (m, 1H), 5.69-5.66 (d, 1H), 4.80 (s, 1H),
4.68-4.66 (d,
26
2H), 4.31-4.28 (m, 2H), 3.86-3.64 (m, 6H), 3.68-3.64
(m, 1H), 3.46-3.31 (m, 3H), 3.0-2.95 (m, 2H), 2.75-
2.67 (m, 2H), 1.93-1.81 (m, 2H), 1.55-1.46 (m, 2H),
1.18 (s, 6H), 1.18-1.16 (m, 3H); LCMS: m/z = 577.5
(M-1-11)+.
1HNMR (DMSO-d6, 400MHz): 5 10.06 (s, 1H), 8.60
(s, 1H), 7.73-7.72 (m, 1H), 7.58 (s, 1H), 7.33 (s, 1H),
NCJITI4 At_ 7.11-7.09 (d, 1H), 6.79 (s, 1H), 6.55 (s, 1H), 6.34-6.27
1-A (m, 111), 6.11-6.04 (m, 111), 5.71-5.68 (m,
111), 5.56-
.53 (t, 1H), 5.01-4.97(m, 111), 4.78-4.75 (m, 1H),
27
4.56-4.54 (d, 2H), 4.19-4.10 (m, 1H), 3.89-3.81 (m,
211), 3.17-3.15 (d, 111), 2.91 (s, 211), 2.59-2.41 (m,
2H), 2.38 (s, 3H), 2.05-2.17 (m, 1H), 2.08 (m, 1H),
1.81 (s, 1H), 1.44 (s, 2H),.1.24 (s, 6H); LCMS: m/z =
532.9 (M+H) .
72
CA 02978170 2017-08-29
WO 2016/142855 PCT/1112016/051302
111 NMR (D1VISO-d6, 400MHz): 8 9.64 (s, 1H), 8.90-
8.64 (m, 1H), 7.69 (s, 1H), 7.57 (m, 1H), 7.33 (m, 1H),
1 0 7.14-7.13 (m, 2H), 6.83 (m, 1H), 6.37 (m,
1H), 6.18-
6.04 (m, 1H), 5.75 (d, 1H), 5.61 (d, 114), 5.10 (m, 1H),
28
4.95 (t, 1H), 4.53 (m, 2H), 4.21-4.17 (t, 21:), 3.93-3.85
H
(m, 4H), 2.89 (m, 1H), 2.14 (s, 3H), 1.81-1.67 (m,
211), 1.44 (m, 2H), 1.21 (d, 6H); LCMS: m/z =
533.2(M-FH)+.
1H NMR (DMSO-d6, 400MHz): 8 10.19 (s, 1H), 8.66
(d, 1H), 7.74 (s, 1H), 7.58 (m, 211), 7.18-7.13 (t, 1H),
1-A 6.83 (m, 1H), 6.54 (s, 1H), 6.35-6.29 (m, 1H), 6.13-
6.05 (m, 1H), 5.72-5.69 (m, 1H), 5.58-5.56 (m, 1H),
29 ? -J. Iv -Th N N '
5.02-4.98 (m, 1H), 4.77-4.74 (m, 1H), 4.65 (s, 2H),
N
I' 4.21-4.14 (m, 1H), 3.89-3.83 (m, 3H), 2.41
(m, 1H),
2.20-2.18 (m, 1H), 1.83 (m, 2H), 1.59-1.479 (m, 3H),
1.24 (s, 6H); LCMS: miz = 537 (M+H) .
11-1 NMR (DMSO-d6, 400MHz): 8 10.05 (d, 1H), 9.00-
8.52 (m, 111), 7.9 (m, 1H), 7.72 (s, 1H), 7.10 (m, 2H),
ol 0 kip
6.89 (m, 1H), 6.39 (m, 1H), 6.21 (d, 1H), 6.10 (d, 1H),
30 NI4HN_N
5.78 (d, 1H), 5.06 (m, 1H), 4.67 (m, 2H), 4.22 (t, 2H),
Ca-11)N 3.91-3.81 (m, 411), 2.9 (m, 211), 2.33 (m,
111), 1.81 (m,
114), 1.44 (m, 3H), 1.22 (d, 6H); LCMS: nrilz = 537.65
(M-FH)+.
1H NMR (DMSO-d6, 400MHz): 8 10.36 (s, 1H), 8.81
1,C13-1,71 rdk.õ.F (d, 1H), 7.72 (s, 1H), 7.58-7.20 (m, 2H),
6.91-6.80 (m,
2H), 6.36-6.29 (m, 1H), 6.13-6.06 (m, 1H), 5.73-5.56
NH (m, 111), 5.05-4.759 (m, 1H), 4.58 (brs, 2H),
4.21-4.10
Ca
31 NN"
w_
(m, 1H), 3.90-3.83 (m, 3H), 3.17-3.15 (m, 2H), 2.90
(brs, 1H), 2.32-2.08 (m, 3H), 1.92-1.82 (m, 1H), 1.56-
1.37 (m, 3H), 1.22 (s, 6H); LCMS: m/z = 537.3
(M+H) .
73
CA 02978170 2017-08-29
WO 2016/142855 PCT/1112016/051302
111 NMR (DMSO-d6, 400MHz): 6 10.13 (s, 1H), 8.7
0 'fly
0 1110 (d, 1H), 7.70-7.40 (m, 311), 7.12 (t, 1H),
6.83 (m, 1H),
6.59-6.52 (m, 1H), 6.13-6.09 (m, 1H), 5.63-5.62 (m,
32 -N114, 1H), 4.64 (s, 2H), 3.79-3.59 (m, 511), 3.49-
3.43 (m,
N' k
N 2H), 3.33-3.04(m, 2H), 3.04(s,2H) 2.16-1.80
(m, 41),
1.55-1.34 (m, 3H), 1.23 (s, 6H); LCMS: m/z =
551.45(M+H)+.
1H NMR (DMSO-d6, 400MHz); 6 10.25 (d, 1H), 8.8
r
o 41) (d, 1H),7.69 (s,1H),7.49-7.16 (rn, 2H), 7.00-
6.70 (m,
2H), 6.56-6.49 (m, 1H), 6.11-6.06 (m, 1H), 5.64-5.60
33 NIHN-N (m, 1H),4.54 (s, 2H), 3.77-3.73 (m, 3H), 3.67-
3.43(m,
4H), 3.30-3.12(m, 2H), 3.05(s,1H) 2.15-1.90 (m, 4H),
1.52-1.33 (m, 3H), 1.19 (s, 6H); LCMS: m/z =
551.3(M+H)+.
1HNMR (DMSO-d6, 400MHz): 69.82 (s, 1H), 8.56 (d,
1H), 7.72 (s, 1H), 7.56 (m, 2H), 7.27 (m, 2H), 7.08-
7.06 (d, 2H), 6.85-6.79 (m, 311), 6.00 (d, 1H), 5.66-
NH
5.63 (d, 1H), 5.07 (s, 1H), 4.55-4.53 (d, 3H), 4.30-
NN
34
(m,1H), 3.94-3.91 (d, 1H), 3.82 (m, 4H), 3.46 (m, 1H),
3.16-2.91 (m, 2H), 2.31-2.25 (m, 3H), 2.13-1.97 (m,
211), 1.82 (s, 211), 1.63-1.54 (m, 2H), 1.23-1.22 (d,
6H); LCMS: m/z = 561.1 (M+H)+.
a
1H NMR (DMSO-d6, 400MHz): 8 9.70 (d, 1H), 8.60-
N ir NH
F 8.90 (d, 1H), 7.70 (s, 1H), 7.50 (s, 1H), 7.06 (m, 2H),
6.85 (m, 2H), 6.09-6.05 (d, 1H), 5.67-5.64 (d, 1H),
NH
35 5.24 (s, 1H), 4.63 (s, 2H), 3.90 (d, 1H), 3.78 (m, 4H),
N N-N
2.90 (m, 1H), 2.29-2.28 (d, 2H), 1.8 (m, 1H), 1.62 (m,
N
4H), 1.37 (m, 4H), 1.19 (s, 611); LCMS: m/z = 565.45
(M+H)+.
74
CA 02978170 2017-08-29
WO 2016/142855 PCT/1112016/051302
Cir1H NMR (DMSO-d6, 400MHz): 8 10.14 (s, 1H), 8.70
iH
N abi F
0 1111 (s, 1H), 7.71 (s, 1H), 7.50-7.28 (m,
2H), 6.87-6.80 (m,
o) 3H), 6.53 (s, 2H), 6.09-6.05 (d, 1H) 5.68-
5.65 (m, 1H),
3
NNH
6 N-N 5.08-5.07 (d, 1H), 4.56 (s, 214), 3.97-3.81 (m,
4H),
N 3.45 (m, 1H), 3.32 (s, 111), 2.89 (s, 2H),
2.09-2.06 (d,
1H), 1.81 (s, 1H), 1.65-1.58 (m, 3H), 1.37-1.35 (d,
31-1), 1.22 (s, 6H); LCMS: m/z = 565.75 (M+H) .
1H NMR (DMSO-d6, 400MHz): 5 9.97 (s, 1H), 8.96-
cir 11
8.65 (d, 1H), 7.75-7.43 (m, 3H), 7.16-7.12 (t, 1H),
o o
F
6.94-6.82 (m, 2H), 6.10-6.03 (m, 1H), 5.69-5.67 (d,
37 1111 1H), 5.09 (s, 1H), 4.80-4.68 (m, 2H), 3.98-3.83
(m,
N N
4H), 2.93 (m, 2H), 2.19-1.99 (m, 211), 1.84 (s, 1H),
1.66-1.62 (m, 3H), 1.38-1.25 (m, 8H); LCMS: m/z =
565.2 (M+H)+.
11-1 NMR (DMSO-d6, 400MHz): ö 9.55 (s,1H), 9.00-
H 8.52 (m, 1H), 8.01-7.99 (d, 1H), 7.68 (s,
1H), 7.60 (m,
1H), 7.02 (m, 2H), 6.90 (m, 1H), 6.35-6.28 (m, 1H),
F 44F 6.05-6.00 (dd, 1H), 5.52-5.49 (dd, 1H), 4.63 (s, 2H),
38 NI1
3.84-3.77 (m, 3H), 3.36-3.33 (m, 2H), 3.25 (m, 1H),
o^)
2.80 (m, 1H), 2.51-2.48 (m, 1H), 1.79-1.74 (m, 3H),
1.67-1.65 (m, 211), 1.60-1.49 (m, 311), 1.40 (m, 211),
1.18 (d, 611), 1.05-1.03 (t, 2H); LCMS: m/z = 579.3
(M+H)+.
11-1 NMR (DMSO-d6, 400MHz): ö 9.84 (s, 1H), 8.7 (d,
1H), 8.00 (d, 1H), 7.74 (s, 1H), 7.07-7.04 (m, 2H),
0 tep
7.10 (t, 1H), 6.90 (m, 1H), 6.37-6.31 (m, 1H), 6.07-
39 NH
6.02 (m, 1H), 5.55-5.52 (m, 1H), 4.63 (s, 2H), 3.86-
3.60 (m, 4H), 3.20 (s, 1H), 2.90 (s, 2H), 2.67-2.52 (s,
1\11
3H), 1.90-1.60 (m, 5H), 1.59-1.40 (m, 5H), 1.23 (s,
6H); LCMS: m/z = 579.35 (M+H) .
CA 02978170 2017-08-29
WO 2016/142855 PCT/1112016/051302
111 NMR (DMSO-d6, 400MHz): 5 10.06 (s, 1H),
ro,1
LN-At4 N 8.76(s, 1H), 8.61 (s, 1H), 8.47 (s, 1H), 8.18 (s, 1H),
o 7.80 (s, 1H), 6.9-0-6.80 (m, 1H), 6.60-6.58
(d, 1H),
0-
6.27-6.23 (d, 1H), 5.85-5.82 (d, 1H), 5.00 (d, 1H),
N --N 4.79-4.77 (d, 2H), 4.51-4.47 (d, 1H), 4.04-
3.97 (m,
5H), 3.86-3.82 (m, 1H), 3.62-3.48 (m, 3H), 3.14-3.06
(m, 2H), 1.97-1.94 (d, 2H), 1.68-1.63 (m, 2H), 1.40-
1.38 (d, 6H); LCMS: m/z = 550.3 (M+H)+.
N 1,4
tilijCig 0
40A LCMS: m/z = 569.5 (M+H).
0 NH
HN 41It
11--µ0
NJ
HN-tiv-('N
40 B Itft
LCMS: m/z = 569.5 (M-1-H).
0 NI -I
HN *
11-0
HN "AN --(ZN
40C
1411k LCMS: m/z = 561.25 (M-FH) .
NH
76
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
r
N N
fiN "INAN 0,0
40D LCMS: m/z = 547.30 (M+H) .
00 NH
N!.."1"L
N x4-
NNN-
703
40E
N
LCMS: m/z = 547.70 (M H) .
Ni(3.NH
Example-4: Synthesis of (S)-N-(1-acryloylpiperidin-3-y1)-3-(((8-isopropy1-2-
((tetrahydro-2H-
pyran-4-yl)amino)pyrazolo[1,5-a][1,3,5]triazin-4-yDamino)methyl)benzamide
(Compound-41).
Step-1: Synthesis of tert-butyl
(S)-3-(3-(((84 sopropy1-2-(methyl thio)p yrazolol 15-
al f1,3,51triazin-4-yl)amino)methyl)benzamido)piperidine-1-carboxylate.
Boc
o 10 No0Boc
CI H2N i N"
"
r%V N
NH
N
N
DIPEA (0.5mL,2.47mmo1) was added to a solution of 4-chloro-8-isopropyl-2-
(methylthio)pyrazolo[1,5-a][1,3,5]triazine (0.3g, 1.23mmo1, intermediate-4)
and tert-butyl (S)-3-
(3-(aminomethyl)benzamido)piperidine-1-carboxylate (0.495g, 1.48mmol,
Intermediate-16) in
acetonitrile (10mL) at 0 C. The resulting reaction mixture was stirred at
ambient temperature for
4h. After completion of the reaction, the reaction mixture was concentrated
under vacuum and
purified by column chromatography using 100-200 silica gel to afford the title
compound (0.4g,
66%). LCMS: m/z = 540(M+H)+.
Step-2:
Synthesis of tert-butyl (S)-3-(3 -(((8-isopropy1-2-(methylsulfonybp yrazolo
1,5-
1-1,3,51triazin-4-ybamino)methvbbenzamido)piperidine-1-carboxylate.
77
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
0
NeCINBoc
IS H NeCIITBoc
NH
HN
N
N N"-
S N
N
mCPBA (1.53g, 5.79mm01) was added portion wise to a solution of tert-butyl (S)-
3-(3-
(((8-isopropy1-2-(methylthio)pyrazolo[1 ,5-a] [1,3 ,5] triazin-4-
yDamino)methyl)benzamido)
piperidine-l-carboxylate (0.8g, 1.44mm01) in DCM (10mL) and stirred for
overnight at RT.
After completion of the reaction, the reaction mixture was extracted with 2M
aq. NaOH and
DCM (10mL). The organic phase was washed with brine, dried over Na2SO4,
filtered and
concentrated to afford the title compound (0.7g, crude). LCMS: m/z =
572(M+H)+.
Step-3: Synthesis of tert-butyl (S)-3-(3-(((8-isopropv1-2-
((tetrahydro-2H-pyran-4-
vflamino)pyrazolo [1,5-a] [1,3,5]tri azin -4-yflamino)methyl)ben
zamido)piperidine-l-carboxyl ate.
eaBoc .01Boe
HN HN
so
401 0
NH2
HN I I FIN
1.-1-=== -N
0µ 51 00,
N
0
A mixture of 4-aminotetrahydropyran (0.25g, 2.45mm01) and tert-butyl (S)-3-(3-
(((8-
isopropy1-2-(methylsulfonyl)pyrazolo [1,5-a] [1,3 ,5] triazin-4-
yDamino)methyl)benzamido)
piperidine-l-carboxylate (0.35g, 0.614mm01) were allowed to heat at 100 C for
2h. After
completion of the reaction, the reaction mixture was cooled to room
temperature and quenched
with ice-water and diluted with ethyl acetate. The aqueous layer was separated
and extracted
with ethyl acetate (2x25mL). The combined organic phase was washed with brine,
dried over
Na2SO4, filtered and concentrated. The residue was purified by 100-200 silica
gel column
chromatography to afford desired title compound (0.16g, 44%). LCMS: miz =
592.9 (M+H) .
Step-4:
Synthesis of (S)-3-(((8-isopropv1-2-((tetrahvdro-2H-pvran-4-vflamino)pvrazolof
al [1,3,5]tri azin-4- v1) amino)methv1)-N-(piperidin-3-14)benz arnide.
78
B
ITN oc FINvONH
* 0 *0
HN HN
N N N N
The process of this step was adopted from step-2 of example-3 (0.10g crude).
LCMS: m/z
=493.4 (M+H)+.
Step-5: Synthesis of (S)-N-(1-acryloylpiperidin-3-y1)-34(8-isopropy1-2-
((tetrahydro-2H-pyran-
4-v1)amino)pyrazolo11,5-a1 11,351th azin-4-yflamino)methyl)benzamide
yCl
wax 0 .3
HN NH
-N __________________________________
N
00,
N
N N
The process of this step was adopted from step-3 of example-3. The obtained
crude
compound was purified by preparative HPLC (Method: A:water, B: Acetonitrile,
Column:
XBridget-18 (150mm*21.2, 5 m) to afford the desired title compound (0.014g,
20%). 1HNMR
(DMSO-d6, 400MHz): ö 9.00 (s, 1H), 8.75 (s, 1H), 8.32-8.30 (m, 1H), 7.84 (s,
1H), 7.71-7.68
(m, 211), 7.51-7.49 (m, 1H), 7.41-7.37 (m, 111), 6.92-6.67 (m, 2H), 6.07-6.03
(t, 111), 5.65-5.61
(m, 1H), 4.69 (s, 2H), 3.96-3.79 (m, 6H), 3.17-3.15 (d, 1H), 2.89 (s, 2H),
1.92-1.76 (m, 3H),
1.64-1.57 (m, 2H), 1.42 (s, 2H), 1.28-1.21 (m, 7H); LCMS: m/z = 546.8 (M+H) .
The below compounds were prepared by procedure similar to the one described in
Example-4 with appropriate variations in reactants, quantities of reagents in
presence of suitable
solvents at suitable reaction conditions. The physicochemical characteristics
of the compounds
are summarized herein below table.
Compd.
Compound structure Analytical data
No.
79
Date recue/Date received 2023-03-24
CA 02978170 2017-08-29
WO 2016/142855 PCT/1112016/051302
1H NMR (DMSO-d6, 400MHz): 5 10.09 (d, 1H), 9.02-
H F
1C-11)r-N 8.4
(m, 1H), 8.22-7.90 (m, 1H), 7.69 (s, 1H), 7.22-7.14
01 0 (m,
2H), 7.10-6.4 (m, 1H), 6.36 (m, 1H), 6.18 (m, 111),
NH 5.75
(d, 1H), 5.03 (m, 111), 4.84 (m, 2H), 4.20 (t, 111),
42
N N-N
\ 3 88-
3 82 (m 3H) 3.33 (m 1H) 2.88 (m 1H) 2.66 (m
N N
1H), 2.29 (m, 1H), 1.82-1.62 (m, 2H), 1.63-1.43 (m,
2H), 1.20 (d, 611), 1.08 (m, 211); LCMS: m/z =
537.7(M-FH)+.
1H NMR (DMSO-d6, 400MHz): 5 9.88 (s, 1H), 8.9 (m,
_0?_Narevr F 1H),
7.93-7.85 (m, 1H), 7.70 (s, 1H), 7.21-7.14 (m,
o 010 2H),
6.92-6.89 (m, 1H), 6.61-6.53 (m, 1H), 6.15-6.10
NH (dd,
1H), 5.68-5.64 (dd, 1H), 4.53 (s, 2H), 3.83-3.79
43
(m, 3H), 3.71-3.66 (m, 2H), 3.55-3.51 (m, 2H), 3.46-
3.27 (m, 3H), 2.88 (m, 1H), 2.22-2.15 (m, 2H), 1.98-
1.97 (m, 2H), 1.83-1.64 (m, 2H), 1.43-1.20 (dd, 6H);
LCMS: m/z = 551.3 (M+H) .
IH NMR (DMSO-d6, 400MHz): 8 9.72-9.67 (d, 1H),
cjIH
8.70 (s, 1H), 7.69 (s, 2H), 7.20-7.15 (m, 3H), 6.87-6.80
I (m,
2H), 6.54 (s, 3H), 6.11-6.06 (d, 1H), 5.69-5.65 (m,
44 /1 N 1-1
n N_N
1H), 5.24-5.23 (d, 1H), 4.53 (s, 2H), 4.04 (s, 2H), 3.98-
:4--
3.95 (d, 1H), 3.82 (s, 211), 2.88 (s, 111), 2.16-2.12 (d,
1H), 1.81 (s, 1H), 1.64 (m, 311), 1.41-1.38 (m, 3H),
1.20-1.19 (d, 6H); LCMS: m/z = 565.75 (M+H)';
1H NMR (DMSO-d6, 400MHz): 59.95-9.93 (d, 1H),
8.50 (m, 1H), 7.66 (s, 1H), 7.41 (m, 1H), 7.18 (m, 1H),
"orN IriNT 7.07-
7.06 (m, 1H), 6.85-6.74 (m, 2H), 6.06-6.02 (d,
1H), 5.64-5.59 (t, 1H), 5.1 (m, 1H), 4.45-4.42 (d, 1H),
N "N
4 28-4 24 (d 1H) 4.06-3.96 (m, 1H), 3.81-3.67 (m,
3H), 3.36 (m, 1H), 2.99-2.84 (m, 3H), 2.67-2.50 (m,
1H), 1.91-1.69 (m, 4H), 1.51-1.45 (m, 3H), 1.39-1.36
(m, 3H), 1.30 (d, 6H), 1.06-1.02 (m, 2H); LCMS: m/z =
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
561.35 (M+H)+.
Example-5: Synthesis of 3-(((8-isopropy1-2-((tetrahydro-2H-pyran-4-
yl)amino)pyrazolo[1,5-
a][1,3,5]triazin-4-yparnino)methyl)phenyl 4-acryloylpiperazine-1-carboxylate
(Compound-46).
Step-1: Synthesis of 3-(((8-isopropy1-2-(methylthio)pyrazolo[1,5-
a1[1,3,51triazin-4-
yflamino)methybphenol.
HO soCI
N so O NH2
NH
S')N H NTJ't,j-N
S N
The process of this step was adopted from step-1 of example-4 (0.5g, 73%).
LCMS: m/z
= 330.2 (M+H)+.
Step-2: Synthesis of 3-(a8-isopropyl-2-(methylsulfonybpyrazolo[1,5-
al[1,3,5]triazin-4-
y1)amino)methybphenol.
HO HO so
NH. NH
NT
N
q' N
,
S
0
The process of this step was adopted from step-2 of example-4 (0.35g, 63%).
LCMS: m/z
= 362.3 (M+H)+.
Step-3: Synthesis of 3-(((8-isopropy1-2-((tetrahydro-2H-pyran-4-
yflamino)pyrazolo[1,5-
al[1,3,51triazin-4-ybamino)methybphenol.
HO HO so
oNH2
NH = NH
N-N oisa
0µ
N N
0
81
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
The process of this step was adopted from step-3 of example-4 (0.22g, 70%).
LCMS: m/z
= 383.2 (M+H)+
Step-4: Synthesis of 1-(tert-butyl) 4-(3-(((8-isopropyl-2-((tetrahydro-2H-
pyran-4-ybarnino)
pyrazolof 1,5-al f 1,3,51triazin-4-yl)amino)methyl)phenyl) piperazine-1,4-
dicarboxylate.
N Boo
HO soOslOr N
BocN N¨f(
NH ¨/ CI EN
N _________________________________________________ -N
N N 03,
HN N
OQ
To a solution of 3-(((8-isopropy1-2-((tetrahydro-21-1-pyran-4-
yDamino)pyrazolo[1,5-
a][1,3,5]triazin-4-yDamino)methyl)phenol (0.227g, 0.59mmo1) in 10mL DCM, was
added
DMAP (0.086g, 0.70mmo1), followed by tert-butyl 4-(chlorocarbonyl)piperazine-
1-carboxylate
(0.147g, 0.59mmo1, synthesized according to procedure depicted in
US2007/270433A1).
Reaction mixture was stirred for 4h at RT. After completion of reaction,
reaction mixture was
quenched to ice cold water and partitioned between water and DCM. The product
was extracted
with DCM (3x25m1), washed with brine, dried over sodium sulphate, filtered and
concentrated to
dryness. The product was purified by100-200 mesh silica column by eluting with
30%-50% ethyl
acetate-hexane to afford the title compound (0.15g, 42%). LCMS: m/z = 595.8
(M+H).
Step-5: Synthesis of 3-(((8-isopropy1-2-((tetrahydro-2H-pyran-4-
yflamino)pyrazolo11,5-
a111,3,51triazin-4-vflamino)methyl)phenyl piperazine-l-carboxylate.
BocN HN
LNTO 8 IP N,e0
8 up
NH ___________________________________________________ NH
14: -N N
12.V. 1V.
N N N
The process of this step was adopted from step-2 of example-3 (0.1g of TFA
salt).
LCMS: m/z = 495.4 (M+H)t
Step-6: Synthesis of 3-(((8-isopropy1-2-((tetrahydro-2H-pvran-4-
vflamino)pvrazolo11,5-
1-1,3,51triazin-4-yl)amino)methyl)phenyl 4-acryloylpiperazine-1-carboxylate.
82
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
trrsrTh
0
*I 0
1101
NH CA.'" NH
Nj'N'N N
H
H
The process of this step was adopted from step-3 of example-3. The obtained
crude
compound was purified by preparative HPLC (0.01% NH4OH in water, B:
Acetonitrile, Column:
Gemini NX C-18 (21.2mm*150mm, 5pm)) to afford desired title compound (0.035g,
26%).
11-INMR (DMSO-d6, 400MHz): 6 8.95-8.66 (d, 1H), 7.68 (s, 1H), 7.31-7.14 (m,
1H), 7.17 (s,
1H), 7.08 (s, 1H), 7.98-7.96 (d, 1H), 6.90-6.87 (m, 1H), 6.81-6.74 (m, 1H),
6.52 (s, 1H), 6.13-
6.08 (m, 1H), 5.70-5.67 (m, 1H), 4.62-4.56 (m, 2H), 3.80-3.78 (m, 4H), 3.60-
3.56 (m, 6H), 3.40-
3.33 (m, 2H), 2.86 (s, 1H), 1.80-1.60 (m, 1H), 1.50-1.38 (m, 4H) 1.18 (s, 6H);
LCMS: m/z =
549.6 (M-FH) .
Example-6: Synthesis
of 3-acryl amido-N-(3-(((84 sopropy1-2-((tetrahydro-2H-pyran -4-
ypamino)pyrazolo[1,5-a][1,3,5]triazin-4-yDamino)methyl)phenyl)benzamide
(Compound-47).
Step-1: Synthesis of N-(3 -(((8-isopropyl-2-((tetrahydro-2H-pyran-4-
ybamino)pyrazolo 1,5-
[1,3,5]triazin-4-yflamino)methyl)pheny1)-3-nitrobenzamide.
H2N 10
02N
0 0 NH
0,N
is OH
N..... x3_
N-L-N
The process of this step was adopted from step-1 of example-3 (0.38g). LCMS:
m/z =
531.60 (M H) .
Step-2: Synthesis of 3-amino-N-(34((8-isopropv1-2-((tetrahvdro-2H-pyran-4-
vbamino)
pyrazolo [1,5-al 1-1,3,51tri azin-4- yflamino)methyl)phen yflbenzamide.
83
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
NO2 NH2
40/ 401 Li Ai
NH ___________ NH
1 0 go
N
N
To a solution of N-(3-4(8-isopropyl-2-((tetrahydro-2H-pyran-4-
yl)amino)pyrazolo [1,5-
a][1,3,5]triazin-4-yDamino)methyl)pheny1)-3-nitrobenzamide (0.38g,0.71mmol)
in
THF:MeOH:Water (3:2:1) were added zinc (0.465g, 7.1mmol) and ammonium chloride
(0.76g,
14.3mm01). The reaction mixture was stirred at room temperature for 4h. After
completion of
reaction, the reaction mixture filtered through celite and diluted with ethyl
acetate. The aqueous
layer was separated and extracted with ethyl acetate (2x25mL). The combined
organic phase was
washed with brine, dried over Na2SO4, filtered and concentrated. The residue
was purified by
100-200 silica gel column chromatography to afford desired title compound
(0.3g, 70%). LCMS:
m/z = 501.20 (M+H)4.
Step-3: Synthesis of 3-acrylamido-N-(3-(((8-isopropyl-2-((tetrahydro-2H-pyran-
4-ybamino)
pyrazolo [1,5-all!, 3,51tri azin-4-vflamino)methyl)phen yflbenzamide.
NH2
40 TF,1 =
0 0
NH __________________________________________________ NH
N _N
00, TX"
N N N N
The process of this step was adopted from step-3 of example-3. The obtained
crude
compound was purified by preparative HPLC (Method: A: water, B: Acetonitrile-
Methanol,
Column:ZORBAX XDB C-18 (21.1mm*150mm, 5pm) to afford desired title compound
(0.022g, 25%).1HNMR (DMSO-d6, 400MHz): El 10.33 (s, 1H), 10.26 (s, 1H), 8.11
(s, 1H), 7.91
(d, 1H), 7.70 (m, 2H), 7.61-7.59 (d, 2H), 7.47 (t, 1H), 7.28 (t, 1H), 7.08 (m,
1H), 6.70 (m, 1H),
6.53 (m, 1H), 6.30 (d, 1H), 5.79-5.75 (m, 2H), 4.62 (m, 2H), 3.81 (m, 3H),
2.90 (m, 1H), 1.81-
1.50 (m, 3H), 1.49-1.2 (m, 3H), 1.21 (d, 6H); LCMS: m/z = 555.2 (M-FH)+.
84
CA 02978170 2017-08-29
WO 2016/142855 PCT/1112016/051302
The below compound was prepared by procedure similar to the one described in
Example-6 with appropriate variations in reactants, quantities of reagents, in
presence of suitable
solvents at suitable reaction conditions. The physicochemical characteristics
of the compounds
are summarized herein below table.
Compd.
Compound structure Analytical
data
No.
11-1 NMR (DMSO-d6, 400MHz): .5 10.63 (s, 1H),
Li 4.6 10.44 (s, 1H), 8.18 (d, 1H), 7.74 (m, 2H), 7.54 (t,
0õ1,11-1 0 ANA
2H), 7.31 (m, 1H), 7.25 (m, 1H), 7.12 (m, 2H),
48 03, 6.40 (m, 1H), 6.21 (d, 1H), 5.76 (d, 1H),
4.62 (m,
N N 2H), 3.88-3.79 (m, 4H), 2.96 (m, 2H), 1.81 (m,
3H), 1.45 (m, 3H), 1.20 (d, 6H); LCMS: m/z =
555.20 (MA-H) .
N/71XL
N
HN "-NA CC)
48A 0NH LCMS: m/z = 569.30 (M+H) .
iffv *
Example-7: Synthesis of (E)-44(3-(((8-isopropyl-2-((tetrahydro-2H-pyran-4-
yDamino)
pyrazolo[1,5-a][1,3,5]triazin-4-yDamino)methypphenypamino)-N,N-dimethylbut-2-
enamide
(Compound-49).
0
I-12N
I)N
NH
0 HN
__________________________________________ = N
N"-
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
To a solution of N4-(3-aminobenzy1)-8-isopropyl-N2-(tetrahydro-2H-pyran-4-
yl)pyrazolo[1,5-a] [1,3,5]triazine-2,4-diamine (0.1g, 0.26mmol, intermediate-
33) and (E)-4-
bromo-N,N-dimethylbut-2-enamide (0.061g, 31.4mm01) in CAN (3mL) was added
K2CO3
(0.157g, 1.136mmo1) at RT, then stirred at 80 C for 4h. After reaction
completion, the reaction
mixture was cooled to room temperature, quenched with water and diluted with
ethyl acetate.
The aqueous layer was separated and extracted with ethyl acetate (2x15mL). The
combined
organic phase was washed with brine, dried over Na2SO4, filtered and
concentrated. The residue
was purified by preparative HPLC (Method: A: 0.02% NH3 in water, B:ACN,
Column: Gemini
NX C18: 150mm*21.2mm) to afford desired title compound (0.028g, 20%). 1H NMR
(DMS0-
.. d6, 400MHz): ö 8.40-8.80 (d, 111), 7.70 (s, 1H), 7.02-6.99 (t, 1H), 6.84
(s, 111), 6.66-6.63 (m,
2H), 6.60-6.54 (d, 2H), 6.44-6.42 (d, 1H), 5.99 (s, 111), 4.44 (s, 2H), 3.89
(s, 5H), 3.30 (m, 41),
2.89 (s, 4H), 2.82 (s, 3H), 1.89 (s, 1H), 1.23 (s, 1H), 1.10 (s, 6H); LCMS:
m/z = 493.6 (M+H)+.
Example-8: Synthesis of (E)-4-(diethylamino)-N-(3-(((8-isopropy1-2-
((tetrahydro-2H-pyran-4-
yl)amino)pyrazolo[1,5-a][1,3,5]triazin-4-yDamino)methyl)phenyl)but-2-enamide
(Compound-
50).
Step-1: Synthesis of (E)-4-bromo-N-(3-(((8-isopropyl-2-((tetrahydro-2H-pyran-4-
ybamino)
pyrazolo [1, 3,51tri azin-4-ybamino)methyl)phenyl)but-2-enamide.
I-12N = N
0
Br
NH O3NHN
0 N
N __________________________________________________ ,Nj: N;L:
N
To a cooled solution of (E)-4-bromobut-2-enoic acid (0.86g, 5.24mmo1) in DCM
(10mL)
was added 2 drops of DMF and followed by oxalyl chloride (0.9mL,10.49mmo1) at
00C, then
stirred at RT for lh, evaporated the solvent completely under vacuum and
dissolved again in
DCM (5mL). In another flask, a solution of N4-(3-aminobenzy1)-8-isopropyl-N2-
(tetrahydro-2H-
pyran-4-yl)pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine (1g, 2.62mmo1,
Intermediate-33) in DCM
(10mL) and DIPEA (1.45mL, 7.87rnmo1) was cooled to 0 C. To this the above
acid chloride in
DCM was added slowly drop wise, reaction mixture was allowed to stirred at RT
for lh. After
completion of the reaction, the reaction mixture quenched with water and then
diluted with DCM
(20mL). The organic layer washed with water followed by brine, dried over
Na2SO4, filtered and
86
concentrated, the residue was purified by 100-200 mesh silica gel column
chromatography to
afford desired title compound (0.7g, 60%). LCMS: rrilz = 530.05 (M+H)+.
Step-2: Synthesis of (E)-4-(diethylamino)-N-(3-(((8-isopropy1-2-((tetrahydro-
2H-pyran-4-
yl)amino)pyrazolof 1,5 -a111,3,51triazin-4-ybamino)methyl)phenyl)but-2-
enamide.
El
Bry
N
FIN --7TH
HN
N)N N N
11
To a stirred solution of (E)-4-bromo-N-(3-(((8-isopropy1-2-((tetrahydro-2H-
pyran-4-
ybamino)pyrazolo[1,5-a][1,3,5]triazin4yDamino)methyl)phenyl)butenamide (0.15g,
0.28mmo1)
and diethylamine (0.042g, 0.568mmo1) in ACN (3mL) was added K2CO3 (0.1g,
0.71mmol) at
RT, then stirred at 80 C for 2h. After completion of reaction, the reaction
mixture was cooled to
room temperature, quenched with water and diluted with ethyl acetate. The
aqueous layer was
separated and extracted with ethyl acetate (2x15mL). The combined organic
phase was washed
with brine, dried over Na2SO4, filtered and concentrated. The residue was
purified by
preparative HPLC (Method: A: 0.1% TFA in water, B: Acetonitrile, Column:
)(Bridge:
150mm*19.0nun) to afford desired title compound as TPA salt, after that passed
this TFA salt
through Van i pure basic resin column to remove TFAto afford final compound
(0.027g, 54%).
111NMR (DMSO-do, 400MHz): 1FINMR (DMSO-d6, 400MHz): .5 10.35 (s, 1H), 9.70 (s,
111),
9.60 (s, 1H), 8.90 (s, 1H), 7.95 (s, 1H), 7.75 (s, 1H), 7.55 (m, 1H), 7.34-
7.30 (t, 1H), 7.15 (s,
1H), 6.81-6.73 (m, 1H), 6.53-6.49 (d, 1H), 4.66 (s, 2H), 4.02-4.00 (t, 2H),
3.92-3.91 (m, 2H),
3.82 (m, 311), 3.20 (s, 211), 3.18-3.14 (m, 411), 3.02-2.97 (m, 1H), 1.69 (s,
1H), 1.48 (s, 2H),
1.27-1.23 (m, 10H); LCMS: m/z = 521.65 (M+H)+.
The below compounds were prepared by procedure similar to the one described in
Example-8 with appropriate variations in reactants, quantities of reagents in
presence of suitable
solvents at suitable reaction conditions. The physicochemical characteristics
of the compounds
are summarized herein below table.
Compd.
Compound structure Analytical data
No.
87
Date recue/Date received 2023-03-24
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
1H NMR (DMSO-d6, 400MHz): 8 10.30-10.10 (d, 1H),
9.50 (s, 1H), 8.74 (s, 2H), 7.86-7.54 (m, 3H), 7.30 (t,
0 we-
1H), 7.12 (s, 1H), 6.90-6.73 (m, 2H), 6.47-6.43 (d, 1H),
51 ccTh 141-11N-N 4.63 (s, 2H), 4.01 (s, 3H), 3.90-3.70 (m, 511),
3.12 (s,
Lf
3H), 2.94 (s, 21), 2.00 (s, 111), 1.84 (s, 1H), 1.66 (s,
1H), 1.46 (s, 2H), 1.24 (s, 6H); LCMS: m/z = 535.7
(M+H)+.
1H NMR (DMSO-d6, 400MHz): 8 10.03 (s, 1H), 7.71
(s, 1H), 7.77-7.75 (m, 2H), 7.26-7.22 (t, 1H), 7.03-7.02
r,NCYortsli."? (d, 1H), 6.9-6.8 (m, 1H), 6.72-6.65 (m, 1H), 6.24-
6.21
NH N (d, 1H), 4.60 (d, 2H), 3.90-3.80 (m, 3H), 3.35-3.30 (m,
52 oTh NN
3H), 3.08-3.07 (d, 2H), 2.907 (s, 1H), 2.67 (s, 1H),
2.45-2.33 (m, 5H), 2.32-2.28 (m, 2H), 1.83 (s, 1H),
1.60-1.45 (m, 2H), 1.23 (s, 7H), 0.99-0.95 (t, 3H);
LCMS: m/z = 562.35 (M-FH)+.
1H NMR (DMSO-d6, 400MHz): 8 9.96 (s, 1H), 8.90 (s,
1H), 8.6 (s, 1H), 7.67 (s, 1H), 7.60-7.50 (m, 1H), 7.22-
7.18 (m, 1H), 6.99-6.97 (m, 1H), 6.88-6.77 (m, 1H),
HN 6.69-6.64 (m, 1H), 6.20-6.16 (m, 1H), 4.58-4.52
(m,
53
N
\ 2H), 3.80-3.72 (m, 3H), 3.44-3.33 (m, 2H), 2.95-2.92
N N
(m, 2H), 2.88-2.82 (m, 111), 2.22-2.20 (m, 611), 1.81-
1.75 (m, 111), 1.60-1.50 (m, 2H), 1.35-1.49 (m, 2H),
1.18 (s, 6H); LCMS: m/z = 493.6 (M-FH)+.
1H NMR (DMSO-d6, 400MHz): ö 10.03 (s, 1H), 8.65
ci\jorNii (s, 1H), 7.71 (s, 1H), 7.56 (m, 2H), 7.25-7.21 (t,
1H),
7.02-7.01 (d, 1H), 6.83 (s, 1H), 6.77-6.71 (m, 1H),
NH
54 oc Ni) 6.26-6.22 (d, 1H), 4.59 (s, 2H), 3.82 (s, 3H),
3.20-3.16
(m, 2H), 2.90 (s, 1H), 2.54-2.32 (m, 4H), 1.82 (s, 1H),
1.72-1.68 (m, 4H), 1.59 (s, 111), 1.45 (s, 2H), 1.37 (s,
2H), 1.22 (s, 6H); LCMS: m/z = 519.30 (MA-H) ..
88
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
1HNMR (DMSO-d6, 400MHz): 5 10.23 (s, 1H), 8.90
(s, 1H), 8.65 (s, 1H), 7.71 (s, 1H), 7.55 (m, 2H), 7.25-
7.21 (t, 1H), 7.03 (s, 1H), 6.83 (s, 1H), 6.73-6.66 (m,
55 111), 6.23-6.19 (d, 1H), 4.59 (s, 2H), 3.82 (s,
4H), 3.05-
3.03 (m, 2H), 2.90 (s, 1H), 2.32 (s, 411), 1.82 (s, 1H),
1.52-1.47 (m, 6H), 1.39-1.37 (d, 3H), 1.22 (s, 6H);
LCMS: m/z = 533.20 (MI-H)'.
(DMSO-4 400MHz): 8 10.05 (s, 1H), 8.65
(s, 1H), 7.71 (s, 1H), 7.56 (m, 2H), 7.25-7.21 (t, 1H),
F¨.01-n-N
7.03-7.01 (d, 1H), 6.83 (s, 1H), 6.76-6.70 (m, 1H),
O N:11,HN. 6.27-6.23 (d, 1H), 5.26-5.11 (m, 1H), 4.59 (s,
2H), 3.82
56 (s, 3H), 3.24-3.18 (m, 4H), 2.87-2.78 (m, 3H),
2.66-
2.58 (m, 2H), 2.34-2.28 (m, 1H), 2.17-2.08 (m, 1H),
1.93-1.81 (m, 2H), 1.59- 1.37 (m, 2H), 1.22 (s, 6H);
LCMS: m/z = 537.60 (M-FH)+.
11-1NMR (DMSO-d6, 400MHz): 5 10.05 (s, 1H), 8.92
(s, 1H), 8.65 (s, 1H), 7.71 (s, 1H), 7.58-7.54 (m, 2H),
FF)C.cr, N 7.26-7.22 (t, 1H), 7.03-7.01 (d, 1H), 6.82 (s, 1H), 6.73-
r N 6.67 (m, 1H), 6.27-6.23 (d, 1H), 4.59 (s, 2H),
3.82 (s,
57
Ta.N.L.N: 3H), 3.26-3.25 (m, 2H), 2.93-2.87 (t, 3H), 2.74-
2.70
11
(m, 2H), 2.33-2.19 (m, 211), 1.83 (s, 111), 1.58 (s, 111),
1.45 (s, 111), 1.36 (s, 2H), 1.22 (s, 6H); LCMS: m/z =
555.60 (M+H)t
11-1NMR (DMSO-d6, 400MHz): ö 10.05 (s, 1H), 8.66
= orN (s, 1H), 7.71 (s, 1H), 7.60-7.50 (m, 2H),
7.27-7.23 (t,
1H), 7.05 (s, 1H), 6.89-6.82 (m, 1H), 6.73-6.68 (m,
Nil
N
58 0,Nrkr, 1H), 6.32 (s, 1H), 4.60 (s, 2H), 3.81 (s, 4H),
3.20-3.16
H (m, 2H), 2.67-2.55 (m, 2H), 2.33-2.32 (m, 2H),
2.90 (s,
2H), 1.81 (s, 4H), 1.58 (s, 2H), 1.44 (s, 2H), 1.36 (s,
1H), 1.22 (s, 6H); LCMS: m/z = 551.20 (MA-H)'.
89
CA 02978170 2017-08-29
WO 2016/142855 PCT/1112016/051302
1H NMR (DMSO-d6, 400MHz): 6 10.13 (s, 1H), 8.95
F
(s, 1H), 8.70 (s, 1H), 7.72 (s, 1H), 7.61 (s, 1H), 7.30-
7.20 (m, 1H), 6.87-6.85 (d, 2H), 6.75-6.68 (m, 1H),
59 NH1N-N 6.22-6.18 (d, 111), 4.59 (s, 2H), 3.82-3.75 (d,
3H), 3.03-
II
3.01 (d, 211), 2.90 (s, 111), 2.66 (s, 111), 2.32 (s, 11),
2.14 (s, 5H), 1.82 (s, 2H), 1.60 (s, 2H), 1.45 (s, 2H),
1.22 (s, 6H); LCMS: m/z = 511.20 (M+1-1)+.
1H NMR (DMSO-d6, 400MHz): 8 9.84 (s, 2H), 8.90 (s,
1H), 8.65 (s, 2H), 7.80 (s, 2H), 7.72 (s, 1H), 7.08 (s,
0 F
3H), 6.90 (s, 211), 6.75-6.70 (m, 2H), 6.45-6.41 (d, 2H),
60 4.67 (s, 2H), 3.90-3.70 (m, 5H), 3.03-3.00 (d,
2H), 2.67
II
1+1 N (s, 2H), 2.20 (s, 6H), 2.12-1.97 (m, 2H), 1.81 (s,
2H),
1.55-1.45 (m, 4H), 1.23 (s, 8H); LCMS: m/z =
511.2(M H) .
1H NMR (DMSO-d6, 400MHz): 5 10.13 (s, 1H), 8.95
F (s, 1H), 8.70 (s, 1H), 7.72 (s, 1H), 7.61 (s, 1H), 7.30-
7.20 (m, 1H), 6.87-6.85 (d, 2H), 6.75-6.68 (m, 1H),
61 Isl' 6.23-6.20 (d, 1H), 4.59 (s, 2H), 3.82-3.75 (d,
3H), 3.58-
3.56 (m, 411), 3.34-3.29 (m, 1H), 3.10-3.08 (m, 2H),
2.90 (s, 1H), 2.36 (s, 4H), 1.86 (s, 1H), 1.53-1.35 (m,
311), 1.22 (s, 6H); LCMS: m/z = 533.30 (M+H)+.
1HNMR (DMSO-d6, 400MHz): 5 9.70 (s, 1H), 8.85 (s,
.At)
1H), 8.58 (s, 1H), 7.71 (s, 1H), 7.51-7.49 (d, 1H), 7.33-
H
NH 7.31 (d, 1H), 7.26-7.22 (t, 1H), 7.13 (s, 1H),
6.87 (s,
62 9 NJ 1H), 6.77-6.71 (m, 1H), 6.49-6.45 (d, 1H), 4.60-
4.59
N
(d, 2H), 3.82 (s, 3H), 2.91-2.90 (m, 1H), 2.66 (s, 1H),
2.40 (s, 6H), 2.33 (s, 2H), 1.83 (s, 1H), 1.46 (s, 2H),
1.23-1.21 (d, 7H); LCMS: m/z = 493.20 (M+H)+.
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
11-1 NMR (DMSO-d6, 400MHz): 5 10.03 (s, 1H), 8.80-
8.60 (d, 1H), 7.69 (s, 1H), 7.58-7.56 (d, 2H), 7.30-7.27
(d, 2H), 6.90-6.71 (m, 2H), 6.27-6.22 (d, 1H), 4.53 (s,
63
(a N N"N 2H), 3.85-3.82 (d, 2H), 3.43 (s, 2H), 3.21-3.19 (d, 3H),
N )4.4'14
2.90 (s, 1H), 1.83 (s, 1H), 1.69 (s, 6H), 1.44 (m, 3H),
1.22 (s, 8H); LCMS: m/z = 519.25 (M+H) .
Example-9: Synthesis of (E) - 1-(4-(dimethylamino)but-2-enoy1)-N-(2-fluoro-5-
(((8-isopropy1-2-
((tetrahydro-2H-pyran-4-yDamino)pyrazolo[1,5-a] [1,3,5]triazin-4-yDamino)
methyl)phenyl)
pyrrolidine-3-carbox amide (Compound-64).
1-1
F arm F 0,1,11
S 0H
0
(2.
*
NgrisT
XIN
To a cooled solution of (E)-4-(dimethylamino)but-2-enoic acid hydrochloride
(0.050g,
0.3mmo1) in DMF (2mL) at 0 C was added HATU (0.137g, 0.30mmol) followed by
DIPEA
(0.1mL, 0.6mmo1) and finally added N-(2-fluoro-5-(((8-isopropy1-2-((tetrahydro-
2H-pyran-4-
yl)amino)pyrazolo[1,5-a][1,3,5]triazin-4-yDamino)methyl)phenyl)pyrrolidine-3-
carboxamide
(0.150g, 0.3mmol; this was prepared by using the procedure of example-3). The
reaction mixture
was stirred for 2h at room temperature. The reaction mixture was quenched with
ice-water and
diluted with ethyl acetate. The aqueous layer was separated and extracted with
ethyl acetate
(2x25mL). The combined organic phase was washed with brine, dried over Na2SO4,
filtered and
concentrated and purified by preparative HPLC (Method: A: 0.01%in ammonia in
water, B:
Acetonitrile-Me0H, Column: EVO C-18 (150mm*21.2, 5 m) to afford desired title
compound
(0.04g, 24%). 1HNMR (DMSO-d6, 400MHz): 6 9.98-9.88 (s, 1H), 9.00 (s, 1H), 8.60
(s, 1H),
7.85 (m, 1H), 7.70 (s, 1H), 7.22-7.15 (m, 2H), 6.64 (m, 1H), 6.63-6.58 (m,
1H), 6.38-6.33 (dd,
1H), 4.54 (s, 2H), 3.82-3.78 (m, 3H), 3.67-3.60 (in, 2H), 3.54 (m, 2H), 3.53-
3.51 (m, 1H), 3.34-
3.27 (m, 1H), 3.02-3.01 (d, 2H), 2.89 (m, 1H), 2.20-2.14 (m, 7H), 2.00-1.98
(m, 1H), 1.83 (m,
1H), 1.64 (m, 1H), 1.45 (m, 2H), 1.21 (d, 6H); LCMS: m/z = 608.75 (M+H)+.
91
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
The below compounds were prepared by procedure similar to the one described in
Example-9 with appropriate variations in reactants, quantities of reagents in
presence of suitable
solvants at suitable reaction conditions. The physicochemical characteristics
of the compounds
are summarized herein below table.
Compd.
Compound structure Analytical data
No.
11-1 NMR (DMSO-d6, 400MHz): 8 10.23-10.20 (m,
PCIYI4 1H),
8.88-8.72 (s, 1H), 7.76 (s, 1H), 7.60 (s, 2H),
7.32-7.30 (m, 1H), 7.10 (s, 1H), 6.90 (s, 1H), 6.72
(m, 1H), 6.09-6.05 (d, 1H), 5.80 (t, 1H), 5.10-4.89
(m, 1H), 4.64 (s, 2H), 4.20-4.19 (m, 1H), 3.90-3.86
(m, 3H), 2.95 (s, 2H), 2.57-2.50 (m, 2H), 2.22 (m,
2H), 1.90-1.88 (d, 3H), 1.78-1.76 (d, 1H), 1.50 (s,
3H), 1.28 (s, 6H); LCMS: m/z = 533.2 (M+H)+.
1H NMR (DMSO-d6, 400MHz): ö 10.19-10.14 (d,
, 1H),
8.9-8.6 (d, 1H), 7.72 (s, 1H), 7.55 (m, 2H),
= o 7.28-
7.24 (t, 1H), 7.10-7.06 (m, 1H), 6.90-6.60 (m,
66 -N 1H),
6.65 (s, 311), 4.98-4.77 (m, 1H), 4.60 (s, 2H),
N N
4.31 (s, 1H), 4.16-4.12 (m, 1H), 3.93-3.82 (m, 3H),
H
2.91 (m, 1H), 2.23-2.14 (m, 1H), 1.84-1.80 (m,
2H), 1.46-1.37 (m, 2H), 1.24 (s, 6H); LCMS: m/z =
517.1 (M+H)+.
1H NMR (DMSO-d6, 400MHz): ö 10.06 (s, 1H),
J9.0-8.65 (m, 2H), 7.70 (s, 1H), 7.50 (m, 2H), 7.26
AIN so
(t, 1H), 7.04 (d, 1H), 6.81 (m, 1H), 5.46 (d, 1H),
5.18 (d, 1H), 4.95 (m, 1H), 4.77 (m, 1H), 4.58 (m,
67
2H), 4.18 (m, 1H), 3.93-3.80 (m, 4H), 2.89 (m,
1H), 2.15 (m, 2H), 1.81 (m, 3H), 1.68 (m, 2H),
1.45 (m, 2H), 1.22 (d, 6H); LCMS: tniz = 533.25
(M+H) .
92
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
111 NMR (DMSO-d6, 400MHz): 8 10.05 (s, 1H),
y...yo Nair pi 8.90 (s, 1H), 8.60 (s,
1H), 7.71 (s, 1H), 7.50 (s,
1H), 7.23 (t, 1H), 7.03 (s, 111), 6.80 (s, 1H), 6.68-
/
6.64 (d, 1H), 6.39-6.38 (d, 1H),4.58 (s, 2H), 4.05
68 NrN-N
(s, 2H), 3.81-3.76 (m, 311), 3.65-3.62 (t, 2H), 3.55-
3.53 (m, 2H), 3.35-3.36 (m, 3H), 3.10 (m, 2H),
2.90 (s, 1H), 2.10 (m, 2H), 2.80 (m, 2H), 1.62-1.45
(m, 314), 1.23 (s, 6H); LCMS: m/z = 577.2 (M+H)+.
1H NMR (DMSO-d6, 400MHz): 8 10.06 (s, 1H),
_eo
8.9 (s, 1H), 7.71 (s, 1H), 7.51 (m, 2H), 7.25-7.21 (t,
¨N\ ().1,14
111), 7.03-7.01 (d, 1H), 6.85 (s, 111), 6.62-6.56 (m,
o
1H), 6.68-6.33 (m, 1H), 4.59 (s, 2H), 3.81-3.76 (m,
69 NH
4H), 3.67-3.61 (m, 2H), 3.54-3.43 (m, 2H), 3.21-
N 3.08 (m, 2H), 30.3-3.01 (d, 2H), 2.90 (s, 1H), 2.18-
2.13 (m, 7H), 1.98-1.90 (m, 2H), 1.60-1.49 (m,
3H), 1.22 (s, 6H); LCMS: m/z = 590.5 (M H) .
11-1 NMR (DMSO-d6, 400MHz): 8 10.04 (s, 1H),
8.90-8.60 (m, 2H), 7.70 (s, 2H), 7.51 (s, 111), 7.35
(s, 1H), 7.11-7.06 (t, 1H), 6.79 (s, 2H), 6.59-6.53
N¨r-5-NalrH
0 *
(m, 1H), 6.32-6.27 (d, 1H), 4.61 (s, 2H), 3.77-3.70
70 N2_ (m,
4H), 3.63-3.60 (m, 211), 3.58-3.53 (m, 111), N,
3.48-3.38 (m, 2H), 3.29-3.08 (m, 2H), 3.01-2.95
(m, 2H), 2.86 (s, 2H), 2.11-1.90 (m, 6H), 1.87-1.77
(m, 1H), 1.52-1.19 (m,311), 1.19 (s, 6H); LCMS:
m/z = 608.3 (M+H)+.
93
CA 02978170 2017-08-29
WO 2016/142855 PCT/1112016/051302
111 NMR (DMSO-d6, 400MHz): 5 10.23 (s, 111),
j)_Nar 8.90-
8.65 (d, 1f1), 7.68 (s, 1H), 7.50 (s, 1H), 7.16
0
(s, 1H), 6.84-6.81 (d, 2H), 6.60-6.53 (m, 1H), 6.32-
/ F
6.28 (d, 1H), 4.55 (s, 2H), 3.76-3.71 (m, 311), 3.60-
71 3.56
(in, 111), 3.51-3.45 (m, 1H), 3.43-3.46 (m,
\-"Nµ
1H), 3.29-3.13 (m, 1H), 3.05-3.02 (m, 2H), 2.87 (s,
1H), 2.63 (s, 211), 2.28 (s, 2H), 2.14-1.89 (m, 711),
1.79 (s, 1H); 1.52-1.32 (s, 3H), 1.19 (s, 6H);
LCMS: m/z = 608.3 (M+H)+.
1H NMR (DMSO-d6, 400MHz): 6 9.97 (s, 1H), 8.6
(s, 1H), 8.5 (s, 1H), 7.71 (s, 1H), 7.52-7.42 (m,
3H), 7.22 (m, 1H), 7.12-7.10 (d, 1H), 6.80 (m, 1H),
I 8 0 LIPP 6.62-
6.59 (m, 2H), 5.40 (s, 1H), 5.10 (s, 1H), 4.5
HN (m,
1H), 4.32 (m, 1H), 4.04-4.01 (m, 111), 3.85-
72
CaNIN31..... 3.72
(m, 3H), 3.33-2.97 (m, 3H), 2.88 (m, 2H),
2.13-2.09 (m, 6H), 1.92 (m, 1H), 1.74-1.68 (m,
3H), 1.56-1.54 (d, 2H), 1.49-1.41 (m, 2H), 1.21 (d,
6H), 1.10-1.06 (t, 2H); LCMS: m/z = 618.5
(M-FH) .
1H NMR (DMSO-d6, 400MHz); 5 10.04 (s, 1H),
8.95-8.65 (m, 111), 7.70 (s, 1H), 7.48 (m, 211), 7.26-
r, 0 7.22 (t, 111), 7.04
(s, 1H), 6.64 (s, 1H), 4.85-4.84
00
(d, 1H), 4.59 (s, 1H), 4.26-4.23 (d, 1H), 3.85-3.82
73 011I (d,
411), 3.69-3.63 (d, 111), 3.34 (s, 111), 3.03 (s,
NH
211), 2.95-2.90 (m, 1H), 2.55-2.54 (m, 2H), 2.45 (s,
NN -14
2H), 2.33-2.32 (m, 2H), 2.13 (s, 4H), 2.04 (s, 211),
1.81 (s, 2H), 1.60 (s, 1H), 1.45 (s, 2H), 1.21 (s,
6H); LCMS: m/z = 606.30 (M+H)+.
94
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
111 NMR (DMSO-d6, 400MHz): 5 9.92 (s, 1H),
8.94 (s, 1H), 8.60 (s, 1H), 7.71 (s, 1H), 7.49 (s,
1H), 7.28 (t, 2H), 7.02 (s, 1H), 6.88-6.81 (m, 111),
6.66-6.44 (m, 1H), 5.11 (s, 1H), 4.80-4.58 (m, 3H),
NH
74 -
N
3.96-3.83 (m, 4H), 3.02-3.01 (d, 111), 2.94-2.90 (d,
N
2H), 2.67 (s, 3H), 2.32 (s, 3H), 2.13 (s, 4H), 2.04-
1.98 (s, 1H), 1.82 (s, 1H), 1.66-1.61 (d, 3H), 1.44-
1.37 (m, 3H), 1.22 (s, 611); LCMS: m/z = 604.25
(M+H)+.
1H NMR (DMSO-d6, 400MHz): ö 8.37 (s, 1H),
8.21 (s, 1H), 7.66 (s, 1H), 7.35-7.31 (m, 1H), 7.24-
istbh
7.22 (m, 1H), 7.18 (s, 1H), 7.04-7.01 (d, 1H), 6.67-
6.61 (m, 1H), 6.51-6.47 (m, 1H), 4.65 (s, 2H), 3.86-
N N
3.84 (m, 3H), 3.64-3.63 (m, 4H), 3.56-3.52 (m,
4H), 3.42-3.35 (m, 4H), 3.10-3.06 (m, 1H)), 2.18
(s, 6H), 1.84-1.81 (m, 2H), 1.55-1.46 (m, 2H),
1.26-1.24 (d, 6H); LCMS: m/z = 606.2 (M+H) .
Example-10: Synthesis of (E)-1-(4-(dimethylamino)-4-oxobut-2-en-1 -y1)-N-(3-
((( 8-isoprop y1-2-
((tetrahydro-2H-pyran-4-yDamino)pyrazolo[1,5-a][1,3,5]triazin-4-yDamino)
methyl)phenyl)azetidine-2-carboxamide (Compound-76).
ri /1,1
0
Br N Wi
NrN-N
5 To a stirred solution of N-(3-(08-isopropy1-2-((tetrahydro-2H-pyran-4-
yl)amino)pyrazolo[1,5-a][1,3,5]triazin-4-yDamino)methyl)phenyl)azetidine-2-
carboxamide (0.1g,
0.21mmol) in ACN (3 mL) was added DIPEA (0.07mL, 0.43mm01) and (E)-4-bromo-N,N-
dimethylbut-2-enamide (0.05g, 0.25mmo1) at 0 C. The reaction mixture was
stirred for 12h at
RT. Water was added and extracted with dichloromethane. The aqueous layer was
separated and
extracted with dichloromethane (2x25mL). The combined organic phase was washed
with brine,
dried over Na2SO4, filtered and concentrated to afford crude residue. The
residue was purified by
prep. HPLC (Method: A: 0.02% Ammonia in water, B: Acetonitrile, Column: WATER
XBridge (19mm*150mm, 5 m)) to afford desired title compound (0.05g, 41%).
1FINMR
(DMSO-d6, 400MHz): 5 9.63 (s, 1H), 8.90-8.60 (m, 1H), 7.70-7.53 (m, 3H), 7.25-
7.21 (t, 1H),
7.04 (s, 1H), 6.84 (s, 1H), 6.55 (s, 2H), 4.58 (s, 2H), 3.80 (s, 3H), 3.67-
3.63 (t, 1H), 3.35-3.19 (m,
5H), 2.96-2.90 (m, 5H), 2.79 (s, 3H), 2.66 (s, 1H), 2.32-2.65 (m, 1H), 2.13-
2.09 (m, 1H), 1.82 (s,
2H), 1.45-1.32 (m, 2H), 1.22 (s, 6H); LCMS: m/z = 576.45 (M+H)+.
Example-11: Synthesis of (E)-N-(3-(((8-isopropyl-2-((tetrahydro-2H-pyran-4-
yl)amino)
pyrazolo [1,5-a] [1,3,5]triazin-4-yl)amino)methyl)pheny1)-1-(4-(pyrrolidin-1-
y1)but-2-
enoyl)piperidine-2-carboxamide (Compound-77).
0
air H N
dr,L Ny0
TT
N 0 40
leOH 0 40 H101)3
NH 0 NH NH
N N
00,
N N N N N
Interemediate
To a cooled solution of (E)-4-bromobut-2-enoic acid (0.28g, 1.7 lmmol) in DMF
(10mL)
at 0 C was added HATU (0.65g, 1.71mmol) followed by DIPEA (0.31mL, 1.71mmol)
and
finally added N-
(3-(48-isopropy1-2-((tetrahydro-2H-pyran-4-yDamino)pyrazolo[1,5-
a][1,3,5]triazin-4-yl)amino)methypphenyl)piperidine-2-carboxamide (0.42g,
0.855mmo1). The
reaction mixture was stirred for lh at room temperature. The reaction mixture
was quenched with
ice-water and diluted with ethyl acetate. The aqueous layer was separated and
extracted with
ethyl acetate (2x25mL). The combined organic phase was washed with brine,
dried over Na2SO4,
filtered and concentrated the crude residue was purified by 100-200 silica gel
column
chromatography to afford desired intermediate (0.3g, 46%). LCMS: miz = 641
(M+2H)+. The
intermediate was dissolved in ACN (5mL) and pyrrolidine (0.067g, 0.93mmo1) and
K2CO3
(0.13g, 0.93mm01) was added at RT, stirred at 80 C for 2h. After reaction
completion, the
reaction mixture was cooled to room temperature, quenched with water and
diluted with ethyl
acetate. The aqueous layer was separated and extracted with ethyl acetate
(2x15mL). The
96
Date recue/Date received 2023-03-24
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
combined organic phase was washed with brine, dried over Na2SO4, filtered and
concentrated.
The residue was purified by preparative HPLC (Method: A: 0.01% TFA in water,
B:
MeOH:CAN (1:1), Column: Zorbax XDB C18 : 150mm*21.2mm) to afford desired title
compound as TFA salt, after that passed this TFA salt through Van i pure basic
resin column to
removal the TFA from compound to afford final compound (0.04g, 26%). 111NMR
(DMSO-d6,
400MHz): ö 9.91 (s, 1H), 8.95-8.66 (d, 1H), 7.70 (s, 1H), 7.64 (s, 1H), 7.54-
7.48 (m, 1H), 7.24-
7.20 (t, 114), 7.03 (s, 1H), 6.89-6.81 (d, 2H), 6.63 (s, 111), 5.11 (s, 1H),
4.57 (m, 211), 3.95-3.92
(in, 4H), 3.40-3.39 (rn, 2H), 3.19-3.18 (d, 1H), 3.00 (s, 1H), 2.89 (s, 1H),
2.67 (s, 111), 2.42 (s,
3H), 2.33-2.32 (d, 1H), 2.11-2.08 (d, 1H), 1.98 (s, 1H), 1.83-1.61 (m, 6H),
1.53 (s, 3H), 1.37 (s,
3H), 1.23 (s, 611); LCMS: rn/z = 630.3 (Mi-H)+.
Example-12: Synthesis of N-(3-4(8-isopropyl-2-((tetrahydro-2H-pyran-4-
yDamino)pyrazolo
[1,5-a][1,3,5[triazin-4-yl)amino)methyl)pheny1)-1-(vinylsulfonyppiperidine-2-
carboxamide
(Compound-78).
=arN 01%11-1
,.ci )(NFI
Cl)S; 13-S--=
NH ________________________________________ 0
RN
013,
N N N N
To the solution of N-(3-(((8-isopropy1-2-((tetrahydro-2H-pyran-4-
yDamino)pyrazolo[1,5-
a][1,3,5]triazin-4-yDamino)methyl)phenyppiperidine-2-carboxamide (0.15 g, 0.3
mmol;
prepared according to procedure of example-3) in DCM (10 rnL) was added Et3N
(0.123 rnL, 0.9
mmol) and 2-chloroethane-1-sulfonyl chloride (0.5 g, 0.3 mmol) at 0 C. After
stirring 2 h at
room temperature, the reaction mixture was quenched with ice-water and diluted
with DCM. The
aqueous layer was separated and extracted with DCM (2x25mL). The combined
organic phase
was washed with brine, dried over Na2SO4, filtered and concentrated the crude
residue was
purified by preparative HPLC (Method: A: water, B: ACN, Column: Zorbax XDB C18
(21.2mmX150 mm, 5 p) to afford desired title compound (0.025g, 10.5 %). 11-
1NMR (DMSO-d6,
400MHz): .5 9.99 (s, 1H), 8.80 (d, 1H), 7.71 (s,1H), 7.60-7.40 (m, 2H), 7.23
(t, 1H), 7.04-7.02
(d, 1H), 6.95-6.75 (m, 1H), 6.66-6.60 (m, 1H), 6.05-5.96 (m, 2H), 4.58 (brs,
2H), 4.49-4.48 (d
97
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
,1H), 3.90-3.70 (m, 4H), 3.55-3.45 (m, 2H), 2.89 (brs, 1H), 2.03-2.00 (m, 1H),
1.85-1.58 (m,
6H), 1.39-133 (m, 4H), 1.22 (s, 6H); LCMS: m/z = 583.0 (M+H) .
Example-13: Synthesis
of N-(24(3-(((8-isopropy1-2-((tetrahydro-2H-pyran-4-
yl)amino)pyrazolo[1,5-a][1,3,5]triazin-4-yDamino)methyl)phenyl)amino)-2-
oxoethyDacrylamide
(Compound-79).
Step-1: Synthesis of tert-butyl
(24(3-(((8-isopropyl-2-((tetrahydro-2H-pwan-4-
vflamino)pyrazolo[1,5-a111,3,51triazin-4-v1)amino)methyl)phenvflamino)-2-
oxoethyl)carbamate.
BocHN
H2N
Ly-
0
NH NHBoc
-'1`= N HOOC¨/ 11H N
N N
N N
To a cooled solution of (tert-butoxycarbonyl)glycine (0.033g, 0.3mmo1) in DMF
(5mL)
at 0 C was added HATU (0.152g, 0.4mmol) followed by DIPEA (0.1mL, 0.62mmo1)
and finally
added
N4-(3 -aminobenz y1)-8-i sopropyl-N2-(tetrahydro-2H-pyran-4-yl)pyrazolo
[1,5-
a][1,3,5]triazine-2,4-diamine (0.1g, 0.26mmo1; Intermediate-33). The reaction
mixture was
stirred for lh at room temperature. The reaction mixture was quenched with ice-
water and
diluted with ethyl acetate. The aqueous layer was separated and extracted with
ethyl acetate
(2x25mL). The combined organic phase was washed with brine, dried over Na2SO4,
filtered and
concentrated the crude residue was purified by 100-200 silica gel column
chromatography to
afford desired title compound (0.12g, crude). LCMS: m/z = 539 (M+H)+.
Step-2: Synthesis of
2-amino-N-(3-(((8-isopropyl-2-((tetrahydro-2H-pyran-4-
v1)amino)pyrazolo[1,5-al11,3,51triazin-4-yflamino)methybphenyl)acetarnide.
BocHN
HiN
0 NH2 H
HiN
0
NH
NH
03,
(130"--'1
N N
N
TEA (1mL) was added to a solution of tert-butyl (24(3-4(8-isopropy1-2-
((tetrahydro-2H-
pyran-4-yDamino)pyrazolo[1,5-a] [1,3 ,5]triazin-4-yDamino)methyl)phenyparnino)-
2-
98
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
oxoethypcarbamate (0.15g, 0.34mmol) in DCM (3mL) at 0 C. Then the reaction
mixture
allowed to stir at room temperature for 2h. After completion of the reaction,
the reaction mixture
was concentrated under vacuum to afford desired title compound (0.15g, crude).
LCMS: m/z =
439 (M-FH) .
Step-3: Synthesis of N-(2-((3-(((8-isopropyl-2-((tetrahydro-2H-pyran-4-
yl)amino)pyrazolo [1,5-
[1,3,5]tri azin-4-v1) amino)methyl)phen yl)amino)-2-ox oethvflacrvl amide.
N H2 H 0
HiN op
0 0 N
111 100
0
O
NH H
NH
_N
00,
N N N N
To a cooled solution of 2-amino-N-(3-4(8-isopropy1-2-((tetrahydro-2H-pyran-4-
yDamino)pyrazolo[1,5-a][1,3,5]triazin-4-yDamino)methyl)phenypacetamide
(0.127g, 0.28mmo1)
in DCM (5mL) added TEA (0.08mL, 0.56mm01) and stirred for 5min and added
acryloyl
chloride (0.026g, 0.28mmo1) drop wise at 0 C. The reaction mixture was
allowed to stir at room
temperature for lh. After completion of the reaction, the reaction mixture
quenched with water
and then diluted with DCM (10mL). Organic layer washed with water followed by
brine, dried
over Na2SO4, filtered and concentrated under vacuum and purified by
preparative HPLC
(Method: A: 0.02%in ammonia in water, B: Me0H : Acetonitrile(1:1), Column:
Gemini NX C-
18 (150mm*21.2, 5 m) to afford the title compound (0.043g, 43%) as free base.
IHNMR
(DMSO-d6, 400MHz): 10.08 (s, 1H), 9.92 (s, 1H), 8.50-8.47 (t, 1H), 7.76 (s,
1H), 7.52 (s, 2H),
7.31-7.27 (t, 1H), 7.08 (s, 1H), 6.85 (s, 1H), 6.41-6.34 (m, 1H), 6.17-6.12
(m, 1H), 5.68-5.65 (m,
1H), 4.64 (s, 2H), 3.99-3.97 (d, 2H), 3.87 (s, 3H), 2.95 (s, 3H), 1.87 (s,
2H), 1.50 (s, 2H), 1.28 (s,
6H); LCMS: m/z = 493.3 (M+H)+.
The below compounds were prepared by procedure similar to the one described in
Example-13 with appropriate variations in reactants, quantities of reagents,
in presence of
suitable solvents at suitable reaction conditions. The physicochemical
characteristics of the
compounds are summarized herein below table.
Compd.
Compound structure Analytical data
No.
99
CA 02978170 2017-08-29
WO 2016/142855 PCT/1112016/051302
111 NMR (DMSO-d6, 400MHz): 5 10.05 (s, 1H), 8.70
(s, 1H), 8.40-8.38 (d, 1H), 7.70 (s, 1H), 7.51 (s, 1H),
11 0 7.24-7.21 (t, 1H), 7.03-7.00 (d, 1H), 6.82
(s, 1H),
80 HN 6.36-6.29 (m, 1H), 6.10-6.05 (m, 11-1), 5.60-
5.57 (m,
1\T"' N-N , 1H), 4.58 (s, 1H), 4.50-4.43 (m, 1H), 3.81 (s, 31),
3.32 (s, 2H), 2.89 (s, 2H), 2.66 (s, 1H), 2.32 (s, 1H),
1.82 (s, 3H), 1.44 (m, 2H), 1.22 (s, 6H); LCMS: m/z
= 507.20 (M+H)+.
0 1H NMR (DMSO-do, 400MHz): 5 10.09 (d, 1H),
9.0-
8.50 (m, 1H), 7.70 (s, 1H), 7.48 (m, 2H), 7.23 (m,
I 0
1H), 7.02 (m, 1H), 6.84 (m, 2H), 6.62 (m, 1H), 6.14
NH
81 (m, 1H), 5.72 (d, 1H), 4.58 (m, 2H), 4.23 (s,
2H),
N 3.81 (m, 3H), 3.32 (m, 1H), 3.10 (m, 2H), 2.87 (m,
2H), 1.82 (m, 2H), 1.44 (m, 2H), 1.22 (d, 6H);
LCMS: m/z = 507.20 (M+H)+.
Yrt%11
HN 1110 1H NMR (DMSO-d6, 400MHz): 5 9.39 (s, 1H), 9.0-
0
8.5 (m, 2H), 8.15 (s, 1H), 7.69 (s, 11-1), 7.57-7.46 (m,
2H), 7.20 (t, 1H), 6.98 (m, 1H), 6.82 (m, 211), 6.33
82
(m, 1H), 6.05 (d, 1H), 5.57 (d, 1H), 4.56 (m, 2H),
N N
3.81 (m, 3H), 2.89 (m, 2H), 1.82 (m, 3H), 1.41 (d,
6H), 1.22 (m, 6H); LCMS: m/z = 521.2 (M+H)+.
1H NMR (DMSO-d6, 400MHz): 5 9.49 (s, 1H), 8.59
H (s, 2H), 7.69 (s, 1H), 7.56 (m, 1H), 7.52 (m,
1H), 7.23
( (t, 1H), 7.03 (m, 1H), 6.81 (m, 1H), 6.25 (m,
1H),
83
6.05 (d, 1H), 5.61 (d, 1H), 4.57 (m, 2H), 3.81 (m,
3H), 2.89 (m, 2H), 1.82 (m, 3H), 1.37 (m, 4H), 1.22
(d, 6H), 0.94 (m, 211); LCMS: m/z = 519.4 (M+H) .
100
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
111 NMR (DMSO-d6, 400MHz): 5 7.69 (s, 1H), 7.57
I -1 0111 (m, 2H), 7.42 (m, 1H), 7.23 (t, 1H),
7.06 (d, 1H), 6.7
NH (m, 1H), 6.64 (m, 1H), 6.15 (m, 1H), 5.67 (d, 1H),
84 o1XN
4.55 (m, 2H), 3.79 (m, 311), 3.35-3.29 (m, 3H), 2.91
(m, 4H), 1.77 (m, 2H), 1.57 (m, 211), 1.44 (in, 41),
1.19 (d, 6H); LCMS: m/z = 533.7 (M+H)+.
Example-14: Synthesis of 4-acrylamido-N-(3-(((8-isopropy1-2-((tetrahydro-2H-
pyran-4-
yl)amino)pyrazolo[1,5-a] [1,3,5]triazin-4-yDamino)methyppheny1)-1-methyl-1H-
pyrazole-3-
carboxamide (Compound-85).
Step-1: Synthesis of N-(34((8-isopropy1-2-((tetrahydro-2H-pyran-4-
yl)amino)pyrazololl,5-
al f 1,3.51triazin-4-ybamino)methyl)pheny1)-1-methyl-4-nitro-1H-pyrazole-3-
carboxamide.
NO2
H2N
-N. N
N 0
\H
N 11-1 COO
N H
N
To a cooled solution of 1-methyl-4-nitro-1H-pyrazole-3-carboxylic acid
(0.108g,
0.62mmo1; US 2009/156582A1) in DMF (10mL) at 0 C was added HATU (0.3g,
0.78mm01)
followed by DIPEA (0.2mL, 1.04mmol) and finally added N4-(3-aminobenzy1)-8-
isopropyl-N2-
(tetrahydro-2H-pyran-4-yl)pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine (0.2g,
0.52mmo1;
intermediate-33). The reaction mixture was stirred for lh at room temperature.
The reaction
mixture was quenched with ice-water and diluted with ethyl acetate. The
aqueous layer was
separated and extracted with ethyl acetate (2x25mL). The combined organic
phase was washed
with brine, dried over Na2SO4, filtered and concentrated the crude residue was
purified by 100-
200 silica gel column chromatography to afford the title compound (0.23g,
82%). LCMS: m/z =
535.1 (M-FF1) .
Step-2: Synthesis of: 4-amino-N-(3-4(8-isopropyl-2-((tetrahydro-2H-pyran-4-
yflarnino)
pyrazolo ,51 tri azin-4-yflamino)methyl)pheny1)-1-methyl-1H-pyrazole-
3-c arbox amide.
101
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
NO2 NH2
o 40 0 11
NH ____________________________________________________ NH
INT-N N N
To a solution of N-(3-(48-isopropy1-2-((tetrahydro-2H-pyran-4-
yDamino)pyrazolo[1,5-
a] [1,3,5]triazin-4-y1) amino)methyl)phen y1)-1-methy1-4-nitro-1H-p yrazole-3-
carbox amide (0.35g,
0.655mm01) in THF:MeOH:Water (3:2:1 ratio, 15mL) were added zinc (0.43g,
6.554mmo1) and
ammonium chloride (0.7g, 13.1mmol). The reaction mixture was stirred at room
temperature for
4h. After completion of reaction the reaction mixture filtered through celite
bed and diluted with
ethyl acetate. The aqueous layer was separated and extracted with ethyl
acetate (2x25mL). The
combined organic phase was washed with brine, dried over Na2SO4, filtered and
concentrated.
The residue was purified by 100-200 silica gel column chromatography to afford
desired title
compound (0.3g, 90%). LCMS: m/z = 504.9 (M+H)+.
Step-3: Synthesis of
4-acrylamido-N-(3-(((8-isopropyl-2-((tetrahydro-2H-pyran-4-
yl)amino)pyrazolo[1,5-al[1,3,51triazin-4-yflarnino)_methyl)pheny1)-1-methy1-1H-
pyrazole-3-
carboxamide.
o,=\1
1\11-12 NH
H
NNyN
tip 0
0 40
CI H
NH N
)`- N
03_
N
N
To a cooled solution of 4-amino-N-(3-(48-isopropy1-2-((tetrahydro-2H-pyran-4-
yDamino)pyrazolo[1,5-a] [1,3,5]triazin-4-yDamino)methyl)pheny1)-1-methyl-1H-
pyrazole-3-
carboxamide (0.2g, 0.39mm01) in DCM (5mL) was added TEA (0.01mL, 0.79mm01) and
stirred
for 5min and added acryloyl chloride (0.035g, 0.39mmo1) in DCM(1mL) drop wise
at 0 C. The
reaction mixture was allowed to stir at room temperature for lh. After
completion of the reaction,
the reaction mixture quenched with water and then diluted with DCM (10mL).
Organic layer
102
CA 02978170 2017-08-29
WO 2016/142855
PCT/1B2016/051302
washed with water followed by brine, dried over Na2SO4, filtered and
concentrated under vacuum
and purified by combiflash column by using 100-200 silica gel and ethyl
acetate and hexane as
eluent to afford the title compound (0.062g, 28%) 1H NMR (DMSO-d6, 400MHz): 8
10.29 (s,
1H), 9.85 (s, 1H), 8.95-8.70 (m, 1H), 8.42 (s, 1H), 7.90 (s, 1H), 7.74 (s,
2H), 7.32-7.30 (t, 1H),
7.13 (s, 1H), 6.89 (s, 1H), 6.68-6.64 (m, 1H), 6.31-6.26 (d, 1H), 5.82-5.79
(d, 1H), 4.67 (s, 2H),
4.00 (s, 4H), 3.87 (s, 4H), 2.93 (s, 2H), 1.90 (s, 2H), 1.52 (s, 2H), 1.28 (s,
611); LCMS: m/z =
559.1(M+H) .
Example-15: Synthesis of 1-acryloyl -N-(34(8-isopropy1-2-
((tetrahydro-2H-pyran-4-
yl)amino)pyrazolo[1,5-a][1,3,5]triazin-4-yparnino)phenypazetidine-2-
carboxamide (Compound-
86).
Step-1: Synthesis of tert-butyl 2-((3((8-isopropy1-2-((tetrahydro-2H-pyran-4-
yl)amino)
pvrazolo [1,5-al [1,3 ,51 tri azin-4-yflamino)phenyl)carbamoyflazetidine-1-
carboxylate.
1101 COO H
HN 11111 N iL
NH2 HN OB c
Boc N
N N N N
The process of this step was adopted from step-1 of example-3 (0.18g, 48%).
LCMS: rraz
= 551.6 (M+H) .
Step-2: Synthesis of N-(34(8-isopropy1-2-((tetraltydro-2H-pyran-4-
yDamino)pyrazolo111.5-
a][1,3,51triazin-4-yflarnino)phenybazetidine-2-carboxamide.
HN 4111 N ItINBoc FIN 41) )(CH
N-NOOJN
H N H
0 N
N N N N
The process of this step was adopted from step-2 of example-3 (0.11g crude).
LCMS: rn/z
= 451.3 (M-1-1-1) .
Step-3: Synthesis of 1- acrylovl -N-(34(84 sopropv1-2-
((tetrahydro-2H-pyran-4-
yflamino)pyrazolo[1,5-al [1,3,5]triazin-4-0)amino)phenybazetidine-2-
carboxamide.
103
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
H 141 N ALj-1
HN N N
N N H ULC I H
N N --
c/),11
The process of this step was adopted from step-3 of example-3. The obtained
crude
compound was purified by preparative HPLC (Method: A: water, B: Acetonitrile-
Methanol,
Column: KINETEX C18 : 21.2mm*150mm) to afford desired title compound (0.035g,
35%). 1H
NMR (DMSO-d6, 400MHz): 8 10.3-10.1 (m, 1H), 7.82 (s, 1H), 7.50-7.70 (m, 1H),
7.34-7.30 (t,
1H), 7.20-6.90 (d, 1H), 6.40-6.33 (m, 1H), 6.18-6.10 (m, 1H), 5.77-5.62 (m,
1H), 5.61-4.90 (m,
1H), 4.88-4.22 (m, 1H), 4.20-3.91 (m, 4H), 3.42-3.30 (m, 2H), 3.30-2.96 (m,
1H), 2.92-2.68 (m,
2H), 2.34-2.33 (m, 2H), 2.26 (s, 1H), 1.87 (s, 2H), 1.48 (s, 2H), 1.27-1.25
(d, 6H); LCMS: m/z =
505.3 (M-FH)+.
The below compound was prepared by procedure similar to the one described in
Example-15 with appropriate variations in reactants, quantities of reagents,
in presence of
suitable solvents at suitable reaction conditions. The physicochemical
characteristics of the
compounds are summarized herein below table.
Compd
Compound structure Analytical data
No
111 NMR (DMSO-d6, 400MHz): 8 10.1-9.87 (m, 2H),
8.25 (s, 1H), 8.05-8.04 (d, 1H), 7.81 (s, 2H), 7.52 (s,
410 N o
jL101. 1H), 7.29-7.25 (t, 1H), 7.20 (s, 1H),
6.90 (s, 1H),
N=74 N-N H
87 CLN 5.57-5.54 (m, 1H), 3.91-3.85 (m, 4H),
2.96-2.93 (m,
2H), 2.67 (s, 1H), 2.33 (s, 2H), 1.84-1.74 (m, 6H),
1.63-1.48 (m, 6H), 1.26-1.24 (d, 6H); LCMS: m/z =
547.75 (M-FH)+.
Example-16: Synthesis of 1-acryloyl-N-(3-(((8-ethy1-24(1-methylpiperidin-4-
yl)oxy)pyrazolo
[1,5-a] [1 ,3,5] triazin-4-yDamino)methyl)phen yppiperidine-4-c arboxamide
(Compound-88).
104
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
0,_7"¨)__0014 N abb
0 tip
NH
NH
)"-=
0 N
HATU (0.15g, 0.39mm01) followed by DIPEA (0.15g, 1.16mmol) was added to a
cooled
solution of 1-acryloylpiperidine-4-carboxylic acid (0.08g, 0.43mmo1) in dry
DMF (5mL) at 0 C.
N-(3-aminobenzy1)-8-ethyl-2-((1-methylpiperidin-4-y1)oxy)pyrazolo[1,5 -a] [1,3
,5]tri azin-4-
amine (0.15g, 0.39mmo1, intermediate-40) was added to above reaction mixture
and the resulting
reaction mixture was stirred for lh at room temperature. After completion of
reaction, the
reaction mixture was quenched with ice-water and diluted with ethyl acetate.
The aqueous layer
was separated and extracted with ethyl acetate (2x50mL). The combined organic
phase was
washed with brine, dried over Na2SO4, filtered and concentrated. The residue
was purified by
prep. HPLC Column:XBRIDGE (19mm x 150mm), 0.01% HCOOH (A), Acetonitrile (B) to
afford desired title compound (0.04g, 18.69%). 1FINMR (DMSO-d6, 400MHz): 5
9.93 (s, 1H),
9.30-9.27 (t, 1H), 7.94 (s, 1H), 7.55 (s, 1H), 7.51-7.49 (d, 1H), 7.25-7.21
(t, 1H), 7.01-6.99 (d,
1H), 6.84-6.77 (m, 111), 6.11-6.06 (m, 1H), 5.68-5.64 (m, 1H), 4.90 (s, 111),
4.61-4.60 (d, 2H),
4.44-4.41 (d, 111), 4.10-4.07 (d, 1H), 3.15-3.05 (m, 211), 2.74-2.52 (m, 4H),
2.35-2.25 (In, 41-1),
1.95-1.85 (m, 2H), 1.81-1.78 (d, 2H), 1.75-1.65 (m, 3H), 1.55-1.35 (m, 3H),
1.23-1.17 (m, 3H);
LCMS: m/z = 548.1 (M+1)+.
The below compounds were prepared by procedure similar to the one described in
Example-16 with appropriate variations in reactants, quantities of reagents,
in presence of
suitable solvents at suitable reaction conditions. The physicochemical
characteristics of the
compounds are summarized herein below table.
Compd.
Compound structure Analytical data
No.
105
CA 02978170 2017-08-29
WO 2016/142855 PCT/1112016/051302
111 NMR (DMSO-d6, 400MHz): 5 10.05-9.97 (d, 1H),
9.39-9.36 (t, 111), 8.05 (s, 1H), 7.53-7.51 (m, 2H),
OyIN T =o o 7.27-7.23 (t, 1H), 7.04-7.02 (d, 1H), 6.95-
6.75 (m,
114), 6.17 (s, 1H), 6.11-6.07 (d, 111), 5.68-5.55 (t,
1H), 4.95-4.81 (m, 1H), 4.64-4.62 (d, 2H), 4.51-4.22
89
N
1
(m, 1H), 4.15-3.95 (m, 1H), 3.29-3.15 (m, 1H), 3.15-
0)N) 2.95 (m, 1H), 2.85-2.55 (m, 211), 2.49-2.35 (m, 1H),
2.25-2.05 (m, 4H), 1.95-1.85 (m, 2H), 1.80-1.55 (m,
3H), 1.45-1.15 (m, 3H), 0.88-0.84 (t, 1H); LCMS;
m/z = 519 (M+H) .
1H NMR (DMS0-4 400MHz): 8 9.80 (s, 1H), 9.28-
H 9.25 (t, 1H), 8.03-8.01 (d, 1H), 7.94 (s, 1H), 7.56-
12
N )114 ram
MP 7.54 (d, 1H), 7.50 (s, 1H), 7.24-7.20 (t, 1H), 6.99-
0
6.97 (d, 1H), 6.38-6.31 (m, 1H), 6.08-6.01 (m, 1H),
90 NH 5.55-5.52 (m, 1H), 4.95-4.75 (m, 1H), 4.61-
4.60 (d,
Nr=-1-N-N
2H), 3.88 (s, 1H), 2.67-2.52 (m, 3H), 2.49-2.18 (m,
1H), 2.11-1.92 (m, 4H), 1.90-1.49 (m, 11H), 1.29-
1.19 (m, 3H), 0.87-0.82 (m, 3H); LCMS: nilz = 561.2
(M-FH) .
H
1H NMR (DMSO-d6, 400MHz): 5 9.77 (s, 1H), 7.95-
0 air PI aihr,
0 LIP 7.93 (d, 111), 7.88 (s, 11-1), 7.48-7.46 (m,
211), 7.19-
7.15 (t, 1H), 6.95-6.93 (d, 111), 6.16-6.10 (m, 1H),
6.03-5.98 (m, 1H), 5.52-5.49 (m, 1H), 4.78 (m, 2H),
91
11-1 1-I 90 2 1-1
NN N\ 455 (s7 4 )7 2942 - (1T17 2H )755 -
(In7 2 )7 228 - -
2.20 (m, 1H), 2.11 (s, 3H), 2.07-2.04 (m, 3H), 1.88-
1.79 (m, 3H), 1.58-1.56 (m, 2H), 1.44-1.41 (d, 2H),
1.22-1.13 (m, 811); LCMS: m/z = 575.4 (M+H)+.
106
CA 02978170 2017-08-29
WO 2016/142855 PCT/1112016/051302
Isomer-I: 1H NMR (DMSO-d6, 400MHz): 5 9.81 (s,
1H), 9.38-9.37 (t, 1H), 8.03-8.01 (d, 1H), 7.96 (s,
1H), 7.57-7.55 (d, 1H), 7.50 (s, 1H), 7.25-7.21 (t,
1H), 7.00-6.99 (d, 111), 6.39-6.32 (m, 1H), 5.56-5.53
(d, 1H), 4.95-4.90 (m, 1H), 4.75-4.61 (m, 311), 3.89
(s, 1H), 3.00-2.95 (m, 2H), 2.67-2.60 (m, 1H), 2.38-
-N 2.33 (m, 2H), 2.22 (s, 31-1), 2.18-2.07 (m,
3H), 1.80-
- ig 1C1r14
= 1.54 (m, 911), 1.27-1.25 (d, 6H); LCMS: m/z = 594.5
92 & (M+H)+.
NH N
93 NN Isomer-2: 1H NMR (DMSO-d6, 400MHz): 5 9.81
(s,
0
1H), 9.37-9.34 (t, 1H), 8.03-8.01 (d, 1H), 7.96 (s,
1H), 7.57-7.55 (d, 1H), 7.52 (s, 1H), 7.25-7.21 (t,
1H), 7.00-6.99 (d, 1H), 6.39-6.32 (m, 1H), 5.56-5.53
(d, 1H), 4.98-4.91 (m, 1H), 4.79 (s, 1H), 4.63-4.61 (d,
2H), 3.89 (s, 1H), 3.01-2.88 (m, 2H), 2.67-2.62 (m,
1H), 2.28-2.23 (m, 2H), 2.18 (s, 3H), 2.17-2.07 (m,
2H), 1.95-1.56 (m, 10H), 1.27-1.25 (d, 6H); LCMS:
m/z = 594.5 (M+H)+.
H NMR (DMSO-d6, 400MHz): 5 10.16 (s, 1H), 9.31-
v
9.28 (t, 1H), 7.92 (s, 1H), 7.55-7.54 (m, 2H), 7.29-
N H
410
7.25 (t, 11-1), 7.05-7.03 (d, 111), 6.37-6.30 (m, 1H),
6.14-6.06 (m, 2H), 5.73-5.74 (m, 1H), 4.83-4.79 (m,
94 N
r12. 2H), 4.62-4.61 (d, 2H), 4.19-4.18 (m, 2H),
3.90 (m,
-,Na)
1H), 2.98-2.94 (m, 1H), 2.67-2.59 (m, 2H), 2.15-2.06
(m, 5H), 1.93-1.91 (m, 2H), 1.63-1.60 (d, 2H), 1.26-
1.24 (d, 6H); LCMS: m/z = 533.2 (M+H)+.
107
CA 02978170 2017-08-29
WO 2016/142855 PCT/1112016/051302
111 NMR (DMSO-d6, 400MHz): 5 10.05-10.03 (d,
1H), 9.30-9.27 (t, 1H), 7.90 (s, 1H), 7.51-7.47 (m,
o 2H), 7.23-7.19 (t, 1H), 7.00-6.98 (d, 1H), 6.57-6.50
(m, 1H), 6.11-6.06 (m, 111), 5.63-5.60 (d, 1H), 5.00-
95 NII 4.95 (m, 1H), 4.56 (s, 211), 3.79-3.74 (m,
2H), 3.68-
). N
3.63 (m, 2H), 3.58-3.48 (m, 4H), 3.17-3.05 (m, 1H),
2.96-2.90 (m, 1H), 2.13-2.02 (m, 2H), 2.02-1.93 (m,
2H), 1.58-1.51 (m, 2H), 1.22-1.20 (d, 6H); LCMS:
m/z = 534.3 (M+H)+.
1H NMR (DMSO-d6, 400MHz): 5 10.00-9.98 (d, 1H),
9.34-9.31 (t, 1H), 7.95 (s, 1H), 7.51 (s, 2H), 7.27-7.22
or
(m, 211), 7.10 (s, 1H), 7.03-7.01 (d, 1H), 6.97 (s, 1H),
6.90-6.79 (m, 1H), 6.11-6.07 (d, 1H), 5.68-5.63 (t,
96 1H), 5.02 (s, 1H), 4.62-4.61 (d, 2H), 4.49-
4.28 (m,
2H), 4.10-4.00 (m, 2H), 3.84-3.80 (m, 1H), 3.23-3.17
(m, 1H), 3.07-2.94 (m, 2H), 2.78-2.67 (m, 1H), 2.33
(m, 1H), 1.97-1.94 (m, 2H), 1.73-1.56 (m, 4H), 1.27-
1.25 (d, 6H); LCMS: m/z = 548.4 (M-FH)+.
1H NMR (DMSO-d6, 400MHz): 5 9.81 (s, 1H), 9.31-
H 9.28 (t, 1H), 8.32 (s, 1H), 8.02-8.00 (d,
1H), 7.94 (s,
N
Li n 111), 7.55-7.51 (m, 211), 7.25-7.21 (t, 114),
7.00-6.98
0 ti,p (d, 111), 6.39-6.32 (m, 1H), 6.08-6.03 (m,
1H), 5.56-
97 NH 5.53 (m, 1H), 5.04-4.99 (m, 1H), 4.61-4.60
(d, 2H),
'
3 88 3 79 (m, 3H), 3.46-3.40 (t, 2H), 3.05-2.94 (m,
111), 2.38 (m, 1H), 1.98-1.94 (m, 211), 1.80-1.70 (m,
4H), 1.63-1.50 (m, 5H), 1.26-1.25 (d, 6H); LCMS:
m/z = 562.4 (M-FH)+.
108
CA 02978170 2017-08-29
WO 2016/142855 PCT/1112016/051302
Isomer-I: 1H NMR (CDC13-d6, 400MHz): 6 7.72 (s,
1H), 7.63 (s, 1H), 7.41-7.35 (m, 211), 7.29-7.26 (m,
1H), 7.08-7.06 (d, 114), 6.95-6.85 (m, 1H), 6.29-6.24
(m, 1H), 6.11-6.04 (m, 111), 5.95-5.85 (d, 1H), 5.63-
5.60 (m, 1H), 5.40-5.25 (m, 1H), 4.85-4.74 (m, 21),
4.15-3.85 (m, 3H), 3.65-3.55 (m, 2H), 3.09-3.06 (m,
1H), 2.38-2.36 (m, 2H), 1.88-1.80 (m, 8H), 1.29-
. kip
98 & XI 1.27(d, 6H); LCMS: m/z = 580.1 (M+H)+.
99 NN 0 N s.s \ Isomer-2: 1HNMR (CDC13-d6, 400MHz): 6
7.71 (s,
Y-F = 1H), 7.56 (s, 1H), 7.47 (s, 1H), 7.43-7.41
(d, 1H),
7.27-7.23 (m, 3H), 7.04-7.02 (m, 211), 6.28-6.23 (m,
1H), 6.10-6.03 (m, 1H), 5.94-5.84 (d, 1H), 5.62-5.59
(d, 1H), 5.35-4.90 (m, 2H), 4.76-4.73 (m, 2H), 4.25-
4.05 (m, 3H), 3.75-3.51 (m, 21-1), 3.06-3.02 (m, 1H),
2.45-2.35 (m, 2H), 2.05-1.70 (m,711), 1.28-1.27 (d,
6H); LCMS: ink = 580.1 (M+H).
1H NMR (DMSO-d6, 400MHz): 6 9.76 (s, 1H), 9.26
iiY(t, 111), 7.98-7.96 (d, 111), 7.90 (s, 11-1), 7.53-7.51 (d,
o C r
1H), 7.46 (s, 11), 7.20-7.17 (m, 1H), 6.96-6.94 (d,
o
1H), 6.34-6.27 (m, 1H), 6.04-5.99 (dd, 1H), 5.51-5.48
100
N :17N-N (dd, 1H), 5.37-5.35 (m, 1H), 4.57-4.56 (d,
211), 3.84-
0)N1)1 3.80 (m, 2H), 3.77-3.66 (m, 3H), 2.15-2.12
(m, 2H),
1.98-1.96 (m, 2H), 1.75-1.64 (m, 4H), 1.51-1.45 (m,
4H), 1.23-1.21 (d, 6H); LCMS: m/z = 548.1 (M+H)t
% 1H NMR (DMSO-d6, 400MHz): 6 9.81 (s, 1H),
9.27
icy, gar
(t, 1H), 8.03-8.01 (d, 1H), 7.94 (s, 1H), 7.58-7.56 (d,
1,11P 1H), 7.49 (s, 1H), 7.25-7.21 (t, 1H), 7.00-
6.98 (d,
101 1H), 6.39-6.32 (m, 1H), 6.08-6.03 (dd, 1H),
5.55-5.52
Nr-N-N
(dd, 1H), 5.37 (m, 1H), 4.61-4.60 (d, 2H), 3.9 (m,
1H), 3.40-3.38 (m, 2H), 2.99-2.96 (m, 1H), 2.67 (m,
1H), 2.66-2.64 (m, 2H), 2.37-2.35 (m, 2H), 2.25 (m,
109
CA 02978170 2017-08-29
WO 2016/142855 PCT/1112016/051302
31), 1.80-1.77 (m, 3H), 1.58-1.53 (m, 3H), 1.27-1.26
(d, 6H), 1.10-1.07 (t, 2H); LCMS: miz = 560.8
(M+H)+.
11-1 NMR (DMSO-d6, 400MHz): ö 10.08-10.07 (d,
1H), 9.27-9.24 (t, 1H), 7.94 (s, 1H), 7.54 (s, 2H),
dirim
0 Rew 7.27-7.23 (t, 1H), 7.05-7.03 (d, 1H), 6.61-
6.54 (m,
1H), 6.15-6.10 (m, 1H), 5.76-5.64 (m, 1H), 4.63-4.62
102 NIHN-N
(d, 2H), 4.03-4.01 (d, 2H), 3.80-3.63 (m, 2H), 3.57-
3.47 (m, 2H), 3.21-3.08 (m, 1H), 3.02-2.96 (m, 1H),
2.18-1.94 (m, 3H), 1.27-1.25 (m, 6H), 0.94-0.92 (d,
6H); LCMS: ink = 506.4 (M+H)+.
1H NMR (DMSO-d6, 400MHz): 8 10.09 (d, 1H), 9.32
NrTi
N
0 !up (t, 1H), 7.95 (s, 1H), 7.57 (d, 1H), 7.51 (d,
1H), 7.27
(t, 1H), 7.05 (d, 1H), 6.62 (m, 1H), 6.15 (d, 1H), 5.67
103 N7N-N (d, 1H), 4.63-4.61 (d, 2H), 4.36-4.34 (d,
2H), 3.72-
3.67 (m, 3H), 3.59-3.53 (m, 1H), 3.46-3.26 (m, 6H),
3.20 (m, 1H), 2.18-2.08 (m, 2H), 1.27-1.25 (d, 6H);
LCMS: mlz = 506.15 (M-H.
1H NMR (DMSO-d6, 400MHz): ö 10.08 (d, 1H), 9.32
0 (t, 1H), 7.95 (s, 1H), 7.57 (s, 1H), 7.50 (s,
1H), 7.27
(t, 1H), 7.04 (d, 1H), 6.61 (m, 1H), 6.15 (d, 1H), 5.6
NH
104 N N (d, 1H), 4.63-4.61 (d, 2H), 4.35-4.33 (d,
2H), 3.82-3.5
"--\
(m, 3H), 3.53-3.42 (m, 3H), 3.41-3.30 (m, 2H), 3.21-
2.97 (m, 6H), 3.00 (m, 1H), 2.19-2.09 (m, 2H), 1.33-
1.25 (d, 6H); LCMS: ink = 550.2 (M-H)";
110
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
111 NMR (DMSO-d6, 400MHz): 5 9.80 (s, 1H), 9.30-
H
H 9.15 (t, 1H), 8.02-8.01 (d, 1H), 7.85 (s, 1H), 7.55-
7.53 (d, 1H), 7.49 (s, 1H), 7.24-7.20 (t, 1H), 6.98-
1,,,,IIN is
6.96 (d, 1H), 6.38-6.32 (m, 111), 6.08-6.03 (m, 1H),
105
IWIN N 5.56-5.52 (m, 1H), 4.81-4.80 (m, 1H),
4.60-4.59 (d,
õNao,N .........\ ....õ:õ.
2H), 3.88 (s, 1H), 2.67-2.58 (m, 2H), 2.45-2.25 (m,
1H), 2.16 (s, 3H), 2.10-2.05 (t, 2H), 1.92-1.85 (m,
2H), 1.80-1.50 (m, 10H), 1.10-1.07 (t, 1H), 0.84-0.74
(m, 4H); LCMS: m/z = 572.9 (M+H)+.
Example-17: Synthesis of 1-acryloyl-N-(3-(48-isopropy1-2-(piperidin-4-
yloxy)pyrazolo[1,5-
a][1,3,5]triazin-4-yparnino)methyl)phenyppiperidine-4-carboxamide (Compound-
106)
Step-1: Synthesis of tert-butyl 4-((4-((3-(1-acryloylpiperidine-4-
carboxamido)benzyl)amino)-8-
isopropylpyrazolo [1,5-al [1,3,5 Itriazin-2-yfloxy)piperidine-1-carboxylate.
0
}õ,õ 0 -------'1-NarH
N ask,
0 0 NRIP
Xi NOOH NH
BoeNa N "". N -1\1\ .1,.
BocNLa N'
The process of this step was adopted from example-16. The obtained crude
compound
was purified by combiflash to afford the title compound (0.1g, 50%). LCMS: m/z
= 647.4
(M+H) .
Step-2: Synthesis of 1 -acryloyl-N-(3-(((8-isoprop y1-2-(piperidin-
4- yloxy)pyrazolo I- 1,5-
al 1-1,3,51triazin-4-ybamino)methyl)phen yflpiperidine-4-c arbox amide.
o
'''"==)I-Nasir
11 H
0 N 41) 0 N OP
1.A. 11H
Boca1,1"- N-Nµ HNia N' N-N
eiN)--........
111
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
TFA (1mL) was added to a solution of tert-butyl 4-44-43-(1-acryloylpiperidine-
4-
carboxamido)benzypamino)-8-isopropylpyrazolo[1,5-a] [1,3 ,5]triazin-2-yl)ox
y)piperidine-1-
carboxylate(0.1g, 0.15mmol)in DCM (10mL) at 0 C. Then the reaction mixture
allowed to stir
at room temperature for 2h. After completion of the reaction, the reaction
mixture was
concentrated under vacuum and purified by prep. HPLC (Method: A: 0.01% Ammonia
in water,
B: Acetonitrile-Methanol, Column: EVA-C-18 (21.2mm*150mm, 5 m)) to afford
desired title
compound (0.06g, 22%). 111 NMR (DMSO-d6, 400MHz): 5 9.93 (s, 1H), 9.39-9.36
(t, 1H), 8.48
(s, 1H), 8.38 (s, 1H), 7.97 (s, 1H), 7.59 (s, 1H), 7.48-7.46 (d, 1H), 7.25-
7.21 (t, 1H), 7.02-7.00 (d,
1H), 6.84-6.77 (m, 1H), 6.11-6.07 (m, 1H), 5.68-5.65 (m, 1H), 5.11 (s, 1H),
4.63-4.61 (d, 2H),
4.45-4.42 (d, 111), 4.11-4.08 (m, 211), 3.23 (m, 211), 3.11-3.08 (m, 311),
3.01-2.94 (m, 1H), 2.70-
2.64 (m, 111), 2.33 (m, 111), 2.08 (m, 211), 1.86-1.78 (m, 311), 1.49-1.40 (m,
2H), 1.27-1.25 (d,
5H); LCMS: m/z = 547.4 (M-FH)+.
The below compound was prepared by procedure similar to the one described in
Example-17 with appropriate variations in reactants, quantities of reagents,
in presence of
suitable solvents at suitable reaction conditions. The physicochemical
characteristics of the
compounds are summarized herein below table.
Compd.
Compound structure Analytical data
No.
111 NMR (DMSO-d6, 400MHz): 5 9.92 (s, 111), 8.36 (s,
N
0 111 P
1H),7.95 (s, 1H), 7.53-7.52 (m, 2H), 7.25-7.21 (t, 111),
7.01-6.99 (d, 111), 6.84-6.77 (m, 111), 6.11-6.06 (m,
1H), 5.67-5.64 (m, 1H), 4.60 (s, 2H), 4.44-4.41 (d, 1H),
107
4.26-4.23 (t, 2H), 4.10-4.07 (m, 2H), 3.6 (s, 2H), 3.16-
2.95 (m, 311), 2.78-2.75 (t, 1H), 2.70-2.57 (m, 2H),
1.81-1.68 (m, 3H), 1.65-1.59 (m, 2H), 1.51-1.43 (m,
2H), 1.27-1.25 (d, 6H); LCMS: m/z = 535.4 (M+H)+.
Example-18: Synthesis of 1-acryloyl -N-(3-(((8-isopropy1-2-((1-methylpiperidin-
4-yl)oxy)
pyrazolo[1,5-a][1,3,5]triazin-4-yDamino)methypphenyl)pyrrolidine-3-carboxamide
(Compound-
108).
Step-1: Synthesis of tert-butyl 34(3-(48-isopronv1-24(1-methylnineridin-4-
yboxv)nyrazolol1,L
al [1,3,5]triazin-4-ybamino)methyl)phen yl)c arbamoyflpyrrolidine-1 -carbox yl
ate.
112
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
H2N Bo cN
411
aBoe
0 ___________________________________________
N NH
N N
N
0 N
To a cooled solution of 1-(tert-butoxycarbonyl)pyrrolidine-3-carboxylic acid
(0.16g,
0.75mmo1) in DMF (4mL) at 0 C was added HATU (0.36g, 0.94mmol) and DIPEA
(0.21mL,
1.26mmo1) and finally added N-(3-aminoben zy1)-8-i sopropy1-24(1 -
methylpiperidin-4-
yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine (0.25g, 0.63mmo1, Intermediate-
41). The reaction
mixture was stirred for 2h at room temperature. The reaction mixture was
quenched with ice-
water and diluted with ethyl acetate. The aqueous layer was separated and
extracted with ethyl
acetate (2x25mL). The combined organic phase was washed with brine, dried over
Na2SO4,
filtered and concentrated to crude residue. The residue was purified by
combiflash to afford the
title compound (0.1g, 50%). LCMS: m/z = 593.4 (M-41)+.
Step-2: Synthesis of N-(3-4(84 soprop y1-24( 1-methylpiperidin-4-
yfloxy)pyrazolo 1- 1,5-
a] [13,51triazin-4-yDamino)methyl)phen yflpyrrolidine-3-c arboxamide.
BocNalr H mar H
N ask. N WI.eam
0 ligH 0
NH _________________________________________
N
N 0 N
TFA (3mL) was added to a solution of tert-butyl 3-((3-(((8-isopropy1-2-((1-
methylpiperidin-4-yl)ox y)pyrazolo [ 1,5-a] [ 1,3,5] triazin-4-
yl)amino)methyl)phenyl)
carbamoyppyrrolidine-1-carboxylate (0.3g, 0.50mmo1)in DCM (10mL) at 0 C. Then
the
reaction mixture allowed to stir at room temperature for 2h. After completion
of the reaction, the
reaction mixture was concentrated under vacuum (0.25g, Crude). LCMS: m/z =
493.4 (M+H)+.
Step-3: Synthesis of 1-acryloyl-N-(3-(((8-isopropyl-24(1-rnethylpiperidin-4-
yl)oxy)pyrazolo
[1,5-al11,3,51triazin-4-yl)amino)methyl)phenybpyrrolidine-3-carboxamide.
113
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
HNON _dam -NrN 1111
0 `..W 0 0 `,"q9P"
CI
NH ______________________________________________________ NH
N
LO)N
To a solution of N-(3-(((8-isopropy1-2-((1-methylpiperidin-4-
yl)oxy)pyrazolo[1,5-
a][1,3,5]triazin-4-yDamino)methypphenyppyrrolidine-3-carboxamide (0.25g,
0.50mmo1) in
DCM (10 mL) was added DIPEA (0.17mL, 1.01mmol) and acryloyl chloride (0.05g,
0.55mmo1)
at 0 C. The reaction mixture was stirred for 2h at rt. Water was added and
extracted with ethyl
acetate. The aqueous layer was separated and extracted with dichloromethane
(2x25mL). The
combined organic phase was washed with brine, dried over Na2SO4, filtered and
concentrated to
afford crude and purified by prep. HPLC (Method: A: 0.01% Ammonia in water, B:
Acetonitrile-
Methanol, Column: EVA-C-18 (21.2mm*150mm, 5 m) to afford desired title
compound (0.06g,
22%). LCMS: m/z = 547.21 (M+H) . 11-1NMR (DMSO-d6, 400MHz): 5 10.50 (s, 1H),
9.95 (s,
1H), 8.18 (s, 2H), 8.06-8.02 (m, 2H), 7.94 (s, 1H), 7.50-7.48 (d, 1H), 7.34-
7.30 (m, 2H), 6.36-
6.33 (m, 1H), 6.09-6.04 (m, 1H), 5.56-5.53 (m, 1H), 4.90 (s, 1H), 3.91 (m,
2H), 3.03-2.99 (m,
2H), 2.71-2.67 (m, 3H), 2.01-1.99 (m, 3H), 1.84-1.57 (m, 8H), 1.29-1.27 (d,
6H); LCMS: m/z =
547.4 (M H)+.
The below compounds were prepared by procedure similar to the one described in
Example-18 with appropriate variations in reactants, quantities of reagents,
in presence of
suitable solvents at suitable reaction conditions. The physicochemical
characteristics of the
compounds are summarized herein below table.
Compd.
Compound structure Analytical data
No.
Isomer-I: 1HNMR (DMSO-d6, 400MHz): 5 10.09-10.07
o
(d, 1H), 9.31-9.28 (t, 1H), 7.93 (s, 1H), 7.53-7.50 (m,
109 & EI
2H), 7.26-7.22 (t, 1H), 7.02-7.01 (d, 1H), 6.60-6.53 (m,
N N N Na 0
110
111), 6.14-6.10 (m, 1H), 5.67-5.64 (m, 1H), 4.85 (s, 1H),
4.59 (d, 2H), 3.79-3.77 (m, 1H), 3.69-3.62 (m, 2H), 3.58-
3.49 (m, 2H), 3.20-3.07 (m, 2H), 3.03-2.92 (m, 2H), 2.69
114
CA 02978170 2017-08-29
WO 2016/142855 PCT/1112016/051302
(s, 1H), 2.20-2.05(m, 6H), 1.97-1.91 (m, 2H), 1.63 (s,
2H), 1.29-1.24 (m, 6H); LCMS: m/z = 547.0 (M H)+.
Isomer-2: iHNMR (DMSO-d6, 400MHz): 8 10.09-10.07
(d, 1H), 9.30-9.27 (t, 1H), 7.93 (s, 1H), 7.53-7.50 (m,
2H), 7.26-7.22 (t, 1H), 7.02-7.00 (d, 1H), 6.60-6.53 (m,
1H), 6.14-6.10 (m, 1H), 5.66-5.64 (m, 1H), 4.84 (s, 1H),
4.61-4.59 (d, 2H), 3.79-3.77(m, 111), 3.69-3.62 (m, 2H),
3.58-3.48 (m, 3H), 3.20-3.07 (m, 1H), 2.97-2.92 (m, 2H),
2.69 (s, 2H), 2.19-2.07 (m, 5H), 1.99-1.91 (m, 2H), 1.64-
1.62 (m, 2H), 1.25-1.24 (m, 6H); LCMS: m/z = 547.0
(M+H)+;
11-1 NMR (DMSO-d6, 400MHz): 8 9.90 (s, 1H), 9.27 (s,
1H), 7.86 (s, 1H), 7.51 (s, 2H), 7.23-7.19 (t, 1H), 6.99-
H
6.98 (d, 1H), 6.83-6.76 (t, 1H), 6.10-6.05 (m, 1H), 5.66-
N= 5.63 (m, 1H), 4.83-4.79 (m, 1H), 4.58 (s, 2H),
4.43-4.40
111 (d, 1H), 4.10-4.06 (d, 1H), 3.15 (s, 1H), 3.09-
3.03 (s,
1H), 2.98-2.91 (m, 1H), 2.66-2.53 (m, 4H), 2.14 (s, 2H),
2.09-2.04 (t, 2H), 1.91-1.81 (m, 2H), 1.89-1.80 (m, 2H),
1.63-1.56 (m, 2H), 1.50-1.40 (m, 2H),1.24-1.23 (d, 6H);
LCMS: mlz = 561.4 (M-+-H).
111 NMR (DMSO-d6, 400MHz): 15 9.89-9.81 (d, 1H), 9.27
H (s, 1H), 7.93 (s, 1H), 7.63-7.58 (m, 2H), 7.28-
7.24 (m,
0 0 %Pi 1H), 7.06-6.04 (m, 1H), 6.85-6.78 (m, 1H), 6.18-
6.11 (m,
112 1,1:4( 111), 5.75-5.73 (m, 1H), 4.85-4.80 (m, 111),
4.61-4.50 (m,
2H), 4.11-3.94 (m, 1H), 3.57-3.39 (m, 111), 3.42-3.35 (m,
0 '14
1H), 3.0-2.95 (m, 1H), 2.60-2.58 (m, 2H), 2.25 (s, 3H),
2.22-2.1 (m, 2H), 1.95-1.75 (m, 2H), 1.63-1.60 (m,
211),1.18 (s, 6H); LCMS: m/z = 563.5 (M+H)+.
115
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
1H NMR (DMSO-d6, 400MHz): 8 10.05 (s, 111), 9.32-
o
ith
9.29 (t, 1H), 7.93 (s, 1H), 7.52-7.48 (m, 2H), 7.28-7.24
s
(t, 1H), 7.05-7.03 (d, 1H), 6.89-6.82 (m, 1H), 6.17-6.13
o)
NH
(111, 111), 5.76-5.73 (d, 1H), 4.87-4.86 (m, 1H), 4.62-4.61
113NL:JNLx
N
(d, 2H), 4.29-4.26 (d, 1H), 4.12-4.11 (d, 1H), 3.89-3.84
(t, 2H), 3.70-3.64 (m, 2H), 3.17-3.16 (d, 2H), 3.00-2.93
(m, 3H), 2.67-2.62 (m, 2H), 2.18-2.13 (m, 31-1), 1.92 (s,
3H), 1.26-1.24 (d, 6H); LCMS: m/z = 563.70 (M+H)t
1H NMR (CDC13-d6, 400MHz): 8 7.83 (s, 1H), 7.71-7.67
tts,C1t41
(m, 2H), 7.36-7.34 (d, 1H), 7.05-7.03 (d, 1H), 6.96-6.94
1-1 "APP'
(m, 1H), 6.27-6.23 (m, 1H), 6.13-6.07 (m, 2H), 5.62-5.59
NH
114 N-N
(m, 1H), 5.15 (s, 1H), 4.72-4.71 (d, 2H), 3.96-3.90 (m,
2H), 3.05-2.94 (m, 2H), 2.49 (s, 3H), 2.45-2.42 (m, 1H),
2.30-2.20 (m, 4H), 2.10-1.65 (m, 9H), 1.51-1.44 (m, 2H),
1.28-1.20 (m, 6H); LCMS: m/z = 574.9 (M+H)+.
1H NMR (DMSO-d6, 400MHz): 5 10.13 (s, 1H), 9.31-
H
tr..N
9.28 (t, 1H), 7.93 (s, 1H), 7.62-7.63 (m, 1H), 7.56 (s,
8 410.4 ahn
1H), 7.29-7.25 (t, 1H), 7.05-7.03 (d, 1H), 6.43-6.36 (m,
0 tip
1H), 6.25-6.20 (m, 1H), 5.74-5.71 (m, 1H), 4.83-4.81 (m,
115 1=1H N
-Nacx,:j3..._ 1H), 4.63-4.61 (d, 2H), 3.87 (s, 1H), 3.16 (d, 1H), 2.98-
2.93 (m, 111), 2.67-2.60 (m, 2H), 2.35 (m, 2H), 2.16-2.10
(m, 4H), 1.92-1.90 (m, 2H), 1.79-1.52 (m, 10H), 1.26-
1.25 (d, 6H); LCMS: rn/z = 575.1 (M+H)t
Example-19: Synthesis
of 1-acryloyl-N-(3-(((84 sopropy1-24(1-methylpiperidin-4-
yl)ox y)pyrazolo [1,5-a] [1,3 ,5] tri azin-4-yDamino)methyl)phen yppiperidine-
3-c arbox amide
(Compound-116)
Step-1: Synthesis of tert-butyl 34(3 -(((8-i sopropy1-2-(methylthio)p
yrazolo11,5-a 1 [1 ,3,51triazin-
4-yl)arnino) methyl)phen yl)c arbamoybpiperidine-l-c arboxyl ate.
116
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
ito NyClo NBoc
Boc
CI NH NH2
N r. 40 0
S N S N
DIPEA (1.2mL, 7.23mmo1) was added to a stifled solution of 4-chloro-8-
isopropy1-2-
(methylthio)pyrazolo[1,5-a][1,3,5]triazine (0.35g, 1.44mmo1; intermediate-4)
and tert-butyl 3-
((3-(aminomethyl)phenyl)carbamoyl)piperidine- 1-carboxylate (0.48g, 1.44mmol,
intermediate-
17) in acetonitrile (10mL) at 0 C. The resulting reaction mixture was stifled
at ambient
temperature for 4h. After completion of the reaction, the reaction mixture was
concentrated
under vacuum and purified the residue in 100-200 mesh silica column by eluting
with 15% ethyl
acetate-hexane to afford the title compound (0.5g, 64%). LCMS: m/z = 540.1
(M+H)+.
Step-2: Synthesis of tert-butyl 34(3-(48-isopropv1-2-
(methylsulfonyl)pyrazolor1,5-
all 1,3,51triazin-4-yl)amino) methyl)phenyl)carbamoyDpiperidine-l-carboxylate.
Boclaff,N
Boci,N aim
0 0 LIP
NH
NH
e'L N
N INT"-
N N
=-=.(1?)k=
S N
8
mCPBA (0.48g, 2.78mmo1) was added portion wise to a stirred solution of tert-
butyl 3-
((3-(((8-i sopropy1-2-(methylthio)pyrazolo [1 ,5-a] [1,3,5] triazin-4-
yl)amino)methyl)phenyl)
carbamoyl) piperidine-1-carboxylate (0.5g, 0.92mmo1) in DCM (100mL). After
reaction
completion the reaction mixture was extracted with 2M aq. NaOH and DCM. The
organic phase
was washed with brine, dried over Na2SO4, filtered and concentrated to afford
the title compound
(0.5g, 94%). LCMS: m/z = 572.2 (M+H)+.
Step-3: Synthesis of tert-butyl 3-43-M8-isopropy1-2-((1-methylpiperidin-4-
yfloxy)pyrazolol1,5-
a1[1,3,51triazin-4-yflamino)methyl)phenybcarbamoyl)piperidine-1-carboxylate.
117
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
BocrairN
0 tei Boctair N
0 "RP
NH HO NH
N
N N ________________________________________
os),
N NN
0 N
NaH (0.042g, 1.05mmol) was added to DMSO (4mL) under inert atmosphere and
stirred
for 15 min. 1-Methylpiperidin-4-ol (0.12g, 1.05mmo1) was added to the reaction
mixture and
stirring continued for 10 min. Added tert-butyl
3-((3-(((8-isopropyl-2-
(methylsulfonyl)pyrazolo[1,5-a][1,3,5]triazin-4-
yDamino)rnethypphenyl)carbamoyl) piperidine-
1-carboxylate (0.2g, 0.35mmo1) and stirring continued for 10 min. The reaction
mixture was
heated to 60 C for lh. After completion of the reaction, the reaction mixture
was cooled to room
temperature, quenched with ice-water and diluted with ethyl acetate. The
aqueous layer was
separated and extracted with ethyl acetate (2x25mL). The combined organic
phase was washed
with brine, dried over Na2SO4, filtered and concentrated. The residue was
purified by 100-200
mesh silica gel column chromatography to afford desired title compound (0.2g,
94%). LCMS:
m/z = 607.2 (M+H)+.
Step-4: Synthesis of
N-(3-(((8-i sopropy1-24(1-methylpiperidin -4-3/1)oxy)pyrazolo [
a] r 1,3,51triazin-4-yl)amino)methyl)phenybpiperidine-3-carboxamide.
HNrarBociflaiiN Aim
RIF
NH ___________________________________________________ NH
N
õNo, N N-=
0 N 0 N
The process of this step was adopted from step-2 of example-18 (0.15g crude).
LCMS:
m/z = 507.2 (M+H) .
Step-5: Synthesis of 1 -acryloyl-N -(3- (((8-isopropyl-2-(( 1 -methylpiperidin-
4-vfloxv)p yrazolo
[1,5-al [1,3,51 triazin-4-yflamino)methyl)phenybpiperidine-3-carboxamide.
118
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
Hair ig N N
c 0 n H
0 gt, ..
NH 0 NH
N NJ
N
0 0
The process of this step was adopted from step-3 of example-18. The obtained
crude
compound was purified by preparative HPLC (Method: A: 5mm ammonium acetate in
water, B:
Acetonitrile-Methanol, Column: Zorbax XDB-C-18 (150mm*21.2mm, 5 m)) to afford
desired
title compound as acetate salt (0.02g, 18%). 1HNMR (DMSO-d6, 400MHz): 8 10.0
(d, 1H), 7.93
(s, 1H), 7.49-7.52 (m, 2H), 7.24 (t, 1H), 7.0 (d, 1H), 6.83-6.85 (m, 2H), 6.08
(m, 1H), 5.63 (t,
1H), 4.82-4.83 (m, 1H), 4.61 (s, 2H), 4.43-4.5 (m, 1H), 4.29-4.32 (m, 1H), 4.0-
4.1 (m, 1H), 2.93-
3.06 (m, 1H), 2.59-2.62 (m, 2H), 2.16 (s, 2H), 2.06-2.11 (m, 2H), 1.91-1.93
(m, 2H), 1.84 (s,
6H), 1.60-1.84 (m, 3H), 1.26 (dd, 6H). LCMS: m/z = 561.25 (M+H) .
The below compounds were prepared by procedure similar to the one described in
Example-19 with appropriate variations in reactants, quantities of reagents,
in presence of
suitable solvenst at suitable reaction conditions. The physicochemical
characteristics of the
compounds are summarized herein below table.
Compd.
Compound structure Analytical data
No.
11-1 NMR (DMSO-d6, 400MHz): 8 9.78-9.77 (d, 1H),
9.33-9.30 (t, 1H), 7.92 (s, 1H), 7.90-7.80 (m, 1H), 7.21-
F
lar
7.12 (m, 2H), 6.95-6.75 (m, 1H), 6.15-6.00 (m, 1H),
o
5.75-5.55 (t, 1H), 4.85-4.75 (m, 1H), 4.58-4.57 (d, 2H),
117
4.55-3.95 (m, 2H), 3.40-3.36 (m, 1H), 3.35-3.15 (m,
1H), 3.05-2.95 (m, 1H), 2.74-2.60 (m, 4H), 2.16-2.08
(m, 4H), 1.95-1.91 (m, 3H), 1.71-1.60 (m, 4H), 1.45-
1.35 (m, 1H), 1.25-1.24 (d, 6H); LCMS: m/z = 578.8
(M-1-11)+.
119
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
1H NMR (DMSO-d6, 400MHz): 5 9.56 (s, 111), 9.32-
H
o 1:2õ F
9.28 (t, 1H), 8.01-8.00 (d, 1H), 7.92 (s, 1H), 7.79-7.77
1.17,1.1
(d, 1H), 7.20-7.15 (t, 1H), 7.12-7.10 (m, 1H), 6.37-631
(m, 1H), 6.08-6.03 (dd, 114), 5.55-5.52 (dd, 1H), 4.84
118 NH
(m, 1H), 4.58-4.57 (d, 2H), 3.87 (m, 1H), 2.97-2.93 (m,
---
1H), 2.66-2.60 (m, 2H), 2.16-2.10 (m, 4H), 1.94-1.91
(m, 3H), 1.80-1.77 (m, 3H), 1.64-1.54 (m, 8H), 1.25-
1.23 (d, 6H); LCMS: m/z = 593.25 (M+H).
1H NMR (DMSO-d6, 400MHz): ö 10.01-9.98 (d, 1H),
9.12 (s, 1H), 7.93 (s, 1H), 7.63-7.60 (d, 1H), 7.48-7.47
it-trl(alrill
(d, 1H), 7.27-7.23 (t, 1H), 7.13-7.11 (d, 1H), 6.90-6.79
o o
11.1) (m, 1H), 6.11-6.07 (d, 1H), 5.69-5.63 (t, 1H), 5.28-5.26
(m, 1H), 4.80 (m, 1H), 4.50-4.47 (m, 1H), 4.33-4.29 (m,
119
N -11-1N-:NT 1H), 4.11-4.00 (m, 1H), 3.23-3.17 (m, 1H), 2.99-2.94
(m, 1H), 2.78-2.67 (m, 4H), 2.17 (s, 3H), 2.11-2.08 (m,
2H), 1.95 (m, 2H), 1.83 (m, 1H), 1.70-1.66 (m, 3H),
1.63-1.58 (d, 3H), 1.56 (m, 1H), 1.26-1.24 (d, 6H);
LCMS: m/z = 575.35 (M+H).
Example-20: Synthesis of 2-(1 -acrylo ylpiperidine-3-carboxamido)-5-(((8-
isoprop y1-24(1-
methylpiperidin-4-yl)ox y)pyrazolo[1,5-a][1,3,5]triazin-4-
yl)amino)methyppyridine 1 -oxide
(Compound-120).
Step-1: Synthesis of tert-butyl 34(5-(((8-isoprony1-2-(methy1thio)nyrazo1o[1,5-
a111,3,51triazin-4-
yflamino)methyl)pyridin-2-ybc arbamoybpiperidine- 1-c arbox ylate.
CD/ANN
N
Bac
GI 0 1,1;XNH2
NN
Boc
The process of this step was adopted from step-1 of example-19 (0.58g, 52%).
LCMS:
m/z = 540.9 (M+H)t
120
CA 02978170 2017-08-29
WO 2016/142855
PCT/1132016/051302
Step-2: Synthesis of 2-(1-(tert-butoxycarbonyflpiperidine-3-carboxamido)-5-
(((8-isopropyl-2-
(methylsulfonyl)pyrazolo[1,5-a-1[1,3,5-1triazin-4-ybamino)methyl)pyridine 1-
oxide.
0
0
C'''.5)-NH
N =-"q21,1 Boc I
-.....
Boc I
...
NH
0
The process of this step was adopted from step-2 of example-19 (0.6g). LCMS:
m/z =
589.35 (M+H)+.
Step-3: Synthesis of 2-(1-(tert-butoxycarbonyl)piperidine-3-carboxamido)-5-
(((8-isopropy1-2-
((1-methylpiperidin-4-yl)oxv)PwazoloI-1.5-al 1-1,3,5-Itriazin-4-
ybamino)methyl)pyridine 1-oxide.
0 0
CIANH 0
q
HOCI B eNNIIC3: e
NH NH
N
T\ -N .1... V ' -.Nos, N .. N.-
- NI
(IN ,A. ,.1......s.._
0
The process of this step was adopted from step-3 of example-19 (0.5g, 50%).
LCMS: nVz
= 624.45 (M+H)+.
Step-4: Synthesis of 5-(((8-i sopropy1-24(1-methylpiperidin-4-
yl)oxy)pyrazolo1-1,5-
al [1,3,51triazin-4-ybamino)methyl)-2-(piperidine-3-carboxamido)pyridine 1-
oxide.
0 0
BooN NEL e
0)1-
( )-0 HNLD'ANH e
____________________________________________ q_o NH , NH
./.. iv
121
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
The process of this step was adopted from step-2 of example-18 (0.4g crude).
LCMS: m/z
= 524.1(M+H) =
Step-5: Synthesis of 1-acryloyl-N-(5-(((8-isopropyl-24( 1-
methylpiperidin -4-
vfloxv)pyrazolo11,5-alll ,3 ,51tri azin-4-yliamino)methyl)-1-(11-oxidany1)-114-
pyridin-2-
yflpiperidine-3-carboxamide.
o o ..,.. q.
F .,,,, NL , JL.NH e
iNO-ANH_
,,,... -'
NFL
NH
The process of this step was adopted from step-3 of example-18. The obtained
crude
compound was purified by preparative HPLC (Method: A: 0.01%Ammonia in water,
B:
Acetonitrile, Column: KINETEX EVO C-18 (21.1mm*150mm, 5pm) to afford desired
title
compound (0.007g,10.2%). 1HNMR (DMSO-d6, 400MHz): 6 10.62-10.56 (m, 1H), 9.26
(s, 1H),
8.36 (s, 1H), 8.22-8.20 (d, 1H), 7.93 (s, 1H), 7.40-7.38 (d, 1H), 6.88-6.78
(m, 1H), 6.1-6.03 (t,
1H), 5.68-5.61 (m, 1H), 4.84 (m, 1H), 4.58 (s, 1H), 4.46-4.43 (m, 1H), 4.19-
3.95 (m, 1H), 2.99-
2.92 (m, 111), 2.85-2.79 (m, 1H), 2.66-2.59 (m, 211), 2.16-2.13 (m, 3H), 1.95-
1.92 (m, 2H), 1.67-
1.62 (m, 2H), 1.36 (m, 1H), 1.25-1.24 (d, 6H), 1.53 (m, 211), 1.29-1.27 (d,
6H); LCMS: m/z =
578.4 (M+H)+.
Example-21: Synthesis of 3-(((8-isopropy1-24(1-methylpiperidin-4-
yl)oxy)pyrazolo[1,5-
a][1,3,5]triazin-4-yDamino)methyl)phenyl 4-acryloylpiperazine-1-carboxylate
(Compound-121).
Step-1: Synthesis of 3-3 -(((8-i soprop v1-24(1-methylpiperidin-4-
vfloxy)pyrazolo11,5-
all1,3,51triazin-4-ybamino)methyl)phenol.
HO so HO so
r''ll
NH NH
1 HO
)..
b
122
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
The process of this step was adopted from step-3 of example-19 (0.25g, 60%).
LCMS:
m/z = 397.4 (M-F1-1)+.
Step-2: Synthesis of 1-(tert-butyl) 4-(3-(((8-isopropyl-24(1-methylpiperidin-4-
yfloxy)
pyrazolo[1,5-a11-1,3,51triazin-4-yl)amino)rnethyl)phenyl)piperazine-1,4-
clicarboxylate.
BocN"Th
HO 40LNO
0 8 40
NH 13 c1\1¨/N \CI NH
N __________________________________________
CY-NT
To
a solution of 3 -(((8-i sopropy1-24(1-methylpiperidin-4-yl)oxy)pyrazolo [1,5-
a] [1,3,5]triazin-4-yDamino)rnethypphenol (0.25g, 0.63mmo1) in 10mL MDC, was
added DMAP
(0.092g, 0.75mm01), followed by tert-butyl 4-(chlorocarbonyl)piperazine-1-
carboxylate
(Synthesized according to literature procedure explained in US2007/270433A1)
(0.157g,
0.63mmo1). Reaction mixture was stirred for 4h at RT and then mixture was
quenched to ice cold
water and partitioned between water and MDC. The product was extracted three
times with
MDC (25m1X3), washed with brine, dried over sodium sulphate, filtered and
concentrated to
dryness. The product was purified by combiflash column by eluting with 30%-50%
ethyl acetate-
hexane to afford the title compound (0.22g, 57%). LCMS: m/z = 609.5 (M+H)t
Step-3: Synthesis of 3-
(((8-isopropyl-2-(( 1 -methylpiperidin-4-yboxy)pyrazolo 1,5-al [1,3,51
triazin-4-yl)amino)methyl)phenyl piperazine-l-carboxylate.
BocN-Th TIN'Th
LNO 8 101 LNO
8 110
NH Nil
N ___________________________________________________________ N
0 N
The process of this step was adopted from step-2 of example-18 (0.1g TFA
salt). LCMS:
m/z = 509.5 (M+H)+.
123
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
Step-4: Synthesis of 3-(((8-isopropyl-2-(( 1 -methylpiperidin-4-
yl)oxy)pyrazolo
triazin-4-yl)amino)methyl)phenyl 4-acrylo ylpiperazin e-l-carbox yl ate.
HN
'=)L1\11
8
0
NH =-=.CI NH
= -
The process of this step was adopted from step-3 of example-18. The obtained
crude
compound was purified by preparative HPLC (0.01% NH4OH in water, B:
Acetonitrile,
Column: Gemini NX C-18 (21.2mm*150mm, 5pm) to afford desired title compound
(0.25g,
12%). 1FINMR (DMSO-d6, 400MHz): ö 9.33-9.30 (m, 1H), 7.93 (s, 1H), 7.36-7.33
(m, 1H),
7.22-7.20 (m, 1H), 7.12 (s, 1H), 6.85-6.78 (m, 1H), 6.17-6.12 (m, 1H), 5.74-
5.72 (m, 1H), 4.88-
4.75 (m, 1H), 4.65-4.64 (m, 2H), 3.65-3.60 (m, 5H), 3.44-3.38 (m, 4H), 3.30-
2.93 (m, 1H), 2.71-
2.60 (m, 2H), 2.20 (s, 3H), 2.0-1.90 (m, 2H), 1.72-1.61 (m, 2H), 1.18 (s, 6H);
LCMS: m/z =
563.5 (M H)-.
Example-22: Synthesis of (E) - 1-(4-(dimethylamin o)bu t-2-enoy1)-N-(3-(((8-
iso prop y1-24( 1-
methyl-piperidin-4-yl)oxy)pyrazolo [1,5-a][1,3,5]triazin-4-
yDamino)methyl)pheny1)-piperidine-
3-carboxamide (Compound-122).
1-iNiarN
0 tip
is
0
NH N..JLoH
'N _____________________________________
õNa
To a stirred solution of (E)-4-(dimethylamino)but-2-enoic acid (0.02g,
0.118mmol) in
DMF (4mL) was added HATU (0.067g, 0.177mm01) followed by DIPEA (0.04mL,
0.23mmo1)
and finally added N-(3-(((8-i sopropy1-2-((l-methylpiperi din-4-
yl)ox y)pyrazolo [1,5-
a] [1,3,5]triazin-4-yl)amino)methyl)phenyl)piperidine-3-carboxamide (0.06g,
0.118mmol, step-4
product of example-19). The reaction mixture was stirred for lh at room
temperature. The
reaction mixture was quenched with ice-water and diluted with ethyl acetate.
The aqueous layer
124
was separated and extracted with ethyl acetate (2x25mL). The combined organic
phase was
washed with brine, dried over Na2SO4, filtered and concentrated. The residue
was purified by
prep. HPLC (Method: A: 0.1% TFA in water, B: Acetonitrile-Methanol, Column:
)(Bridge C-18
(150mm*19nun, 5 m)) to afford desired title compound(0.15g, 23%).1HNMR (DMSO-
d6,
400MHz): 8 10.01 (s, 1H), 7.98 (s, 1H), 7.47-7.57 (m, 2H), 7.26 (t, 1H), 7.03
(d, 1H), 6.94 (t,
1H), 6.56-6.57 (m, 1H), 5.21 (s, 1H), 5.02-5.03 (m, 1H), 4.65-4.66 (m, 2H),
4.47 (d, 1H), 4.25
(d, 1H), 4.06-4.07 (m, 2H), 3.87-3.89 (m, 3H), 3.40-3.41 (m, 4H), 2.97-2.99
(m, 2H), 2.76-2.77
(m, 6H), 2.28 (d, 2H), 2.28 (d, 2H), 1.99 (d, 2H), 1.80 (m, 3H), 1.66 (m, 1H),
1.26 (d, 6H).
LCMS: m/z = 618.25 (M+H)+.
The below compounds were prepared by procedure similar to the one described in
Example-22 with appropriate variations in reactants, quantities of reagents,
in presence of
suitable solvents at suitable reaction conditions. The physicochemical
characteristics of the
compounds are summarized herein below table.
Compd.
Compound structure Analytical data
No.
1H NMR (DMSO-d6, 400MHz): ö 9.77 (s, 1H),
9.31 (s, 1H), 7.92 (s, 11-1), 7.85 (m, 1H), 7.21-7.16
,rnornayill 00
(t, 1H), 7.13-7.12 (m, 1H), 6.59 (m, 2H), 4.85-4.83
123 HN
(m, 1H), 4.57 (s, 2H), 4.44 (d, 1H), 4.2 (d, 1H),
N
cri..õ14 4.01 (t, 1H), 2.98-2.92 (m, 4H), 2.72-2.66 (m, 4H),
2.16 (s, 3H), 2.12-2.09 (m, 7H), 1.92 (m, 3H),
1.72-1.61 (m, 414), 1.32 (m, 114), 1.25-1.23 (d,
6H); LCMS: m/z = 636.40 (M+H)+.
1H NMR (DMSO-d6, 400MHz): 8 9.80 (s, 1H),
MITITHN4CLirri 9.56 (s, 2H), 9.372-9.32 (m, 1H), 8.18-8.16 (d,
0 4111 1H), 7.93 (s, 1H), 7.73-7.71 (d, 1H), 7.17-
7.08 (m,
4,1 2H), 6.53-6.47 (m, 1H), 6.34-6.30 (d, 111),
5.18 (m,
124
Nac,..1.:1,1)1__ 1H), 4.99 (m, 1H), 4.58-4.55 (t, 3H), 3.91-3.85 (m,
311), 3.46-3.43 (m, 111), 3.30-3.27 (m, 111), 3.12-
3.10 (m, 3H), 2.95-2.93 (m, 111), 2.78-2.73 (m,
5H), 2.45 (m, 1H), 2.24-2.20 (m, 1H), 2.14-2.11
125
Date recue/Date received 2023-03-24
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
(m, 1H), 1.96 (m, 1H), 1.72-1.64 (m, 4H), 1.57-
1.54 (m, 4H), 1.22-1.21 (d, 6H); LCMS: miz =
650.35 (M+H)+.
Example-23: Synthesis of 4-acryl amido-N-(34(8-isopropy1-24(1-
methylpiperidin-4-
yl)ox y)pyrazolo [1,5-a] [1,3 ,5] tri azi n-4-yl)amino)phenyl)benzamide
(Compound-125).
400 0
HN
.)`= N pi IS 0
0 .A.1=T
Step-1: Synthesis of N-(3-((8-isopropyl-2-
(methylthio)pyrazolo 11,5-alll ,3,51triazin-4-
yflamino)pheny1)-4-nitrobenzamide.
0
CI
0 HN .1W." N
isv = __________ 0( -N 1101
N 02N 1111115 NI i2 NO2
S N
DIPEA (0.7mL, 4.13mmol) was added to a stirred solution of 4-chloro-8-
isopropy1-2-
(methylthio)pyrazolo[1,5-a] [1,3,5]triazine, (0.2g, 0.82namo1; Intermediate-4)
(Synthesized
according to procedure described in W02013/128028) and N-(3-aminopheny1)-4-
nitrobenzamide
(0.21g, 0.82mmo1, Intermediate-15) in acetonitrile (5mL) at 0 C. The
resulting reaction mixture
was stirred at ambient temperature for 4h. After completion of the reaction,
the reaction mixture
was concentrated under vacuum and purified the residue in 100-200 mesh silica
column by
eluting with 15% ethyl acetate-hexane to afford the title compound (0.15g,
40%). LCMS: m/z =
464.05 (M+H)+.
Step-2: Synthesis of N-(34(84 so propy1-2-(methylsulfonyl)pyrazolo [1,5-al [1
,3,51triazin-4-
yflamino)pheny1)-4-nitrobenzamide.
is 0 ios 0
HN HN
1
NO2 ___________________________________________________ 1µ11 101
N-N1
NO,
0 I
126
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
The process of this step was adopted from step-2 of example-19 (0.15g, 93%).
LCMS:
m/z = 496.1 (M-41)+.
Step-3: Synthesis
of N-(34(8-isopropy1-24(1-methylpiperidin-4-yboxy)pyrazolo11,5 -al
11,3,51triazin-4-yl)amino)pheny1)-4-nitrobenzamide.
0
01111
HN N
FIN 11 =so
N
N NO2 HO
--õLa N NO2
N
0 N
The process of this step was adopted from step-3 of example-19 (0.1g, 66%).
LCMS: m/z
= 531.15 (M-FH)+.
Step-4: Synthesis of 4-Amino-N-(3-((8-isopropy1-2-((1-methylpiperidin-4-
yl)oxy)pyrazolo 11,5-
a1[1,3,51 triazin-4-yl)amino)phenyl)benzamide.
o 1.01 HN N
N
N H is
ti 40
Na \ NO2 _ NH2
0 N
10% Pd/C (0.02g) was added to a solution of N-(34(8-isopropy1-2-(0-
methylpiperidin-4-
ypoxy)pyrazolo[1,5-a] [1,3 ,5] tri azin-4-yDamino)pheny1)-4-nitrobenzamide
(0.1g, 0.18mmol) in
methanol (5mL). The reaction mixture was stirred under hydrogen balloon
pressure for 4h at
room temperature. The reaction mixture was filtered over celite bed, celite
bed washed with
methanol. The filtrate was concentrated to obtain title compound (0.08g
crude). LCMS: m/z =
501.15 (M+H)+.
Step-5: Synthesis of
4-acryl amido-N-(34( 8-i sopropy1-24(1 -methvlpiperidin-4-vflox y)
pyrazolo11,5-a 111,3,51 triazin-4-yl)amino)phenyl)benzamide.
o
*0
HN N NH2 101
HN
H 40 -N H
mo, N
0 N
The process of this step was adopted from step-3 of example-18. The obtained
crude
compound was purified by prep. HPLC (Method: A: lOmm ammonium acetate in
water, B:
127
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
Acetonitrile-Methanol, Column: XDB-C-18 (250mm*21.2mm, 5 m)) to afford desired
title
compound as acetate salt(0.008g, 10%). 1HNMR (DMSO-d6, 400 MHz): 6 10.5 (s,
1H), 10.2 (s,
1H), 8.25 (s, 1H), 8.03 (s, 1H), 7.98 (d, 2H), 7.81 (d, 2H), 7.53-7.54 (m,
1H), 7.41 (d, 1H), 7.37
(d, 1H), 6.44-6.52 (m, 2H), 6.30 (dd, 111), 5.81 (dd, 111), 4.9-4.92 (m, 1H),
3.16 (s, 3H), 2.94-
3.05 (m, 4H), 2.59-2.60 (m, 3H), 1.62-1.65 (m, 2H), 1.28 (d, 6H). LCMS: m/z =
555.45 (M-FH)+.
The below compounds were prepared by procedure similar to the one described in
Example-23 with appropriate variations in reactants, quantities of reagents at
suitable reaction
conditions. The physicochemical characteristics of the compounds are
summarized herein below
table.
Compd.
Compound structure Analytical data
No.
1H NMR (DMSO-d6, 400MHz): 6 10.52 (s, 1H),
9.95 (s, 1H), 8.18 (s, 2H), 8.06-8.04 (m, 1H), 8.02
110N (m, 1H), 7.94 (s, 2H), 7.50-7.48 (d, 1H), 7.34-7.30
126 H y
'11 (m, 2H), 6.36-6.33 (m, 1H), 6.09-6.04 (d, 1H),
5.56-5.53 (d, 1H), 4.91 (m, 1H), 3.91 (m, 1H),
3.03-2.99 (m, 3H), 2.67-2.50 (m, 3H), 2.18-2.01
(m, 311), 1.99-1.84 (m, 2H), 1.81-1.57 (m, 711),
1.29-1.27 (d, 614); LCMS: m/z = 561.40 (M+H)+.
1H NMR (DMSO-d6, 400MHz): 6 10.52 (s, 1H),
10.05 (s, 1H), 8.01-7.99 (d, 1H), 7.45-7.43 (d, 1H),
7.37-7.35 (d, 1H), 7.32-7.28 (t, 1H), 6.86-6.79 (m,
HN Nfti 1H), 6.12-6.07 (dd, 1H), 5.68-5.65
(dd, 1H), 4.89
127
_N H
NT (m, 1H), 4.5 (d, 1H), 4.1 (m, 1H), 3.38-3.36 (m,
---
2H), 3.10-3.02 (m, 111), 3.0-2.98 (m, 1H), 2.7-2.62
(m, 411), 2.15-2.11 (m, 2H), 2.11-2.06 (m, 2H),
1.99-1.97 (m, 2H), 1.86-1.83 (m, 2H), 1.66-1.64
(m, 2H), 1.53 (m, 214), 1.29-1.27 (d, 6H); LCMS:
m/z = 546.8 (M+H)+.
Example-24: Synthesis of N-(1-acryloylpiperidin-4-y1)-34(8-isopropy1-2-((1-
methylpiperidin-4-
yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-yDamino)benzamide (Compound-128).
128
CA 02978170 2017-08-29
WO 2016/142855 PCT/1112016/051302
Step-1: Synthesis of tert-buty1-4-(34(8-isopropy1-2-(methylthio)pyrazolol1,5-
al [1,3,51triazin-4-
yl)amino)benz amido)pi peridine-l-c arboxyl ate.
1,-,r)
)N N El2N UN
* OH
_______________________________________________ - N L.,,N Floc
N N
S)N
The process of this step was adopted from step-1 of example-23 (0.5g crude);
LCMS:
m/z = 526.40 (M+H)+.
Step-2: Synthesis of tert-butyl 4-(34(8-isopropy1-2-
(methylsulfonyl)pyrazolol1,5-
all 13,51tri azin-4-y1) amino)benzamido)piperidi ne-l-c arbox yl ate.
1401 1401 HN
NN 0 -0Boc N N0 Bac
_
The process of this step was adopted from step-2 of example-19 (0.4g, 75%).
LCMS: m/z
= 556.26 (M-H)+.
Step-3: Synthesis of tert-butyl 4-(34(8-isopropy1-24(1-methylpiperidin-4-
yboxy)pyrazolor1,5-
al [1,3,51triazin-4-yl)amino)benzamido)piperidine-1-carboxylate.
HN LI 1[4,,r--1
0 'ClisiBoc HN
N 'N "NT\
0 i.õNBoc
N ,õ-C)%) HO
N
The process of this step was adopted from step-3 of example-19 (0.2g, 47%).
LCMS: m/z
= 593.90 (M+1)+.
Step-4: Synthesis of 3 -((8-isopropyl-2-(( 1-methylpiperidin-4-
yboxy)pyrazolo11,5-
1-1,3,51triazin-4-ybamino)-N-(piperidin-4-yl)benzamide.
140 H
HN
HN N
0 L.,..õN Boo
-N 0 ====,-NH
0 N
129
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
The process of this step was adopted from step-2 of example-18 (0.15g crude).
LCMS:
m/z = 493.40 (M+H)+.
Step-5: Synthesis of N-(1-acryloylpiperidin-4-y1)-34(8-isopropy1-24(1-
methylpiperidin-4-
v1)oxv)pyrazolo11,5-al [1 ,3 ,51tri azin-4-y1) amino)benzamide.
140 1401
NiIN
.-%CN-N 0 N111 CI "'IC*" Hij. 0
0
The process of this step was adopted from step-3 of example-19. The obtained
crude
compound was purified by preparative HPLC (Method: A: 0.01% NH4OH in water, B:
Acetonitrile, Column: Kinetex EVO C-18 (21.2mm*150mm, 5 m)) to afford desired
title
compound (0.010g,9%).1HNMR (DMSO-d6, 400MHz): 5 8.35-8.33 (d, 1H), 8.21 (s,
1H), 8.02
(s, 1H), 7.86-7.84 (d, 1H), 7.65-7.63 (d, 1H), 7.50-7.46 (t, 1H), 6.85-6.78
(m, 1H), 6.11-6.07 (m,
1H), 5.69-5.66 (m, 1H), 4.87-4.84 (m, 1H), 4.39-4.36 (m, 1H), 4.07-3.98 (m,
2H), 3.22-3.14 (m,
2H), 3.04-2.97 (m, 111), 2.83-2.80 (m, 211), 2.67-2.61 (m, 2H), 2.15-2.10 (m,
411), 2.08-1.98 (m,
2H), 1.88 (m, 2H), 1.87-1.68 (m, 2H), 1.66-1.45 (m, 2H), 1.28-1.27 (d, 611);
LCMS: m/z =
547.40 (M+H)+.
The below compound was prepared by procedure similar to the one described in
Example-24 with appropriate variations in reactants, quantities of reagents,
in presence of
suitable solvents at suitable reaction conditions. The physicochemical
characteristics of the
compounds are summarized herein below table.
Compd.
Compound structure Analytical data
No.
1H NMR (DMSO-d6, 400MHz): 5 10.65 (s, 11),
140 0
8.31-8.30 (d, 1H), 8.13 (s, 1H), 7.94 (s, 1H), 7.78 (s,
1_1 N 0 C y 111), 7.56 (s, 1H), 7.42 (m,
1H), 6.81-6.50 (m, 111),
129 6.06-6.02 (m, 111), 5.64-5.61 (d, 1H), 4.81 (m, 111),
N1
0 IXN
3.99-3.90 (m, 311), 3.75 (m, 1H), 2.99-2.92 (m, 3H),
2.69-2.59 (m, 2H), 2.07-2.04 (m, 2H), 2.03-1.95 (m,
2H), 1.95-1.92 (m, 2H), 1.73 (m, 2H), 1.63-L61 (m,
130
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
2H), 1.39 (m, 2H), 1.25-1.23 (d, 6H); LCMS: m/z =
547.2 (M-FH)+.
Example-25: Synthesis of (E)-4-(4-(dimethylamino)but-2-enamido)-N-(34(8-
isopropy1-2-((1-
methylpiperidin-4-ypoxy)pyrazolo[1,5-a][1,3,5]triazin-4-
yparnino)phenyl)benzamide
(Compound-130).
40
0 0
40 FIN N
H 110
yz, N H2 ______________________
NLLN
0 N 0 N
Oxalyl chloride (0.025g, 0.2mmol) was added to a solution of bromocrotonoic
acid
(0.033g, 0.2mm01) in dry DCM (2mL) was added followed by one drop of DMF was
added. The
reaction mixture was stirred for 2h at room temperature and evaporated under
reduced pressure
to obtain (E)-4-bromobut-2-enoyl chloride. This was dissolved in dry DCM (5
mL) and added to
a solution of 4-amino-N-(34(84 sopropy1-24(1-methylpiperidin-4-yDox
y)pyrazolo [1,5-
a][1,3,5]triazin-4-yl)amino)phenyl)benzamide (0.05g, 0.1mmol; step-5 product
of example-23)
in acetonitrile (2mL) at 0 C. The resulting mixture was stirred for lh at
same temperature and
dimethyl amine (1mL, 20 mmol) was added and continued stirring for 4h at room
temperature.
The reaction mixture was quenched with ice-water and diluted with ethyl
acetate. The aqueous
layer was separated and extracted with ethyl acetate (2x25mL). The combined
organic phase was
washed with brine, dried over Na2SO4, filtered and concentrated. The residue
was purified by
prep. HPLC (Method: A: Ammonium acetate, B: Acetonitrile-Water (1:1), Column:
Gemini-NX
to afford desired title compound (0.05g, 20%). 1FINMR (DMSO-d6, 400MHz): 5
10.68-10.65 (d,
2H), 10.32-10.29 (d, 111), 9.91 (s, 1H), 8.25-8.19 (d, 1H), 8.08 (s, 1H), 8.00-
7.98 (d, 2H), 7.84-
7.82 (d, 2H), 7.55-7.52 (t, 1H), 7.47-7.37 (m, 2H), 6.82-6.75 (m, 1H), 6.51-
6.48 (d, 1H), 5.33 (s,
1H), 5.11 (s, 1H), 3.96 (s, 3H), 3.51-3.48 (d, 2H), 3.35-3.32 (m, 21), 3.17-
3.02 (m, 4H), 2.82 (s,
7H), 2.72-2.71 (m, 2H), 2.33 (s, 1H), 2.24-2.21 (d, 1H), 2.05-1.98 (t, 1H),
1.81-1.78 (m, 1H),
1.31-1.29 (d, 6H); LCMS: m/z = 612.4 (M+H)+.
Example-26: Synthesis of (1s,4s)-44(E)-4-(dimethylamino)but-2-enamido)-N-(3-
((8-isopropyl-
2-((1-methylpiperidin-4-ypoxy)pyrazolo[1,5-a] [1,3,5]triazin-4-
yl)amino)phenyl)cyclohexane-1-
carbox amide (Compound-131).
131
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
= NI, 0 uN NY1,õ(1
N 11
H
121. NH2
0 s'N IT
To a cooled solution of (E)-4-(dimethylamino)but-2-enoic acid hydrochloride
(0.025g,
0.15mmol) in DMF (2mL) at 0 C was added HATU (0.068g, 0.18mmol) followed by
DIPEA
(0.52mL, 0.30mmo1) and added (1,4-cis)-4-amino-N-(34(8-isopropy1-24(1-
methylpiperidin-4-
ybox y)pyrazolo [1 ,5-a] [1,3 ,5] tri azi n-4-yl)amino)phenyl)c yclohex ane-1 -
c arboxamide (0.076g,
0.15mmol). The reaction mixture was stirred for 2h at room temperature. The
reaction mixture
was quenched with ice-water and diluted with ethyl acetate. The aqueous layer
was separated
and extracted with ethyl acetate (2x25mL). The combined organic phase was
washed with brine,
dried over Na2SO4, filtered and concentrated (0.025g, 26%). 1HNMR (DMSO-d6,
400MHz): 5
10.52 (s, 1H), 9.94 (s, 1H), 8.02 (s, 1H), 7.98-7.94 (m, 2H), 7.50-7.48 (d,
1H), 7.36-7.28 (m,
2H), 6.56-6.49 (m, 1H), 6.21-6.17 (d, 1H), 4.91-4.86 (m, 1H), 3.89 (m, 1H),
3.41-3.40 (m, 2H),
3.17 (d, 1H), 2.99-2.66 (m, 2H), 2.66-2.51 (m, 2H), 2.50-2.49 (m, 1H), 2.44-
2.32 (m, 2H), 2.09-
2.00 (m, 7H), 1.98-1.97 (m, 2H), 1.86-1.81 (m, 2H), 1.73-1.55 (m, 6H), 1.25-
1.23 (d, 6H), 1.10-
1.07 (m, 2H); LCMS: ink = 618.50 (M+H)+.
The below compounds were prepared by procedure similar to the one described in
Example-26 with appropriate variations in reactants, quantities of reagents,
in presence of
suitable solvents at suitable reaction conditions. The physicochemical
characteristics of the
compounds are summarized herein below table.
Compd.
Compound structure Analytical data
No.
1H NMR (DMSO-d6, 400MHz): 5 10.5 (s,
1H), 9.95 (s, 1H), 8.02-7.99 (d, 2H), 7.91 (d,
10 NA. ,
1H), 7.46 (d, 1H), 7.36-7.28 (m, 2H), 6.57-
132 6.50 (m, 1H), 6.01 (d, 1H), 4.93 (m, 1H), 3.58
(m, 1H), 3.04-2.91 (m, 4H), 2.67-2.63 (m,
2H), 2.32-2.29 (m, 2H), 2.13-2.10 (m, 3H),
2.07-2.00 (m, 7H), 1.97-1.89 (m, 2H), 1.89-
1.87 (m, 4H), 1.69-1.64 (m, 2H), 1.55-1.46
132
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
(m, 3H), 1.33-1.27 (d,6H). LCMS: m/z =
618.45 (M+H) .
11-1 NMR (DMSO-d6, 400MHz): 8 10.76-10.74
(d, 1H), 10.02-9.55 (m, 2H), 8.40 (m, 1H),
8.18 (s, 1H), 8.05 (s, 1H), 7.88-7.83 (t, 1H),
7.66-7.64 (d, 1H), 7.50-7.46 (t, 1H), 7.22 (s,
RN 110 I
2H), 7.09 (s, 3H), 6.96 (s, 1H), 6.88-6.83 (dd,
o N Nol
1H), 6.58-6.52 (m, 111), 5.18 (m, 1H), 4.43-
133 4.40
(m, 1H), 3.94-3.90 (d, 1H), 3.85-3.77 (m,
211), 3.47 (m, 111), 3.16 (m, 211), 3.01-2.94
(m, 1H), 2.91 (m, 2H), 2.77-2.74 (m, 2H),
2.68 (s, 1H), 2.59 (m, 1H), 2.19 (m, 1H), 2.04-
2.00 (m, 1H), 1.91 (m, 111), 1.79-1.77 (m,
2H), 1.61 (m, 1H), 1.41 (m, 1H), 1.27-1.25 (d,
611); LCMS: m/z = 604.2 (M+H)+.
1H NMR (DMSO-d6, 400MHz): ö 10.69 (s,
1H), 8.32-8.30 (d, 111), 8.25 (s, 1H), 8.04 (s,
1H), 7.87-7.85 (d, 1H), 7.66-7.64 (d, 1H),
7.52-7.46 (t, 1H), 6.66-6.56 (m, 1H), 4.91-
.A. NI 0 ir
4.90 (m, 1H), 4.39-4.36 (m, 1H), 4.06-4.03
134 (m,
3H), 3.20-3.15 (m, 2H), 3.06-3.00 (m,
3H), 2.79-2.66 (m, 3H), 2.32-2.08 (m, 9H)
2.00-1.99 (m, 2H), 1.86 (m, 2H), 1.72-1.70
(m, 2H), 1.43-1.41 (m, 2H), 1.29-1.27 (d, 6H),
1.19-1.06 (m, 1H); LCMS: m/z = 604.40
(M+H)+.
Example-27: Synthesis of (1s,4s)-4-(((E)-4-(dimethylamino)-4-oxobut-2-en-1-
yDamino)-N-(3-
(((8-isopropyl-2-((1-methylpiperidin-4-y1)oxy)pyrazolo [1,5-a] [1,3 ,5] tri
azin-4-
yl)amino)methyl)phenyl)cyclohexane-l-carboxamide (Compound-135).
133
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
Step-1: Synthesis of tert-butyl ((ls,4s)-44(3-W8-isopropy1-24(1-
methylpiperidin-4-
yl)oxy)pyrazolo11,5-a111,3,51triazin-4-
ybamino)methyl)phenybcarbamoyl)cyclohexyl)
carbamate
BocHN..ct.,y
0
H2N
N riar
..0)LOH
0 tlitIP
BocHN
NH
N NH
õNa
0 N
0 N
The process of this step was adopted from step-1 of example-18 (0.3g, 95%).
LCMS: m/z
= 621.85 (M+H)+.
Step-2: Synthesis of
(1s,4s)-4-amino-N-(3-(((8-isopropy1-24(1-methylpiperidin-4-
vfloxv)byrazolof 1,5-al 11,3 ,51tri azin-4-y1) amino)methyl)phenybc yclohex
ane-l-carbox amide.
BocHN,..arriNi H2N0.1)4
0 0
N
NH H
= -N rsi
N TV-
0 N 0 N
The process of this step was adopted from step-2 of example-18 (0.2g, 94.7).
LCMS: m/z
= 521.45 (M+H)+.
Step-3: Synthesis of (1s,4s)-4-WE)-4-(dimethylamino)-4-oxobut-2-en-1-yflamino)-
N-(3-(((8-
isopropyl-2-((1-methylpiperidin-4-yDoxy)pyrazolol1,5-al[1,3,51triazin-4-
yflamino)methyn
phenyl)cyclohexane-1-carboxamide:
0
*
0
0
0
NH ______________________________________ I
NH
=Ok -N
N
N
To a solution of (1,4-cis)-4-amino-N-(3-(((8-isopropy1-2-((1-methylpiperidin-4-
yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-yDamino)methyl)phenyl)cyclohexane-1-
carboxamide
134
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
(0.1g,0.19mmol) and (E)-4-bromo-N,N-dimethylbut-2-enamide (0.044g,0.23mmo1) in
ACN
(3mL) was added DIPEA (0.06mL,0.384mmo1) at RT, then stirred for 12hr, After
reaction
completion, quenched with water and diluted with ethyl acetate. The aqueous
layer was
separated and extracted with ethyl acetate (2x15mL). The combined organic
phase was washed
.. with brine, dried over Na2SO4, filtered and concentrated. The residue was
purified by
preparative HPLC (Method: A: 0.1% TFA in Water, B:ACN, Column: EVO C18
(21.2mrn x
150mm particle size 5 m)) to afford desired title compound (0.030g, 20%). 1H
NMR (DMSO-d6,
400MHz): ö 9.84 (s, 111), 7.97 (s, 1H), 7.85 (m, 1H), 7.55-7.53 (d, 1H), 7.48
(s, 111), 7.25-7.21
(t, 1H), 7.05-6.96 (m, 2H), 6.70-6.66 (m, 1H), 5.12 (s, 1H), 4.62 (s, 2H),
4.25-4.19 (m, 3H),
3.44-3.43 (d, 511), 3.09-2.89 (m, 411), 2.80-2.77 (m, 3H), 2.66 (s, 1H), 2.32-
2.35 (m, 3H), 2.11-
2.10 (m, 2H), 1.86-1.84 (d, 211), 1.74-1.68 (m, 41), 1.62-1.57 (m, 2H), 1.22
(s, 611); LCMS: ink
= 632.80 (M+H)+.
Example-28: Synthesis of Synthesis of 1-acryloyl-N-(3-(((8-isopropy1-2-
methoxypyrazolo[1,5-
a][1,3,5]triazin-4-yDamino)methyl)phenyl)piperidine-4-carboxamide (Compound-
136). SteD-1:
Synthesis of 8-i soprop y1-2-methoxy-N-(3-n itrobenzyl)pyrazolo [1 ,3,5]tri
azin-4-amine:
02N is
02N op
NH NH
N-N N
N N =
4R%
N
µ0
NaH (0.08g, 2.05mmo1) was added to DMSO (4mL) under inert atmosphere and
stirred
for 15 min. tert-butyl (4-hydroxybutyl)carbamate (0.38g, 2.05mmo1) was added
to the reaction
mixture and continued stirring for 10 min. 8-isopropy1-2-(methylsulfony1)-N-(3-
nitrobenzyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine (0.2g, 0.51mmol) was added
and stirred for 10
min. Then the reaction mixture allowed to heat at 60 C for lh. After
completion of the reaction,
cooled to room temperature and was quenched with ice-water and diluted with
ethyl acetate. The
aqueous layer was separated and extracted with ethyl acetate (2x25mL). The
combined organic
phase was washed with brine, dried over Na2SO4, filtered and concentrated. The
residue was
.. purified by 100-200 silica gel column chromatography to afford desired
title compound (0.1g,
57%). LCMS: m/z = 343.2 (M+H)+.
135
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
Step-2: Synthesis of N-(3-aminobenzy1)-8-isopropy1-2-methoxypyrazolol1,5-al 1-
1,3,51triazin-4-
amine:
02N is .2N
NH
1TH
N N NNN
To a solution of 8-isopropy1-2-methoxy-N-(3-nitrobenzyppyrazolo[1,5-
a][1,3,5]triazin-4-
amine (0.1g, 0.29mm01) in THF:MeOH:Water (3:2:1) were added zinc (0.08g,
1.46mmo1) and
ammonium chloride (0.078g, 1.46mmo1). The reaction mixture was stirred at room
temperature
for 4h. After completion of reaction the reaction mixture filtered through
celiteand diluted with
ethyl acetate. The aqueous layer was separated and extracted with ethyl
acetate (2x25mL). The
combined organic phase was washed with brine, dried over Na2SO4, filtered and
concentrated.
The residue was purified by 100-200 silica gel column chromatography to afford
desired title
compound (0.06g, Crude). LCMS: m/z = 313.25 (M+H) .
Step-3: Synthesis of 1-acrvloyl-N-(3-(((8-isopropv1-2-methoxvovrazolol1,5-
all1,3,51triazin-4-
v1)amino)methyl)phenvflpiperidine-4-carboxamide:
II
H2N N dak.
NH _________________________________________________ NH
0 tep
N
i0)1s1)1
The process of this step was adopted from example-16. The obtained crude
compound
was purified by combiflash to afford the title compound (0.05g, 65.7%). 1HNMR
(DMSO-d6,
400MHz): 6 9.92 (s, 1H), 9.30-9.27 (t, 1H), 7.95 (s, 1H), 7.55-7.51 (m, 2H),
7.25-7.21 (t, 1H),
7.02-7.01 (d, 1H), 6.84-6.77 (m, 1H), 6.11-6.06 (d, 1H), 5.67-5.64 (d, 1H),
4.60-4.59 (d, 2H),
4.44-4.41 (d, 1H), 4.10-4.07 (d, 1H), 3.83 (s, 3H), 3.59 (s, 1H), 3.07-2.98
(m, 2H), 2.67-2.57 (m,
4H), 1.81-1.75 (t, 214), 1.49-1.46 (m,3H), 1.27-1.25 (d, 6H); LCMS: m/z =
478.3 (M+H)+.
136
CA 02978170 2017-08-29
WO 2016/142855
PCT/1132016/051302
Example-29: Synthesis of (E)-4-(dimethylamino)-1-(4-(2-(((8-isopropy1-2-
((tetrahydro-2H-
pyran-4-yl)amino)pyrazolo[1,5-a] [1,3 ,5] triazin-4-yl)ami
no)methyl)phenyl)piperazin-l-yl)but-2-
en-l-one (Compound-137).
Step-1: Synthesis of tert-butyl 4424 ((8-i soprop y1-2-
(methylthio)pyrazolo11,5-a111,3,51triazin-4-
ynamino)methyl)phen yflpiperazine-1 -c arboxyl ate
(--'NBoc
B
N NH
N N kW NH2 N
'S)N
The process of this step was adopted from step-1 of example-4 (0.8g, 80%).
LCMS: m/z
= 498.2 (M-4-1-1)+.
Step-2: Synthesis of 4-(tert-butoxycarbony1)-142-(((8-isopropy1-2-
(methylsulfonyl)pyrazolo
[1,5-a] [1,3,5] triazin-4-ybamino)rnethyl)phenybpiperazine 1-oxide.
11101 r,
(,
BocN) NH
NH BocNt
N _____________________________________________________ NN
NµSN
S N
The process of this step was adopted from step-2 of example-4 (0.7g, crude).
LCMS: m/z
= 546.3 (M+H)+.
Step-3: Synthesis of 4-(tert-butoxycarbony1)-1-(2-(((8-isopropyl-2-
((tetrahydro-2H-pyran-4-
yl)amino)pyrazolo11,5-a1[1,3,5]triazin-4-yflamino)methyl)phenyl)piperazine 1-
oxide.
40) ry,-+401
NH2
NH
Cl') Hoc:N/.,NH
0 N
N N N _______________________________________________ N
NN
µN,
The process of this step was adopted from step-3 of example-4 (0.6g, crude).
LCMS: m/z
= 567.7 (M+H) .
137
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
Step-4: Synthesis of 8-isopropyl-N4-(2-(piperazin-1-yl)benzyl)-N2-(tetrahydro-
2H-pyran-4-
yl)pyrazolof 1,5-al [1,3,51triazine-2,4-diamine.
9- (110
BocN
NH
NH
N
N"---
0
The process of this step was adopted from step-4 of example-4 (0.40g, crude).
LCMS:
mh = 451.3 (M-FH)+.
Step-6: Synthesis of (E)-4-(dimethylamino)-1-(4-(2-4(8-isopropy1-2-
((tetrahydro-2H-pyran-4-
yflamino)pyrazolor 1,5-a 1 [1,3,51triazin-4-yflamino)rnethyl)phenyl)piperazin-
1-y1)but-2-en-1-one.
I 0
HIGN
NH N.iLoH0 N.õ>
NH
N
N N
To a cooled solution of (E)-4-(dimethylamino)but-2-enoic acid (0.073g,
0.44mmo1) in
DMF (5mL) at 0 C was added HATU (0.25g, 0.666mm01) followed by DIPEA (0.32mL,
1.77mmo1) and finally added 8-isopropyl-N4-(2-(piperazin-1-yl)benzyl)-N2-
(tetrahydro-2H-
pyran-4-3/1)pyrazolo[1,5-a][1,3,5]triazine-2,4-diarnine(0.2g, 0.444rnmo1). The
reaction mixture
was stirred for lh at room temperature. The reaction mixture was quenched with
ice-water and
diluted with ethyl acetate. The aqueous layer was separated and extracted with
ethyl acetate
(2x25mL). The combined organic phase was washed with brine, dried over Na2SO4,
filtered and
concentrated the crude residue was purified by preparative HPLC (Method: A:
0.01% TFA in
water, B: ACN: Me0H, Column: Kinetex Evo C18:(150mm*21.2mm) to afford desired
title
compound as TFA salt. To removal TFA passed the compound through van i pure
basic resin
column using Me0H as eluent to afford the title compound as free base (0.07g,
38%). 1H NMR
(DMSO-d6, 400MHz): 5 8.80-8.50 (d, 1H), 7.72 (s, 1H), 7.23-7.16 (m, 3H), 7.06
(t, 1H), 6.80 (s,
1H), 6.64-6.63 (m, 2H), 4.76-4.74 (d, 2H), 3.82-3.73 (m, 8H), 3.04-3.03 (d,
2H), 2.92-2.86 (m,
5H), 2.67 (s, 1H), 2.45 (s, 1H), 2.15 (s, 6H); 1.82 (s, 1H), 1.46 (s, 2H),
1.24-1.22 (d, 7H); LCMS:
m/z = 562.45 (M+H)+.
138
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
Example-30: Synthesis of
(E)-1-(4-(48-i sopropy1-2-((tetrahydro-2H-pyran-4-
yl)amino)pyrazolo [1,5-a] [1,3,5] triazin-4-yparnino)methyppiperidin-1-y1)-4-
(pyrrolidin-l-yl)but-
2-en-l-one (Compound-138).
Step-1: Synthesis of tert-butyl 4-( ((8-i soprop y1-2-(methylthio)pyrazolo11,5-
a111,3 ,51triazin-4-
yflamino)methybpiperidine-l-carbox yl ate.
Hoc
CI
N
1%1-- N-- BocNaõ _____________ NH
NH2 N
N N--
S N
S
tert-Butyl 4-(aminomethyDpiperidine-1-carboxylate (0.619 g, 2.89 mmol) was
added to a
solution of 4-ehloro-8-isopropyl-2-(methylthio)pyrazolo[1,5-a][1,3,5]triazine
(0.7 g, 2.89 mmol)
in acetonitrile (50 mL) at 0 'C. The resulting reaction mixture was stirred at
ambient temperature
for 15 h. After completion of the reaction, the reaction mixture was
concentrated under vacuum
and purified the residue in 100-200 mesh silica column by eluting with 5%
ethyl acetate-hexane
to afford the title compound (0.9 g, 74 %). LCMS: m/z = 421.4 (M+H)t
Step-2: Synthesis of tert-butyl 4-(((8-isopropyl-2-(methylsulfonyl)pyrazolof
1,5-al 11,3,51triazin-
4-yflamino)methyDpiperidine-1-carboxylate.
Boc Boc
r
NH NH
N _________________________________________________ N
The process of this step was adopted from step-2 of example-4 (0.5 g, 58 %).
LCMS: m/z
= 453.4 (M-FH)+.
Step-3: Synthesis of tert-butyl
4-(((8-isopropy1-2-((tetrahydro-2H-pyran-4-
yl)amino)pyrazolo[1,5-al[1,3,51triazin-4-yflamino)methyl)piperidine-1-
carboxylate.
139
CA 02978170 2017-08-29
WO 2016/142855 PCT/1112016/051302
Boc
r IN Boc
r IN
X __________________________________________________ X
.2N----
r-----?
NH NH
-1,
0 1
¨gINIL-------
o N N
0 H
The process of this step was adopted from step-3 of example-4 (0.32 g, 67.6
%). LCMS:
m/z = 474.5 (M+H)+.
Step-4: Synthesis of 8-isopropyl-N4-(piperidin-4-ylmethyl)-N2-(tetrahydro-2H-
pyran-4-
yl)pyrazolo 11,5-al11,3,51triazine-2,4-diamine.
Boc H
ri, 1 r
X X
NH NH
___________________________________________ p
..."...... .1. N
H H
The process of this step was adopted from step-4 of example-4 (0.22 g, 93.6%).
LCMS:
m/z = 374.1 (M+H)+.
Step-4: Synthesis of (E)-4-bromo-1-(4-(((8-isopropy1-2-((tetrahydro-2H-pyran-4-
ybamino)
pyrazolo [1,5-a111,3,51triazin-4-ybamino)methyl)piperidin-1-y1)but-2-en-1-one.
Br
Llyo
H
N
0
NH Br.....õ.-k..õ,A,OH X
NH
rl N)`-.e. N-N _______________________________________ ),.. N
Oa r 7:c..._
.--.'N--IN --- \
---
H
To a cooled solution of (E)-4-bromobut-2-enoic acid (0.66 g, 0.8 mmol) in DMF
(10 mL)
at 0 C was added HATU (0.3 g, 0.8 mmol) followed by DIPEA (0.139 mL, 0.8
mmol) and
finally added 8-isopropyl-N4-(piperidin-4-ylmethyl)-N2-
(tetrahydro-2H-pyran-4-y1)
pyrazo1o[1,5-a][1,3,5]triazine-2,4-diamine (0.15 g, 0.4 mmol). The reaction
mixture was stirred
140
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
for 1 h at room temperature. The reaction mixture was quenched with ice-water
and diluted with
ethyl acetate. The aqueous layer was separated and extracted with ethyl
acetate (2x25 mL). The
combined organic phase was washed with brine, dried over Na2SO4, filtered and
concentrated.
The residue was purified by 100-200 silica gel column chromatography to afford
desired title
compound (0.135 g, 86.5 %). LCMS: m/z = 522.0 (M+H)+.
Step-5: Synthesis of (E)-1-(4-(((8-isopropy1-2-((tetrahvdro-2H-pyran-4-
vbamino)pvrazolo [ 1,5-
a] f 1,3,51triazin-4-yl)amino)methvflpiperidin-1-0)-4-(pvrrolidin-1-vbbut-2-en-
1-one.
Br
11.,r0
r r
ON H
N N
N
N N "-
Oa
N
K2CO3 (0.09 g, 0.65 mmol) and pyrrolidine (0.028 g, 0.39 mmol) was
sequentially
added to a solution of (E)-4-bromo-1-(4-(((8-isopropyl-2-((tetrahydro-2H-pyran-
4-yDamino)
pyrazolo [1,5-a] [1, 3,5] tri azin-4-yDamino)methyppiperidin-1 -yl)but-2-en-1-
one (0.17 g, 0.33
mmol) in ACN (10 mL) and the resulting mix was allowed to stir for 4 h at 60
'C. The reaction
mixture was quenched with water and diluted with ethyl acetate. The aqueous
layer was
separated and extracted with ethyl acetate (2x25 mL). The combined organic
phase was washed
with brine, dried over Na2SO4, filtered and concentrated. The residue was
purified by prep.
HPLC (Method- A: 0.1% formic acid in water, B: Acetonitrile-Methanol, Column:
KINETEXC18 (21.2mm*150mm, 5 m)) to afford desired title compound (0.02 g,
11.9%).
11-1NMR (DMSO-d6, 400MHz): 6 8.30 (d, 1H), 7.68 (s, 1H), 6.89 (d, 1H), 6,54-
6.64 (m, 2H),
4.38-4.35 (d, 1H), 4.02-3.99 (d, 1H), 4.87-4.84 (d, 2H), 3.40-3.29 (m, 2H),
3.16 (d, 2H), 3.04-
2.86 (m, 2H), 2.58-2.41 (m, 8H), 2.02-1.97 (m, 2H), 1.88-1.78 (m, 211), 1.68-
1.67 (m, 511), 1.53-
1.45 (m, 2H), 1.23-1.2 (m, 6H),1.06-1.04 (m, 2H); LCMS: m/z = 511.80 (M+H)+.
Example-31: Synthesis of 1-acryloyl-N-(3-(((3-isopropy1-5-((tetrahydro-2H-
pyran-4-
yl)amino)pyrazolo[1,5-a]pyrimidin-7-yDamino)methyl)phenypazetidine-2-
carboxamide
(Compound-139).
141
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
Step-1: Synthesis of 5-chloro-34 sopropyl-N-(3-nitrobenz yflpyrazolo 1,5 -al
pyrimidin-7-amine.
02N to
Cl
O2N NI12
NH
CI
CI The process of this step was adopted from step-1 of example-4 (0.8g, 99%).
LCMS:m/z =
346 (M+H)+.
Step-2: Synthesis of tert-butyl (5-chloro-3-isopropylpyrazolo [1,5-alpyrimidin-
7-y1)(3-
nitrobenzyl)carbamate.
02N 02N
NH NBoc
XL¨N-N\
cr
CI
To a solution of 5-chloro-3-isopropyl-N-(3-nitrobenzyl)pyrazolo[1,5-
a]pyrimidin-7-
amine(0.8g, 2.3 lmmol) in CC14 (20mL) was added (BOC)20 (0.6g, 2.78mm01),
followed by
DMAP (0.028g, 0.23mmo1) and reaction mixture was stirred at room temperature
for lh. After
completion of the reaction, the reaction mixture was concentrated to afford
the title compound
(1g, 86%). LCMS: m/z = 446 (M+H)+.
Step-3: Synthesis of tert-butyl (3-isopropyl-5-((tetrahydro-2H-pyran-4-
yflamino) pyrazolor1,5-
al pyrimi din-7-y1)(3 -nitrobenzyl)carbamate.
02N is 02N 40
NH2
NBoc NBoc
0
jiµl -TN\ ' tl=i\T\
Cl N 1N1
To a solution of tert-butyl (5-chloro-3-isopropylpyrazolo[1,5-a]pyrimidin-7-
y1)(3-
nitrobenzyl)carbamate (1g, 2.24mmo1) and tetrahydro-2H-pyran-4-amine (0.68g,
6.74mmo1) in
142
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
toluene (20mL) was added Na01I3u (0.31g, 3.28mmo1) and degassed with N2 gas
for 10min.
Then added BINAP (0.2g, 0.33mm01) followed by Pd2(dba)3 (0.1g, 0.11mmol), then
reaction
mixture was heated to 100 C for 12h. After completion of the reaction, the
reaction mixture was
cooled to room temperature and filtered through celite bed and washed with
ethyl acetate
(2x20mL). The filtrate was concentrated under vacuum and purified by column
chromatography
using 100-200 silica gel to afford the title compound (0.8g, 70%). LCMS: m/z =
511 (M+H)+.
Step-4: Synthesis of tert-butyl (3-aminobenzyl)(3-isopropy1-5-((tetrahydro-2H-
pyran-4-
yl)amino)pyrazolol1,5-alpyrimidin-7-yl)carbamate.
02N
u2N is
NBoc NBoc
cia "Nµ
N
N
To a solution of tert-butyl (3-
isopropy1-5-((tetrahydro-2H-pyran-4-
yl)ami no)pyrazolo [1,5-a] pyrimidin-7-y1)(3 -nitrobenz yl)carb amate
(0.8g, 1.56mnaol) in
THF:MeOH:Water (3:2:1 ratio, 20mL) were added zinc (1.02g, 15.68mmol) and
ammonium
chloride (1.7g, 31.36mmo1). The reaction mixture was stirred at room
temperature for 4h. After
completion of reaction, the reaction mixture was filtered through celite and
diluted with ethyl
acetate. The aqueous layer was separated and extracted with ethyl acetate
(2x25mL). The
combined organic phase was washed with brine, dried over Na2SO4, filtered and
concentrated.
The residue was purified by 100-200 silica gel column chromatography to afford
desired title
compound (0.6g, 87%). LCMS: m/z = 480.8 (M+H)+.
Step-5: Synthesis of tert-butyl (3-(1 -acryloyl azeti di ne-2-carbox
amido)benzyl)(3-isopropyl-5-
((tetrahydro-2H-pyran-4-yflamino)pyrazolol1,5-alpyrimidin-7-yl)carbamate.
H2N
0 0
NBoc
NBoc
BOOd
N 1=1
N
143
The process of this step was adopted from example-1 (0.3g, crude). LCMS: m/z =
617.9
(M+H)+.
Step-6: Synthesis of 1-acryloyl-N-(3-(((3-i sopropy1-5-((tetrahydro-2H-pyran-4-
yflamino)
pyrazolo [ 1 ,5-alp yrimidin-7-yflamino)meth yflphenybazetidine-2-c
arboxamide.
rCrlytil /C111,111 rN,
irl) 0 tip 0 w
NBoc ____________________________________________ NH
n
53
NN N
The process of this step was adopted from step-2 of example-2. The obtained
crude
compound was purified by preparative liPLC (Method: A: 0.02% Ammonia in water,
B:
ACN:Me0H (1:1) Column: XBridge C18 : ( 150m11*21.2nun) to afford desired title
compound
as free base(0.1g, 10%). 1HNMR (DMSO-d6, 400MHz): 5 10.17 (s, 1H), 7.83-7.81
(m, 1H), 7.61
(s, 1H), 7.58-7.52 (m, 2H), 7.29-7.25 (m, 1H), 7.05-7.02 (t, 1H), 6.57-6.55
(m, 2H), 6.36-6.29
(m, 1H), 6.13-6.05 (m, 2H), 5.72-5.69 (m, 1H), 5.58-5.57 (m, 1H), 5.01 (s,
2H), 4.43-4.42 (d,
2H), 4.21-4.15 (m, 1H), 3.88-3.79 (m, 2H), 3.37-3.34 (m, 2H), 2.95-2.92 (m,
1H), 2.20 (m, 1H),
1.84-1.81 (d, 2H), 1.38-1.33 (m, 2H), 1.24-1.22 (d, 6H); LCMS: m/z = 518.8
(M+H)+.
Although the present application has been illustrated by certain of the
preceding
examples, it is not to be construed as being limited thereby; but rather, the
present application
encompasses the generic area as hereinbefore disclosed. Various modifications
and embodiments
can be made without departing from the spirit and scope thereof. For example,
the following
compounds which can be prepared by following similar procedure as described
above with
suitable modifications known to the one ordinary skilled in the art are also
included in the scope
of the present application.
Nf1XL et.
1111--cceC r. Nft-
9.)
\ NH
N9)
0
140 --C-}-d4111 141 11,
142 0
143
144
Date recue/Date received 2023-03-24
CA 02978170 2017-08-29
WO 2016/142855 PCT/1B2016/051302
el'Ls
HrelNyi...0C1
N
n..)Mret4Nlj
N
HNA._III,41 ...C/N'''.
.N2N-1Ø0--
* 0 ..
(3___''xi
NH
05-NH
Ficri
..=)_0
144 145 148 147
HNINjc 1' 3(71.1.-- µ14
'IV N
HN-.4N 'lc% ..-04--
Nci)
N *
NH
NH
NH
0 0.......
0
149
-,----"-/ 150
3If-XL
5(.1)---. N
õxi- N j,,I 1 N
Hr,r4N_KoCN"-- HN--",V11.õ.
....0
'31 N
N
FINAN-ko--GN---
N * 0 *
NH
H
).-NH \ NH 153
0....N HN R
151 152 f-µ0
4, i R =. F, Me,
OMe, CI
NJ
L
N!"--3CL-
N N
5142.--
HNA, I 0
HN N¨sI N 'N N
A'NANNC
* H
* H
nriHNAIYAN-0
0 H
....NH NNH
-
NH
N--= 165 108
154
HIA...N HN I
FIN lit
rs) 11--ko rt.
NO /XL N4-3(1-
--
11,r,0 4N
N
y µ14 N N
HN -4NA ,C0
HI4-'4NA, CO HN-4NANO
* N cr...4)N * N
H (N....1
H
158 t....9"- N * 159
N.,/ Fl 157
'JO - N-- R = H, Me, El, I-Pr, cPr
R = I-1, Me, Et, I-Pr, cPr R= H, Ms, Et, i-Pr, cPr
R R
pi,XL
'Pi 14,4-1XL
N
HN-4NANO HN-j*Nj 0
0
* H
cri N
160
N st. ....kits..:JH 151
)LiO'P'1.-C
N
. R ...H, Me, Et, I-Pr,
- cPr
145
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
Example-32: Biochemical assay for CDK7:
The ability of compounds to inhibit CDK7 kinase activity was tested in a TR-
FRET assay
using 5 nM of CDK7/CycH/MNAT1 obtained from Invitrogen, USA. Test compounds
were
pre-incubated with the kinase at room temperature for 60 mm. After incubation,
substrate mix
[100 nM Ultra-light MBP (Perkin Elmer, USA) and 1m1VI ATP (Sigma)] was added.
The above
reaction was stopped by the addition of 40 mM EDTA after 60 minutes of kinase
reaction. 1 nM
Eu-labelled antiphospho-MBP antibody [Perkin Elmer, USA] was added, mixed well
and the
fluorescence emission at 615 nm and 665 nm [excitation at 340 nm] was
measured. The final
DMSO concentration in the assay was 1%. For IC50 determination, appropriate
concentrations
were made by 1/3rd serial dilutions of 10 mM DMSO stock solution of test
compound. All the
fluorescence measurements were made in a Victor 3 Multilabel Counter [Perkin
Elmer, USA].
The IC50 was determined by fitting the dose response data to sigmoidal curve
fitting equation
using GraphPad Prism software V5. To identify compounds that inhibit CDK7
irreversibly, time
depended inhibition studies were carried by pre-incubating compound with the
enzyme at three
time points (20, 60 and 180min) and carrying out assay as described above.
Selected compounds were screened in the above mentioned assay procedure. The %
inhibition of the selected compounds and the IC50 values are summarised in the
below table;
wherein group "A" refers to an IC50 value of less than or equal to 300 nM,
group "B" refres to
IC50 value in range of 300.01 to 1000 nM and group "C" refres to IC50 value of
greater than 1000
nM.
Compound % inhibition Compound % inhibition
IC50 IC50
No. @ 10 M No. @ 10 M
1. 88 B 2. 98 A
3. 96 A 4. 93 A
5. 94 A 6. 91 A
7. 91 C 8. 96 A
9. 85 C 10. 89
11. 89 B 12. 92
13. 93 B 14. 97 A
146
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
Compound % inhibition Compound % inhibition
IC5o IC50
No. @ 10 pM No. @ 10 pM
15. 98 A 16. - A
17. 84 C 18. 101 A
19. 100 A 20. 100 A
_
21. 96 A 22. 98 A
23. 98 A 24. 98 A
25. 99 A 26. 95 B
27. 100 A 28. 99 A
29. 98 A 30. 98 A
31. 100 A 32. 91 A
33. 86 B 34. 73 C
35. 99 A 36. 91 B
37. 91 A 38. 95 A
39. 76 C 40. 99 A
41. 92 B 42. 99 A
43. 79 B 44. 94 A
45. 73 C 46. 98 A
-
47. 100 A 48. 98 A
. . .
49. 84 C 50. 97 A
51. 91 B 52. 96
53. 99 A 54. 98 A
55. 99 A 56. 97 A
'
57. 84 C 58. 96 B
59. 98 A 60. 98 A
61. 76 C 62. 97 A
63. 94 B 64. 91 B
147
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
Compound % inhibition Compound % inhibition
ICso IC50
No. @ 10 pM No. @ 10 pM
65. 86 C 66. 98 A
67. 91 B 68. 92 B
69. 98 A 70. 85 B
_
71. 92 B 72. 84 B
73. 101 A 74. 99 A
75. 97 A 76. 81 C
77. 99 A 78. 100 A
79. 96 A 80. 94 B
81. 98 A 82. 93 B
83. 96 A 84. 97 A
85. 99 A 86. 99 A
87. 32 88. 97 A
. ,
89. 38 - 90. 95 A
91. 94 A 92. 97 A
93. 96 A 94. 99 A
95. 93 A 96. 87 B
97. 87 B 98. 88 B
99. 82 C 100. 82 B
101. 96 A 102. 82 B
103. 80 C 104. 78 C
105. 92 A 106. 91 C
107. 95 A 108. 99 A
109. 98 A 110. 99 A
111. 95 A 112. 99 A
113. - A 114. 97 A
148
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
Compound % inhibition Compound % inhibition
ICso IC50
No. @ 10 pM No. @ 10 pM
115. 94 A 116. 92 A
117. 95 A 118. 93 B
119. 99 A 120. 93 A
_
121. 93 A 122. - A
123. 96 A 124. 94 A
125. 86 A 126. 80 C
127. 95 A 128. 93 A
129. 94 A 130. 97 A
131. 86 B 132. 90 A
133. 97 A 134. 97 A
135. 97 A 136. 73 C
137. 99 A 138. 64 C
139. 98 A 40A. - A
40B. A 40C. A
40D. - B 48A. - A
Example-33: In vivo efficacy of CDK7 inhibitor in the MV4-11 human acute
myeloid
leukemia (AML) cancer xenograft model.
The effect of the CDK7 inhibitor to inhibit the growth of MV4-11 xenograft
tumors
implanted in mice was evaluated. Briefly, MV4-11 cells were grown in Iscove's
Modified
Dulbecco's Medium (Sigma Aldrich) medium supplemented with 10% FBS
(Invitrogen) and 1%
penicillin streptomycin (Invitorgen). To establish tumors, 15 X 106 MV4-11
cells were injected
subcutaneously in 200 1 of 1:1 HBSS (Sigma: H4641) and ECM gel (Corning) into
the right
hind flank of male atthymic nude mice (Envigo). Tumor volume was measured
thrice a week and
body weight was monitored daily. To estimate tumor volumes, the length (D) and
width (d), of
the xenograft tumors were measured manually with calipers and the tumor volume
was
149
CA 02978170 2017-08-29
WO 2016/142855
PCT/1112016/051302
calculated using the formula:Tumor volume = (D x d2)/2. Treatment was
initiated when the
average tumor size had reached approximately 250 mm3. The animals were
randomized based
on tumor volumes into two groups of seven animals each. To evaluate efficacy,
compound-115
was administered intraperitoneally once per day (q24h/ qd schedule). The
treatment period was
for 14 days after which the overall efficacy was evaluated based on tumor
volume changes
observed during the treatment period. Tumor volumes were analyzed using one-
way ANOVA
with Dunnett's multiple comparisons test for comparison of treatment versus
control group.
Results are shown in graph (figure-1).
Example-34: Inhibition of RNA Polymerase II CTD Phosphorylation in Cell
Western
assay:
25000 cells (MDA-MB-231/NCI-H358) were seeded in 96 well black clear bottom
plate
incubated for overnight before addition of selected compound. 3 fold dilutions
of selected
compound diluted in DMSO starting from 10 M, added to cells and incubated for
4 hours at
37 C, 5% CO2 incubator. Cells were washed once with 100 1 of phosphate
buffered saline
(sigma # P3813), then fixed with 100 l/well of 4 % Para foinialdehyde for 60
min at room
temperature, in dark. The cells were washed 3 times with 100 1 of wash buffer
(PBS with 0.1 %
Triton-X-100), later blocked for 2 hours at room temperature in blocking
buffer (5 % BSA in
PBST). Cells were stained overnight at 4 C with Phospho RNA Pol It (S5)
(Millipore #04-1572,
Abcam #5131) or Phospho RNA Poll! (Ser-2), antibody (Bethyl labs #A300-654-A)
in blocking
buffer. Post incubation cells were washed with Delifia wash buffer (Perkin
Elmer # 4010-0010).
Cells were treated with LANCE secondary antibodies (LANCE Eu-W1024 perkin
elmer # AD-
0076 for phospho Ser-5 CTD RNA poi-ii and Delfia Eu-Ni anti rabbit IgG Perkin
elmer #
AD0106 for phospho Ser-2 CTD RNA pol-II) for 2 hours in assay buffer (Perkin
Elmer #1244-
111), Cells were washed 3 times with Delfia wash buffer post incubation,
Enhancement solution
(Perkin Elmer #1244-105) added and incubated for 20 mins. Europium readings
were taken in
Victor-3 instrument. Cell normalization was done using Hoechst dye (0.5 gimp.
The inhibition (EC50 in M) of RNA polymerase II CTD phosphosphorylation for
selected compounds was evaluated in below table:
Selected compounds were screened in the above mentioned assay procedure. The
EC50
values are summarised in the below table; wherein group "A" refers to an EC50
value of less than
150
CA 02978170 2017-08-29
WO 2016/142855 PCT/1112016/051302
or equal to 1 M, group "B" refres to EC50 value in range of 1 to 10 M and
group "C" refres to
EC50 value of greater than 10 M.
Compound EC50 Compound EC50
No. No.
1 A 2 A
. .
3 A 4 A
B 6 B
8 A 13 B
14 B 15 C
18 A 20 A
21 A 24 A
32 B 38 B
_
69 ' B 78 A
83 A 85 B
. -
88 B 90 B
91 C 92 B
93 - B 94 A
95 A 96 B
97 B 101 B
_
105 C 106 B '
107 B 108 B
109 B 110 B
111 B 114 B
115 A 116 B
117 B 119 C '
122 C 124 C
125 A . 128 B
129 B 131 C
132 C . 134 B
151
